<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     f10k2020_oramedpharma.htm     <description>      ANNUAL REPORT      <text>       <title>       </title>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          UNITEDSTATES          <br/>          SECURITIES AND EXCHANGE COMMISSION          <br/>          WASHINGTON, D.C. 20549         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 14pt">         <b>          FORM10-K         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         ☒        </font>        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Forthe Fiscal Year Ended          <u>           August 31, 2020          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         or        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         ☐        </font>        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Commissionfile number          <u>           000-50298          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 14pt">         <b>          <u>           ORAMEDPHARMACEUTICALS INC.          </u>         </b>        </font>        <b>         <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          <br/>         </font>        </b>        <font style="font: 10pt Times New Roman, Times, Serif">         (Exact Name of Registrant as Specified in its Charter)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Delaware            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: center; width: 2%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             98-0376008            </b>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (State    or Other Jurisdiction of Incorporation or Organization)           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (I.R.S.    Employer Identification No.)           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">           </font>          </td>         </tr>         <tr>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1185    Avenue of the Americas, Third Floor, New York, NY            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             10036            </b>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Address    of Principal Executive Offices)           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Zip    Code)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <u>           844-967-2633          </u>          <br/>         </b>         (Registrant’s Telephone Number, Including Area Code)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Securitiesregistered pursuant to Section 12(b) of the Act:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 33%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Title    of each class            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Trading    symbol            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 33%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name    of each exchange on which registered            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common Stock, par    value $0.012           </font>          </td>          <td style="text-align: center; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ORMP           </font>          </td>          <td style="text-align: center; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Nasdaq Capital    Market, Tel Aviv Stock Exchange           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Securitiesregistered pursuant to Section 12(g) of the Act:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <u>           None.          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         (Title of class)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐     No ☒        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐     No ☒        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒      No☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes ☒      No ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="text-align: left; width: 25%; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large accelerated filer           </font>          </td>          <td style="vertical-align: bottom; width: 25%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>          <td style="vertical-align: top; width: 25%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left; width: 25%; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accelerated filer           </font>          </td>          <td style="vertical-align: bottom; width: 25%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>         </tr>         <tr>          <td style="text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated filer           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☒           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller reporting company           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☒           </font>          </td>         </tr>         <tr>          <td colspan="2" style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth company           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report. ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes ☐      No ☒        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theaggregate market value of the voting and non-voting common equity held by non-affiliates as of the last business day of the registrant’smost recently completed second fiscal quarter was $60,800,854, based on a price of $4.08, being the last price at which the sharesof the registrant’s common stock were sold on The Nasdaq Capital Market prior to the end of the most recently completedsecond fiscal quarter.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicatethe number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date:23,675,530 shares of common stock issued and outstanding as of November 24, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ORAMEDPHARMACEUTICALS INC.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          FORM10-K          <br/>          (FOR THE FISCAL YEAR ENDED AUGUST 31, 2020)         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          TABLEOF CONTENTS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="background-color: rgb(204,238,255)">          <td colspan="2" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_001">             PART I            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; width: 7%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 86%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_002">             ITEM 1. BUSINESS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center; width: 7%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_003">             ITEM 1A. RISK FACTORS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_004">             ITEM IB. UNRESOLVED STAFF COMMENTS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_005">             ITEM 2. PROPERTIES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_006">             ITEM 3. LEGAL PROCEEDINGS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_007">             ITEM 4. MINE SAFETY DISCLOSURES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td colspan="2" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_008">             PART II            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_009">             ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_010">             ITEM 6. SELECTED FINANCIAL DATA.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_011">             ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            24           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_012">             ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            30           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_013">             ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_014">             ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_015">             ITEM 9A. CONTROLS AND PROCEDURES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_016">             ITEM 9B. OTHER INFORMATION.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td colspan="2" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_017">             PART III            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            33           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_018">             ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            33           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_019">             ITEM 11. EXECUTIVE COMPENSATION.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            38           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_020">             ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_021">             ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_022">             ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            51           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td colspan="2" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_023">             PART IV            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#a_024">             ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            52           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">            <a href="#a_025">             ITEM 16. FORM 10-K SUMMARY.            </a>           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         i         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As used in this AnnualReport on Form 10-K, the terms “we,” “us,” “our,” the “Company,” and “Oramed”mean Oramed Pharmaceuticals Inc. and our wholly-owned subsidiaries, Oramed Ltd. an Israeli corporation, and Oramed HK Limited,a Hong Kong corporation, unless otherwise indicated. All dollar amounts refer to U.S. dollars unless otherwise indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnAugust 31, 2020, the exchange rate between the New Israeli Shekel, or NIS, and the dollar, as quoted by the Bank of Israel, wasNIS 3.362 to $1.00. Unless indicated otherwise by the context, statements in this Annual Report on Form 10-K that provide thedollar equivalent of NIS amounts or provide the NIS equivalent of dollar amounts are based on such exchange rate.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          CAUTIONARYSTATEMENT REGARDING FORWARD-LOOKING STATEMENTS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thestatements contained in this Annual Report on Form 10-K that are not historical facts are “forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,”“anticipates,” “intends,” “plans,” “planned expenditures,” “believes,”“seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-lookingstatements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in thisAnnual Report on Form 10-K. Additionally, statements concerning future matters are forward-looking statements. We remind readersthat forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors andinvolve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements, orindustry results, to be materially different from any future results, performance, levels of activity, or our achievements, orindustry results, expressed or implied by such forward-looking statements. Such forward-looking statements appear in Item 1 -“Business” and Item 7 - “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”as well as elsewhere in this Annual Report on Form 10-K and include, among other statements, statements regarding the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    expected development and potential benefits from our products in treating diabetes;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the prospects of    entering into additional license agreements, or other partnerships or forms of cooperation with other companies or medical    institutions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            future milestones,    conditions and royalties under the license agreement with Hefei Tianhui Incubator of Technologies Co., Ltd., or HTIT;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our research and    development plans, including pre-clinical and clinical trials plans and the timing of enrollment, obtaining results and conclusion    of trials, including without limitation, our expectation that we will initiate two six-month Phase III clinical trials, and    our expectation to file a Biologics License Application thereafter;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our belief that    our technology has the potential to deliver medications and vaccines orally that today can only be delivered via injection;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the competitive    ability of our technology based product efficacy, safety, patient convenience, reliability, value and patent position;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the potential market    demand for our products;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our expectation    that in the upcoming year our research and development expenses will continue to be our major expenditure;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our expectations    regarding our short- and long-term capital requirements;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our outlook for    the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 3; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         ii         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            information with    respect to any other plans and strategies for our business; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             ourexpectations regarding the impact of the coronavirus, or COVID-19, pandemic, including on our clinical trials and operations.            </font>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Althoughforward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, such statementscan only be based on facts and factors known by us at the time of such statements. Consequently, forward-looking statements areinherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomesdiscussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in resultsand outcomes include, without limitation, those discussed herein, including those risks described in Item 1A. “Risk Factors”,and expressed from time to time in our other filings with the Securities and Exchange Commission, or SEC. In addition, historicresults of scientific research, clinical and preclinical trials do not guarantee that the conclusions of future research or trialswould not suggest different conclusions. Also, historic results referred to in this Annual Report on Form 10-K could be interpreteddifferently in light of additional research, clinical and preclinical trials results. Readers are urged not to place undue relianceon these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. Except as required bylaw, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstancethat may arise after the date of this Annual Report on Form 10-K. Readers are urged to carefully review and consider the variousdisclosures made throughout the entirety of this Annual Report on Form 10-K which attempt to advise interested parties of therisks and factors that may affect our business, financial condition, results of operations and prospects.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">       </p>       <!-- Field: Page; Sequence: 4; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         iii         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_001">          </a>          PARTI         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_002">          </a>          ITEM1. BUSINESS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          DESCRIPTIONOF BUSINESS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Researchand Development         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, includingan oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules orpills for delivery of other polypeptides. We utilize Clinical Research Organizations, or CROs, to conduct our clinical studies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Throughour research and development efforts, we have successfully developed an oral dosage form intended to withstand the harsh environmentof the stomach and intestines and effectively deliver active insulin or other proteins, such as Glucagon-like peptide-1, or GLP-1,leptin, and others. The excipients in the formulation are not intended to modify the proteins chemically or biologically, andthe dosage form is designed to be safe to ingest. We plan to continue to conduct clinical trials to show the effectiveness ofour technology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Oralinsulin          </i>         </b>         : Our proprietary flagship product, an orally ingestible insulin capsule, or ORMD-0801, allows insulin to travelfrom the gastrointestinal tract via the portal vein to the bloodstream, revolutionizing the manner in which insulin is delivered.It enables the passage in a more physiological manner than current delivery methods of insulin.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          FDAGuidance:         </i>         In August 2017, the U.S. Food and Drug Administration, or FDA, instructed us that the regulatory pathway for thesubmission of ORMD-0801 would be a Biologics License Application, or BLA. If approved the BLA pathway would grant us 12 yearsof marketing exclusivity for ORMD-0801, from the approval date, and an additional six months of exclusivity may be granted tous if the product also receives approval for use in pediatric patients.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Phase IIb Study:        </i>        In May 2018, we initiated a three-month dose-ranging Phase IIb clinical trial of ORMD-0801 (Cohort A). This placebo controlled,randomized, 90-day treatment clinical trial was conducted on 269 type 2 diabetic patients in multiple centers throughout the UnitedStates pursuant to an Investigational New Drug application, or IND, with the FDA. The primary endpoints of the trial were to assessthe safety and evaluate the effect of ORMD-0801 on HbA1c levels over a 90-day treatment period. Secondary endpoints of the trialincluded measurements of fasting plasma glucose, or FPG, post-prandial glucose, or PPG levels, during a mixed-meal tolerance test,or MMTT, and weight. In May 2019, we initiated an extension of this protocol for approximately 75 type 2 diabetic patients, whowere dosed using a lower dosage of insulin (Cohort B).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">        <i>         CohortA        </i>        : In November 2019, we announced positive results from the initial cohort of the Phase IIb trial. Patients randomized in thetrial to once-daily ORMD-0801 achieved a statistically significant (p-value 0.036) reduction from baseline in HbA1c of 0.60% (0.54%with placebo adjustment). This 0.54% reduction in HbA1c is clinically meaningful. Treatment with ORMD-0801 demonstrated an excellentsafety profile, with no serious drug-related adverse events and with no increased frequency of hypoglycemic episodes when comparedto placebo. In addition, during this 90-day trial, no weight gain was observed. In the initial cohort, 269 U.S.-based patientswere enrolled and treated with a dose-increasing approach: 16 mg initial dose, titrated to 24 mg per dose, and then titrated to32 mg per dose. Patients were randomized into three groups to assess dosing frequency: once-daily (32 mg per day), twice-daily(64 mg per day), thrice daily (96 mg per day). There was a corresponding placebo for each treatment arm. Two hundred nine (209)patients completed treatment to the 12-week endpoint and were included in the data analysis (24 subjects did not complete the full12 weeks of treatment). The twice-daily arms achieved statistically significant (p-value 0.042) reductions from baseline in HbA1cof 0.59% (0.53% with placebo adjustment). The thrice-daily arm did not meet statistical significance (p-value 0.093). In addition,due to evidence of treatment-by-center interaction, two sites (36 patients (13.4% of enrolled subjects)) were excluded from thestatistical analysis as they showed results opposite from the rest of the statistically significant results. Our internal investigationas well as an independent investigation did not find a cause for such discrepancy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          CohortB         </i>         : In February 2020, we announced positive topline data from the second and final cohort of the Phase IIb trial with a differentregimen across three daily dose ranges (8 mg, 16 mg, 32 mg). Patients randomized in the trial treated with 8 mg of ORMD-0801 once-dailyachieved a statistically significant (p-value 0.028) observed mean reduction of 1.29% from baseline and a least square mean reductionof 0.95% from baseline, or 0.81% adjusted for placebo. Patients who had HbA1c readings above 9% at baseline and received 8 mgof oral insulin once-daily experienced a 1.26% reduction in HbA1c by week 12. Treatment with ORMD-0801 at all doses demonstratedan excellent safety profile, with no serious drug-related adverse events and with no increased frequency of hypoglycemic episodesor weight gain compared to placebo. The primary efficacy endpoint was a reduction in HbA1c at week 12.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Phase III Study        </i>        :Based on guidance received from the FDA as part of the end-of-phase II meeting process for our oral insulin candidate, ORMD-0801,we have submitted to the FDA the protocols for our upcoming pivotal Phase III studies. In line with the FDA’s expectationsand recommendations, we intend to conduct two Phase III studies concurrently in patients with type 2 diabetes. These studies involveabout 1,125 patients to provide evidence of ORMD-0801’s safety and efficacy in type 2 diabetic patients over a treatmentperiod of 6 to 12 months. A geographically diverse patient population will be recruited from multiple sites throughout the UnitedStates, European, and Israel. Our phase III study will be composed from 2 protocols:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">        <i>         ORA-D-013-1        </i>        :This study will treat type 2 diabetic patients with inadequate glycaemic control who are currently on 1, 2 or 3 oral glucose-loweringagents. This U.S. study will recruit 675 patients from 75 clinical sites located throughout the U.S. Patients will be randomized1:1:1 in this double-dummy study into cohorts of: 8 mg ORMD-0801 once-daily at night and placebo 45 minutes before breakfast; 8mg ORMD-0801 twice-daily, at night and 45 minutes before breakfast; and placebo twice-daily, at night and 45 minutes before breakfast.The primary endpoint of the study is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycaemic control asassessed by HbA1c, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks.We expect to initiate this trial on the fourth quarter of 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">        <i>         ORA-D-013-2        </i>        :This study will include type 2 diabetic patients with inadequate glycaemic control who are managing their condition with eitherdiet alone or with diet and metformin monotherapy. A total of 450 patients will be recruited through 36 sites in the U.S. and 25sites in Western Europe and Israel. Patients will be randomized 1:1 into two cohorts dosed with: 8 mg ORMD-0801 at night; and placeboat night. The primary endpoint is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycaemic control as assessedby HbA1c over a 26-week treatment period, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasmaglucose at 26 weeks. We expect to initiate this trial on the first half of 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we successfullycomplete the pivotal studies, we expect to conduct a pre-BLA meeting with the FDA to finalize the plans and data for the BLA submission.After BLA submission and review, if the BLA is approved by the FDA, a full 12 years of marketing exclusivity would be granted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         NASH Study:        </i>        InJune 2020, we presented preliminary data from our open-label study of the first 8 patients of a planned 40-patient multi-center(U.S., Europe and Israel) pilot study, aimed to assess the safety, tolerability, and early effects of 16 mg ORMD-0801 (2x8 mg capsules)on liver fat in type 2 diabetic patients with nonalcoholic steatohepatitis, or NASH. The 12-week, once-daily treatment had no seriousadverse events, and induced an observed mean 6.9±6.8% reduction in liver fat content (p value: 0.035), and the relativereduction was 30%, as measured by MRI-derived proton density fat fraction. In parallel, concentrations of gamma-glutamyltransferase(GGT), a key marker of chronic hepatitis, were significantly lower after 12 weeks of treatment as compared to baseline (-14.6±13.1U/L; p value: 0.008).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Type1 Study:         </i>         In November 2019, we initiated a crossover study of type 1 diabetic patients to compare the effects of ORMD-0801given once daily versus the effects of ORMD-0801 given three times daily. This study showed no statistically significant, or clinicallymeaningful differences in total exogenous insulin requirements, or plasma glucose levels in type 1 diabetic subjects treated withORMD-0801 8mg dosed once daily in the evening compared to those dosed with ORMD-0801 three times daily.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           OralGLP-1          </i>         </b>         : GLP-1 is an incretin hormone, which stimulates the secretion of insulin from the pancreas. In addition to our flagshipproduct, the ORMD-0801 insulin capsule, we are using our technology for an orally ingestible GLP-1 capsule, or ORMD-0901.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In February 2019, wecompleted a Phase I pharmacokinetic trial to evaluate the safety and pharmacokinetics of ORMD-0901 compared to placebo. Based onthis trial results, we will conduct a follow-up Phase I trial in type 2 diabetic patients which will start its enrollment by theend of 2020 in the United States under an IND submitted to the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table gives an overview of the above described primary R&amp;D pipeline:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <img alt="" src="img_001.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourclinical trials are planned in order to substantiate our results as well as for purposes of making future filings for drug approval.We also plan to conduct further research and development by deploying our proprietary drug delivery technology for the deliveryof other polypeptides in addition to insulin, and to develop other innovative pharmaceutical products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>          Other Products:         </i>        </b>        We are developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule. We anticipate initiatinga proof of concept single dose study for this candidate to evaluate its pharmacokinetics and pharmacodynamics (glucagon reduction)in 10 type 1 adult diabetic patients. During the third quarter of 2020, we finalized the study without any safety issues, and weare waiting for the final lab results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           RawMaterials          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ouroral insulin capsule is currently manufactured by Fidelio Healthcare, a diversified European Contract Development and ManufacturingOrganization (CDMO) in the pharmaceutical and healthcare industries.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InJuly 2010, Oramed Ltd. entered into the Manufacturing and Supply Agreement, or MSA, with Sanofi-Aventis Deutschland GMBH, or Sanofi-Aventis.According to the MSA, Sanofi-Aventis will supply Oramed Ltd. with specified quantities of recombinant human insulin to be usedfor clinical trials. We also entered into an Insulin Supply Agreement in September 2020 with Hefei Tianmai Biological TechnologyDevelopment Limited, who will also supply Oramed Ltd. with specified quantities of recombinant human insulin to be used for clinicaltrials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wepurchase, pursuant to separate agreements with third parties, the raw materials required for the manufacturing of our oral capsule.We generally depend upon a limited number of suppliers for the raw materials. Although alternative sources of supply for thesematerials are generally available, we could incur significant costs and disruptions if we need to change suppliers. The terminationof our relationships with our suppliers or the failure of these suppliers to meet our requirements for raw materials on a timelyand cost-effective basis could have a material adverse effect on our business, prospects, financial condition and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          MarketOverview         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Diabetes is a diseasein which the body does not produce or properly use insulin. Insulin is a hormone that causes sugar to be absorbed into cells, wherethe sugar is converted into energy needed for daily life. The cause of diabetes is attributed both to genetics (type 1 diabetes)and, most often, to environmental factors such as obesity and lack of exercise (type 2 diabetes). According to the InternationalDiabetes Federation, or IDF, an estimated 463 million adults (20-79 years) worldwide suffered from diabetes in 2019 and the IDFprojects this number will increase to 700 million by 2045. Also, according to the IDF, in 2019, an estimated 4.2 million peopledied from diabetes. According to the American Diabetes Association, or ADA, in the United States there were approximately 34.2million people with diabetes, or 10.5% of the United States population in 2018. Diabetes is a leading cause of blindness, kidneyfailure, heart attack, stroke and amputation. The latest report of the ADA that analyzed the economic costs of diabetes in theU.S in 2017 indicates that the total cost of diagnosed diabetes in the United States in 2017 was $327 billion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          IntellectualProperty         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weown a portfolio of patents and patent applications covering our technologies, and we are aggressively protecting these technologydevelopments on a worldwide basis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Leadership         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Management          </i>         </b>         :We are led by an experienced management team knowledgeable in the treatment of diabetes. Our Chief Scientific Officer, MiriamKidron, PhD, is a recognized pharmacologist and a biochemist and the innovator primarily responsible for our oral insulin technologydevelopment and know-how.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           ScientificAdvisory Board          </i>         </b>         : Our management team has access to our internationally recognized Scientific Advisory Board whose membersare thought-leaders in their respective areas. The Scientific Advisory Board is comprised of Dr. Roy Eldor, Professor Ele Ferrannini,Professor Avram Hershko, Dr. Harold Jacob, Dr. Julio Rosenstock and Dr. Jay Skyler.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Strategy         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weplan to ultimately seek a strategic commercial partner, or partners, with extensive experience in the development, commercialization,and marketing of insulin applications and/or other orally digestible drugs. We anticipate such partner or partners would be responsiblefor, or substantially support, late stage clinical trials (Phase III) to increase the likelihood of obtaining regulatory approvalsand registrations in the appropriate markets in a timely manner. We further anticipate that such partner, or partners, would alsobe responsible for sales, marketing and support of our products in these markets. Such planned strategic partnership, or partnerships,may provide a marketing and sales infrastructure for our products as well as financial and operational support for global clinicaltrials, post marketing studies, label expansions and other regulatory requirements concerning future clinical development. In2015 we successfully executed this strategy when we, Oramed Ltd. and HTIT entered into a Technology License Agreement pursuantto which we granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macauand Hong Kong, or the Territory, related to our oral insulin capsule, ORMD-0801. Any future strategic partner, or partners, mayalso provide capital and expertise that would enable the partnership to develop new oral dosage forms for other polypeptides.While our strategy is to partner with an appropriate party, no assurance can be given that we will in fact be able to reach anagreeable partnership with any third party. Under certain circumstances, we may determine to develop one or more of our oral dosageforms on our own, either world-wide or in select territories.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inaddition to developing our own oral dosage form drug portfolio, we are, on an on-going basis, considering in-licensing and othermeans of obtaining additional technologies to complement and/or expand our current product portfolio. Our goal is to create awell-balanced product portfolio that will enhance and complement our existing drug portfolio.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          PotentialMaterial Impact of COVID-19         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The COVID-19 pandemichas negatively impacted the global economy, disrupted consumer spending and global supply chains and created significant volatilityand disruption of financial markets. Although to date the COVID-19 pandemic has not had a material adverse effect on us, the COVID-19pandemic may have a material adverse effect on our business and financial performance in the future. The extent of the impact ofthe COVID-19 pandemic, including our ability to execute our business strategies as planned, will depend on future developments,including the duration and severity of the pandemic, which are highly uncertain and cannot be predicted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Although,as of the date of this Annual Report on Form 10-K, we do not expect any material impact on our long-term activity, the extentto which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted,including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat itsimpact, among others.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Patentsand Licenses         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wemaintain a proactive intellectual property strategy, which includes patent filings in multiple jurisdictions, including the UnitedStates and other commercially significant markets. We hold 26 patent applications currently pending, with respect to various compositions,methods of production and oral administration of proteins and exenatide. Expiration dates for pending patents, if granted, willfall between 2026 and 2039.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We hold 79 patents,2 of which were issued during the fiscal year ended August 31, 2020, or fiscal 2020, including patents issued by the United States,Swiss, German, French, U.K., Italian, Netherlands, Swedish, Spanish, Australian, Israeli, Japanese, New Zealand, South African,Russian, Canadian, Hong Kong, Chinese, European and Indian patent offices that cover a part of our technology, which allows forthe oral delivery of proteins; patents issued by the Australian, Canadian, European, Austrian, Belgian, French, German, Irish,Italian, Luxembourg, Monaco, Netherlands, Norwegian, Spanish, Swedish, Swiss, U.K., Israeli, New Zealand, South African, Russianand Japanese patent offices that cover part of our technology for the oral delivery of exenatide; and patents issued by the European,Austrian, Belgian, Denmark, French, German, Irish, Italian, Luxembourg, Monaco, Netherlands, Norway, Spanish, Swedish, Swiss, U.K.and Japanese patent offices for treating diabetes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Consistentwith our strategy to seek protection in key markets worldwide, we have been and will continue to pursue the patent applicationsand corresponding foreign counterparts of such applications. We believe that our success will depend on our ability to obtainpatent protection for our intellectual property.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourpatent strategy is as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Aggressivelyprotect all current and future technological developments to assure strong and broad protection by filing patents and/or continuationsin part as appropriate,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Protecttechnological developments at various levels, in a complementary manner, including the base technology, as well as specific applicationsof the technology, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Establishcomprehensive coverage in the United States and in all relevant foreign markets in anticipation of future commercialization opportunities.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wealso rely on trade secrets and unpatentable know-how that we seek to protect, in part, by confidentiality agreements. Our policyis to require our employees, consultants, contractors, manufacturers, outside scientific collaborators and sponsored researchers,our board of directors, or our Board, technical review board and other advisors, to execute confidentiality agreements upon thecommencement of employment or consulting relationships with us. These agreements provide that all confidential information developedor made known to the individual during the course of the individual’s relationship with us is to be kept confidential andnot disclosed to third parties except in specific limited circumstances. We also require signed confidentiality or material transferagreements from any company that is to receive our confidential information. In the case of employees, consultants and contractors,the agreements provide that all inventions conceived by the individual while rendering services to us shall be assigned to usas the exclusive property of our Company. There can be no assurance, however, that all persons who we desire to sign such agreementswill sign, or if they do, that these agreements will not be breached, that we would have adequate remedies for any breach, orthat our trade secrets or unpatentable know-how will not otherwise become known or be independently developed by competitors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Out-LicensedTechnology         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InJune 2010, Oramed Ltd. entered into a joint venture agreement with D.N.A Biomedical Solutions Ltd., or D.N.A, for the establishmentof Entera Bio Ltd., or Entera.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Under the terms ofa license agreement, as amended, that was entered into between Oramed Ltd. and Entera in August 2010, we out-licensed technologyto Entera, on an exclusive basis, for the development of oral delivery drugs for certain indications to be agreed upon betweenthe parties. The out-licensed technology differs from our main delivery technology that is used for oral insulin and GLP-1 analogand is subject to different patent applications. Entera’s initial development effort is for an oral formulation for the treatmentof osteoporosis. In March 2011, we entered into a patent transfer agreement, or the Patent Transfer Agreement, to replace the originallicense agreement pursuant to which Oramed Ltd. assigned to Entera all of its right, title and interest in and to the patent applicationthat it had licensed to Entera in August 2010. Under this agreement, Oramed Ltd. is entitled to receive from Entera royalties of3% of Entera’s net revenues and a license back of that patent application for use in respect of diabetes and influenza.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InMarch 2011, we also consummated a transaction with D.N.A, whereby we sold to D.N.A 47% of Entera’s outstanding share capitalon an undiluted basis, retaining a 3% interest as of March 2011. In consideration for the shares sold to D.N.A, we received, amongother payments, ordinary shares of D.N.A. The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange and its quoted priceis subject to market fluctuations, and may, at times, have a price below the value on the date we acquired such shares. In addition,the ordinary shares of D.N.A have historically experienced low trading volume; as a result, there is no guarantee that we willbe able to resell the ordinary shares of D.N.A at the prevailing market prices. During the years ended August 31, 2020, 2019 and2018, we did not sell any of the D.N.A ordinary shares. As of August 31, 2020, we held approximately 5.6% of D.N.A’s outstandingordinary shares.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of August 31, 2020,Entera had not yet realized any revenues. On December 11, 2018, Entera announced that it had entered into a research collaborationand license agreement, or the Amgen License, with Amgen Inc. related to research of inflammatory disease and other serious illnesses.As reported by Entera, under the terms of the Amgen License, Entera will receive a modest initial technology access fee from Amgenand will be responsible for preclinical development at Amgen’s expense. Entera will be eligible to receive up to $270,000,000in aggregate payments, as well as tiered royalties up to mid-single digits, upon achievement of various clinical and commercialmilestones if Amgen decides to move all of these programs forward. To the extent the Amgen License results in net revenues as definedin the Patent Transfer Agreement, Oramed Ltd. will be entitled to the aforementioned royalties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnNovember 30, 2015, we, Oramed Ltd. and HTIT entered into a Technology License Agreement, or TLA, and on December 21, 2015, theseparties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016and July 24, 2016, or the License Agreement. According to the License Agreement, we granted HTIT an exclusive commercializationlicense in the Territory, related to our oral insulin capsule, ORMD-0801, or the Product. Pursuant to the License Agreement, HTITwill conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to our subsidiary’stechnology and ORMD-0801 capsule, and will pay (i) royalties of 10% on net sales of the related commercialized products to besold by HTIT in the Territory, or Royalties, and (ii) an aggregate of $37.5 million, of which $3 million was payable immediately,$8 million will be paid subject to our entry into certain agreements with certain third parties, and $26.5 million will be payableupon achievement of certain milestones and conditions. In the event that we will not meet certain conditions, the Royalties ratemay be reduced to a minimum of 8%. Following the final expiration of our patents covering the technology in the Territory in 2033,the Royalties rate may be reduced, under certain circumstances, to 5%. The royalty payment obligation shall apply during the periodof time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expirationof the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in theTerritory, or the Royalty Term. The License Agreement shall remain in effect until the expiration of the Royalty Term. The LicenseAgreement contains customary termination provisions. Through August 31, 2020, we received aggregate milestone payments of $20.5million.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        On August 21, 2020, we received aletter from HTIT, disputing certain pending payment obligations of HTIT under the TLA. The payment obligation being disputed is$4 million, out of which only an amount of $2 million has been received and has been included in Deferred revenue in each of theconsolidated balance sheets as of the fiscal years ended August 31, 2020, and 2019. In addition, the dispute includes a paymentobligation of $2 million for certain milestones that we assert it met under the TLA subsequent to the fiscal year ended August31, 2020. We wholly dispute the claims made by HTIT and has been engaged in discussions and exchanges with HTIT in an attempt toclarify and resolve disagreements between the parties regarding milestone payments and work plan implementation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wealso entered into a separate securities purchase agreement with HTIT, or the SPA, pursuant to which HTIT invested $12 millionin us in December 2015. In connection with the License Agreement and the SPA, we received a non-refundable payment of $500,000as a no-shop fee.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          GovernmentRegulation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           TheDrug Development Process          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Regulatoryrequirements for the approval of new drugs vary from one country to another. In order to obtain approval to market our drug portfolio,we need to go through a different regulatory process in each country in which we apply for such approval. In some cases, informationgathered during the approval process in one country can be used as supporting information for the approval process in anothercountry. As a strategic decision, we decided to first explore the FDA regulatory pathway. The following is a summary of the FDA’srequirements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 10; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheFDA requires that pharmaceutical and certain other therapeutic products undergo significant clinical experimentation and clinicaltesting prior to their marketing or introduction to the general public. Clinical testing, known as clinical trials or clinicalstudies, is either conducted internally by life science, pharmaceutical or biotechnology companies or is conducted on behalf ofthese companies by CROs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theprocess of conducting clinical studies is highly regulated by the FDA, as well as by other governmental and professional bodies.Below we describe the principal framework in which clinical studies are conducted, as well as describe a number of the partiesinvolved in these studies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Protocols.Before commencing human clinical studies, the sponsor of a new drug or therapeutic product must submit an IND application to theFDA. The application contains, among other documents, what is known in the industry as a protocol. A protocol is the blueprintfor each drug study. The protocol sets forth, among other things, the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Who                                         must be recruited as qualified participants,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            How                                         often to administer the drug or product,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            What                                         tests to perform on the participants, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            What                                         dosage of the drug or amount of the product to give to the participants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InstitutionalReview Board. An institutional review board is an independent committee of professionals and lay persons which reviews clinicalresearch studies involving human beings and is required to adhere to guidelines issued by the FDA. The institutional review boarddoes not report to the FDA, but its records are audited by the FDA. Its members are not appointed by the FDA. All clinical studiesmust be approved by an institutional review board. The institutional review board’s role is to protect the rights of theparticipants in the clinical studies. It approves the protocols to be used, the advertisements which the company or CRO conductingthe study proposes to use to recruit participants, and the form of consent which the participants will be required to sign priorto their participation in the clinical studies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         ClinicalTrials. Human clinical studies or testing of a potential product are generally done in three stages known as Phase I through PhaseIII testing. The names of the phases are derived from the regulations of the FDA. Generally, there are multiple studies conductedin each phase.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         PhaseI. Phase I studies involve testing a drug or product on a limited number of healthy or patient participants, typically 24 to 100people at a time. Phase I studies determine a product’s basic safety and how the product is absorbed by, and eliminatedfrom, the body. This phase lasts an average of six months to a year.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         PhaseII. Phase II trials involve testing of no more than 300 participants at a time who may suffer from the targeted disease or condition.Phase II testing typically lasts an average of one to two years. In Phase II, the drug is tested to determine its safety and effectivenessfor treating a specific illness or condition. Phase II testing also involves determining acceptable dosage levels of the drug.Phase II studies may be split into Phase IIa and Phase IIb sub-studies. Phase IIa studies may be conducted with patient volunteersand are exploratory (non-pivotal) studies, typically designed to evaluate clinical efficacy or biological activity. Phase IIbstudies are conducted with patients defined to evaluate definite dose range and evaluate efficacy. If Phase II studies show thata new drug has an acceptable range of safety risks and probable effectiveness, a company will generally continue to review thesubstance in Phase III studies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         PhaseIII. Phase III studies involve testing large numbers of participants, typically several hundred to several thousand persons. Thepurpose is to verify effectiveness and long-term safety on a large scale. These studies generally last two to three years. PhaseIII studies are conducted at multiple locations or sites. Like the other phases, Phase III requires the site to keep detailedrecords of data collected and procedures performed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         BiologicalLicense Application. The results of the clinical trials for a biological product are submitted to the FDA as part of a BLA. Followingthe completion of Phase III studies, assuming the sponsor of a potential product in the United States believes it has sufficientinformation to support the safety and effectiveness of its product, the sponsor will generally submit a BLA to the FDA requestingthat the product be approved for marketing. The application is a comprehensive, multi-volume filing that includes the resultsof all clinical studies, information about the drug’s composition, and the sponsor’s plans for producing, packagingand labeling the product. The FDA’s review of an application can take a few months to many years, with the average reviewlasting 18 months. Once approved, drugs and other products may be marketed in the United States, subject to any conditions imposedby the FDA. Approval of a BLA provides 12 years of exclusivity in the U.S. market.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 11; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         PhaseIV. The FDA may require that the sponsor conduct additional clinical trials following new drug approval. The purpose of thesetrials, known as Phase IV studies, is to monitor long-term risks and benefits, study different dosage levels or evaluate safetyand effectiveness. In recent years, the FDA has increased its reliance on these trials. Phase IV studies usually involve thousandsof participants. Phase IV studies also may be initiated by the company sponsoring the new drug to gain broader market value foran approved drug.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Similarto the U.S., a European sponsor of a biological product may submit a Marketing Approval Application to the EMA for the registrationof the product. The approval process in Europe consists of several stages, which together are summed up to 210 days from the timeof submission of the application (net, without periods in which the sponsor provides answers to questions raised by the agency)following which, a Marketing Approval may be granted. During the approval process, the sponsor’s manufacturing facilitieswill be audited in order to assess Good Manufacturing Practice compliance.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thedrug approval process is time-consuming, involves substantial expenditures of resources, and depends upon a number of factors,including the severity of the illness in question, the availability of alternative treatments, and the risks and benefits demonstratedin the clinical trials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           OtherRegulations          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Variousfederal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory practices, theexperimental use of animals, the environment and the purchase, storage, movement, import, export, use, and disposal of hazardousor potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with ourresearch are applicable to our activities. They include, among others, the U.S. Atomic Energy Act, the Clean Air Act, the CleanWater Act, the Occupational Safety and Health Act, the National Environmental Policy Act, the Toxic Substances Control Act, andResources Conservation and Recovery Act, national restrictions on technology transfer, import, export, and customs regulations,and other present and possible future local, state, or federal regulation. The compliance with these and other laws, regulationsand recommendations can be time-consuming and involve substantial costs. In addition, the extent of governmental regulation whichmight result from future legislation or administrative action cannot be accurately predicted and may have a material adverse effecton our business, financial condition, results of operations and prospects.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Competition         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Competitionin General          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Competitionin the area of biomedical and pharmaceutical research and development is intense and significantly depends on scientific and technologicalfactors. These factors include the availability of patent and other protection for technology and products, the ability to commercializetechnological developments and the ability to obtain regulatory approval for testing, manufacturing and marketing. Our competitorsinclude major pharmaceutical, medical products, chemical and specialized biotechnology companies, many of which have financial,technical and marketing resources significantly greater than ours. In addition, many biotechnology companies have formed collaborationswith large, established companies to support research, development and commercialization of products that may be competitive withours. Academic institutions, governmental agencies and other public and private research organizations are also conducting researchactivities and seeking patent protection and may commercialize products on their own or through joint ventures. We are aware ofcertain other products manufactured or under development by competitors that are used for the treatment of the diseases and healthconditions that we have targeted for product development. We can provide no assurance that developments by others will not renderour technology obsolete or noncompetitive, that we will be able to keep pace with new technological developments or that our technologywill be able to supplant established products and methodologies in the therapeutic areas that are targeted by us. The foregoingfactors could have a material adverse effect on our business, prospects, financial condition and results of operations. Thesecompanies, as well as academic institutions, governmental agencies and private research organizations, also compete with us inrecruiting and retaining highly qualified scientific personnel and consultants.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 12; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Competitionwithin our sector is increasing, so we will encounter competition from existing firms that offer competitive solutions in diabetestreatment solutions. These competitive companies could develop products that are superior to, or have greater market acceptance,than the products being developed by us. We will have to compete against other biotechnology and pharmaceutical companies withgreater market recognition and greater financial, marketing and other resources.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourcompetition will be determined in part by the potential indications for which our technology is developed and ultimately approvedby regulatory authorities. In addition, the first product to reach the market in a therapeutic or preventive area is often ata significant competitive advantage relative to later entrants to the market. Accordingly, the relative speed with which we, orour potential corporate partners, can develop products, complete the clinical trials and approval processes and supply commercialquantities of the products to the market are expected to be important competitive factors. Our competitive position will alsodepend on our ability to attract and retain qualified scientific and other personnel, develop effective proprietary products,develop and implement production and marketing plans, obtain and maintain patent protection and secure adequate capital resources.We expect our technology, if approved for sale, to compete primarily on the basis of product efficacy, safety, patient convenience,reliability, value and patent position.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Competitionfor Our Oral Insulin Capsule          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weanticipate the oral insulin capsule to be a competitive diabetes drug because of its anticipated efficacy and safety profile.The following are some of the treatment options for type 1 and type 2 diabetic patients:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Insulininjections,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Insulinpumps, or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acombination of diet, exercise and oral medication which improve the body’s response to insulin or cause the body to producemore insulin.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ScientificAdvisory Board         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wemaintain a Scientific Advisory Board consisting of internationally recognized scientists who advise us on scientific and technicalaspects of our business. The Scientific Advisory Board meets periodically to review specific projects and to assess the valueof new technologies and developments to us. In addition, individual members of the Scientific Advisory Board meet with us periodicallyto provide advice in their particular areas of expertise. The Scientific Advisory Board consists of the following members, informationwith respect to whom is set forth below: Dr. Roy Eldor, Professor Ele Ferrannini, Professor Avram Hershko, Dr. Harold Jacob, Dr.Julio Rosenstock and Dr. Jay Skyler.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Roy Eldor          </i>          ,          <i>           MD, PhD,          </i>         </b>         joined the Oramed Scientific Advisory Board in July 2016. He is an endocrinologist, internistand researcher with over twenty years of clinical and scientific experience. He is currently Director of the Diabetes Unit atthe Institute of Endocrinology, Metabolism &amp; Hypertension, Tel-Aviv Sourasky Medical Center. Prior to that, Dr. Eldor servedas Principal Scientist at Merck Research Laboratories, Clinical Research - Diabetes &amp; Endocrinology, Rahway, New Jersey. Hehas previously served as a senior physician in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital,Jerusalem, Israel; and the Diabetes Division at the University of Texas Health Science Center in San Antonio, Texas (under theguidance of Dr. R.A. DeFronzo). Dr. Eldor is a recognized expert, with over 35 peer reviewed papers and book chapters, and hasbeen a guest speaker at numerous international forums.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           ProfessorEle Ferrannini          </i>          ,          <i>           MD,          </i>         </b>         joined the Oramed Scientific Advisory Board in February 2007. He is a past President to theEuropean Association for the Study of Diabetes, which supports scientists, physicians and students from all over the world whoare interested in diabetes and related subjects in Europe, and performs functions similar to that of the ADA in the United States.Professor Ferrannini has worked with various institutions including the Department of Clinical &amp; Experimental Medicine, Universityof Pisa School of Medicine, and CNR (National Research Council) Institute of Clinical Physiology, Pisa, Italy; and the DiabetesDivision, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas. He has also had extensive trainingin internal medicine and endocrinology, and has specialized in diabetes studies. Professor Ferrannini has received a Certificateof the Educational Council for Foreign Medical Graduates from the University of Bologna, and with cum laude honors completed asubspecialty in Diabetes and Metabolic Diseases at the University of Torino. He has published over 500 original papers and 50book chapters and he is a “highly cited researcher,” according to the Institute for Scientific Information.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 13; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           ProfessorAvram Hershko, MD, PhD          </i>         </b>         , joined the Oramed Scientific Advisory Board in July 2008. He earned his MD degree (1965) and PhDdegree (1969) from the Hebrew University-Hadassah Medical School of Jerusalem. Professor Hershko served as a physician in theIsrael Defense Forces from 1965 to 1967. After a post-doctoral fellowship with Gordon Tomkins at the University of San Francisco(1969         <b>          -         </b>         72), he joined the faculty of the Haifa Technion becoming a professor in 1980. He is now Distinguished Professorin the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion. Professor Hershko’s main research interestsconcern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study. Professor Hershko and hiscolleagues showed that cellular proteins are degraded by a highly selective proteolytic system. This system tags proteins fordestruction by linkage to a protein called ubiquitin, which had previously been identified in many tissues, but whose functionwas previously unknown. Subsequent work by Professor Hershko and many other laboratories has shown that the ubiquitin system hasa vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction andDNA repair. Professor Hershko was awarded the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanoverand their colleague Irwin Rose. His many honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), theLasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001).Professor Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the U.S. Academy of Sciences(2003).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Harold Jacob, MD          </i>         </b>         , joined the Oramed Scientific Advisory Board in November 2016. Since 1998, Dr. Jacob has served as thepresident of Medical Instrument Development Inc., a company which provides a range of support and consulting services to start-upand early stage companies as well as patenting its own proprietary medical devices. Since 2011, Dr. Jacob has also served as anattending physician at Hadassah University Medical Center, where he has served as the director of the gastrointestinal endoscopyunit since September 2013. Dr. Jacob has advised a spectrum of companies in the past and he served as a consultant and then asthe Director of Medical Affairs at Given Imaging Ltd., from 1997 to 2003, a company that developed the first swallowable wirelesspill camera for inspection of the intestine. He has licensed patents to a number of companies including Kimberly-Clark Corporation.Since 2014, Dr. Jacob has served as the Chief Medical Officer and a director of NanoVibronix, Inc., a medical device company usingsurface acoustics to prevent catheter acquired infection as well as other applications, where he served as Chief Executive Officerfrom 2004 to 2014. He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. John’sEpiscopal Hospital and South Nassau Communities Hospital from 1986 to 1995, and was a Clinical Assistant Professor of Medicineat SUNY from 1983 to 1990. Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publicationsin the field of gastroenterology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Julio Rosenstock, MD          </i>         </b>         , joined the Oramed Scientific Advisory Board in January 2020. Dr. Rosenstock is the current Directorof the Dallas Diabetes Research Center at Medical City Dallas and a Clinical Professor of Medicine at the University of TexasSouthwestern Medical Center, Dallas. He received his medical degree from the University of Costa Rica School of Medicine and completedFellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK, and at theUniversity of Texas Southwestern Medical Center. His clinical research efforts focus on exploring novel agents and therapeuticstrategies to improve glycemic control. Over the last 30 years, he has participated in hundreds of clinical trials and has hadan active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator andscientific advisor. He has authored or co-authored 296 peer-reviewed manuscripts and numerous abstracts. Dr. Rosenstock is a memberof the National Board of Directors of the ADA and is currently an Associate Editor of Diabetes Care.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Jay Skyler, MD, MCAP          </i>         </b>         , joined the Oramed Scientific Advisory Board in January 2020. Dr. Skyler is Professor of Medicine,Pediatrics, &amp; Psychology in the Division of Endocrinology, Diabetes &amp; Metabolism, Department of Medicine, University ofMiami Leonard M. Miller School of Medicine. He previously held the position of Director of the Division of Endocrinology, Diabetes&amp; Metabolism. In addition, Dr. Skyler is Deputy Director of Clinical Research and Academic Programs at the Diabetes ResearchInstitute, and an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado atDenver. Dr. Skyler’s research focuses on the clinical aspects of diabetes, specifically the conduct of randomized controlledclinical trials. From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial - Type 1 (DPT-1)and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to prevent type 1 diabetes.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 14; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Employees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave been successful in retaining experienced personnel involved in our research and development program. In addition, we believewe have successfully recruited the clinical/regulatory, quality assurance and other personnel needed to advance through clinicalstudies or have engaged the services of experts in the field for these requirements. As of August 31, 2020, we have contractedwith twelve individuals for employment or consulting arrangements. Of our staff, four are senior management, four are engagedin research and development work, and the remaining four are involved in administration work.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          AdditionalInformation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Additionalinformation about us is contained on our Internet website at www.oramed.com. Information on our website is not incorporated byreference into this report. On our website, under “Investors”, “SEC Filings”, we make available free ofcharge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reportsfiled or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soonas reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and ExchangeCommission, or the SEC. Reports filed with the SEC are made available on its website at www.sec.gov. The following Corporate Governancedocuments are also posted on our website: Code of Ethics, Whistleblowing Policy and the Charters for each of the Audit Committee,Compensation Committee and Nominating Committee of our Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_003">          </a>          ITEM1A. RISK FACTORS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Aninvestment in our securities involves a high degree of risk. You should consider carefully the following information about theserisks, together with the other information contained in this Annual Report on Form 10-K before making an investment decision.Our business, prospects, financial condition and results of operations may be materially and adversely affected as a result ofany of the following risks. The value of our securities could decline as a result of any of these risks. You could lose all orpart of your investment in our securities. Some of the statements in “Item 1A. Risk Factors” are forward-looking statements.The following risk factors are not the only risk factors facing our Company. Additional risks and uncertainties not presentlyknown to us or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          RisksRelated to Our Business         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wecontinue, and in the future expect, to incur losses         </b>         .        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Successfulcompletion of our development programs and our transition to normal operations are dependent upon obtaining necessary regulatoryapprovals from the FDA prior to selling our products within the United States, and foreign regulatory approvals must be obtainedto sell our products internationally. There can be no assurance that we will receive regulatory approval of any of our productcandidates, and a substantial amount of time may pass before we achieve a level of revenues adequate to support our operations.We also expect to incur substantial expenditures in connection with the regulatory approval process for each of our product candidatesduring their respective developmental periods. Obtaining marketing approval will be directly dependent on our ability to implementthe necessary regulatory steps required to obtain marketing approval in the United States and in other countries. We cannot predictthe outcome of these activities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Basedon our current cash resources and commitments, we believe we will be able to maintain our current planned development activitiesand the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that we will notneed additional funds prior to such time. If there are unexpected increases in our operating expenses, we may need to seek additionalfinancing during the next 12 months.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 15; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wewill need substantial additional capital in order to satisfy our business objectives.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Todate, we have financed our operations principally through offerings of securities and we will require substantial additional financingat various intervals in order to continue our research and development programs, including significant requirements for operatingexpenses including intellectual property protection and enforcement, for pursuit of regulatory approvals, and for commercializationof our products. We can provide no assurance that additional funding will be available on a timely basis, on terms acceptableto us, or at all. In the event that we are unable to obtain such financing, we will not be able to fully develop and commercializeour technology. Our future capital requirements will depend upon many factors, including:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continued                                         scientific progress in our research and development programs,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Costs                                         and timing of conducting clinical trials and seeking regulatory approvals and patent                                         prosecutions,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Competing                                         technological and market developments,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our                                         ability to establish additional collaborative relationships, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Effects                                         of commercialization activities and facility expansions if and as required.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifwe cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our researchand development programs or to enter into license or other arrangements with third parties to commercialize products or technologiesthat we would otherwise seek to develop ourselves and commercialize ourselves. In such event, our business, prospects, financialcondition and results of operations may be adversely affected as we may be required to scale-back, eliminate, or delay developmentefforts or product introductions or enter into royalty, sales or other agreements with third parties in order to commercializeour products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wehave a history of losses and can provide no assurance as to our future operating results.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wedo not have sufficient revenues from our research and development activities to fully support our operations. Consequently, wehave incurred net losses and negative cash flows since inception. We currently have only licensing revenues and no product revenues,and may not succeed in developing or commercializing any products which could generate product revenues. We do not expect to haveany products on the market for several years. In addition, development of our product candidates requires a process of pre-clinicaland clinical testing, during which our products could fail. We may not be able to enter into agreements with one or more companiesexperienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we will notbe able to market our product candidates. Eventual profitability will depend on our success in developing, manufacturing, andmarketing our product candidates. As of August 31, 2020, August 31, 2019 and August 31, 2018, we had working capital of $35,975,000,$28,016,000 and $26,484,000, respectively, and stockholders’ equity of $32,879,000, $19,393,000 and $31,112,000, respectively.During fiscal 2020 and the fiscal years ended August 31, 2019, or fiscal 2019, and 2018, we generated revenues of $2,710,000,$2,703,000 and $2,449,000, respectively. For the period from our inception on April 12, 2002 through August 31, 2020, fiscal 2020,fiscal 2019 and fiscal 2018, we incurred net losses of $92,614,000, $11,511,000, $14,355,000 and $12,727,000, respectively. Wemay never achieve profitability and expect to incur net losses in the foreseeable future. See “Item 7. Management’sDiscussion and Analysis of Financial Condition and Results of Operations.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Werely upon patents to protect our technology.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thepatent position of biopharmaceutical and biotechnology firms is generally uncertain and involves complex legal and factual questions.We do not know whether any of our current or future patent applications will result in the issuance of any patents. Even issuedpatents may be challenged, invalidated or circumvented. Patents may not provide a competitive advantage or afford protection againstcompetitors with similar technology. Competitors or potential competitors may have filed applications for, or may have receivedpatents and may obtain additional and proprietary rights to compounds or processes used by or competitive with ours. In addition,laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the UnitedStates.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 16; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Patentlitigation is becoming widespread in the biopharmaceutical and biotechnology industry and we cannot predict how this will affectour efforts to form strategic alliances, conduct clinical testing or manufacture and market any products under development. Ifchallenged, our patents may not be held valid. We could also become involved in interference proceedings in connection with oneor more of our patents or patent applications to determine priority of invention. If we become involved in any litigation, interferenceor other administrative proceedings, we will likely incur substantial expenses and the efforts of our technical and managementpersonnel will be significantly diverted. In addition, an adverse determination could subject us to significant liabilities orrequire us to seek licenses that may not be available on favorable terms, if at all. We may be restricted or prevented from manufacturingand selling our products in the event of an adverse determination in a judicial or administrative proceeding or if we fail toobtain necessary licenses.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wemay be unable to protect our intellectual property rights and we may be liable for infringing the intellectual property rightsof others.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourability to compete effectively will depend on our ability to maintain the proprietary nature of our technologies. We currentlyhold several pending patent applications in the United States, Canada, Brazil, Europe, India, Hong Kong, Japan and China for ourtechnologies covering oral administration of insulin and other proteins and oral administration of exenatide and proteins and79 patents issued by the United States, Australian, Canadian, Chinese, Israeli, Japanese, New Zealand, South African, Russian,European, Hong Kong, Swiss, German, Spanish, French, United Kingdom, Italian, Indian, Austrian, Belgian, Irish, Swedish, Denmark,Luxembourg, Monaco, Norway and Netherlands patent offices for our technologies covering oral administration of insulin and otherproteins, or for our technologies covering oral administration of exenatide, or for methods and compositions for treating diabetes.Further, we intend to rely on a combination of trade secrets and non-disclosure and other contractual agreements and technicalmeasures to protect our rights in our technology. We intend to depend upon confidentiality agreements with our officers, directors,employees, consultants, and subcontractors, as well as collaborative partners, to maintain the proprietary nature of our technology.These measures may not afford us sufficient or complete protection, and others may independently develop technology similar toours, otherwise avoid our confidentiality agreements, or produce patents that would materially and adversely affect our business,prospects, financial condition and results of operations. We believe that our technology is not subject to any infringement actionsbased upon the patents of any third parties; however, our technology may in the future be found to infringe upon the rights ofothers. Others may assert infringement claims against us or against companies to which we have licensed our technology, and ifwe should be found to infringe upon their patents, or otherwise impermissibly utilize their intellectual property, our abilityto continue to use our technology could be materially restricted or prohibited. If this event occurs, we may be required to obtainlicenses from the holders of this intellectual property, enter into royalty agreements, or redesign our products so as not toutilize this intellectual property, each of which may prove to be uneconomical or otherwise impossible. Licenses or royalty agreementsrequired in order for us to use this technology may not be available on terms acceptable to us, or at all. These claims couldresult in litigation, which could materially adversely affect our business, prospects, financial condition and results of operations.Further, we may need to indemnify companies to which we licensed our technology in the event that such technology is found toinfringe upon the rights of others.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourcommercial success will also depend significantly on our ability to operate without infringing the patents and other proprietaryrights of third parties. Patent applications are, in many cases, maintained in secrecy until patents are issued. The publicationof discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlyingdiscoveries were made and patent applications are filed. In the event of infringement or violation of another party’s patent,we may be prevented from pursuing product development or commercialization. See “Item 1. Business—Description of Business—Patentsand Licenses.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Atpresent, our success depends primarily on the successful commercialization of our oral insulin capsule.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thesuccessful commercialization of our oral insulin capsule is crucial for our success. At present, our principal product is theoral insulin capsule. Our oral insulin capsule is in a clinical development stage and faces a variety of risks and uncertainties.Principally, these risks include the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Futureclinical trial results may show that the oral insulin capsule is not well tolerated by recipients at its effective doses or isnot efficacious as compared to placebo,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Futureclinical trial results may be inconsistent with previous preliminary testing results and data from our earlier studies may beinconsistent with clinical data,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 17; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Evenif our oral insulin capsule is shown to be safe and effective for its intended purposes, we may face significant or unforeseendifficulties in obtaining or manufacturing sufficient quantities or at reasonable prices,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ourability to complete the development and commercialization of the oral insulin capsule for our intended use is significantly dependentupon our ability to obtain and maintain experienced and committed partners to assist us with obtaining clinical and regulatoryapprovals for, and the manufacturing, marketing and distribution of, the oral insulin capsule on a worldwide basis,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Evenif our oral insulin capsule is successfully developed, commercially produced and receives all necessary regulatory approvals,there is no guarantee that there will be market acceptance of our product, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ourcompetitors may develop therapeutics or other treatments which are superior or less costly than our own with the result that ourproducts, even if they are successfully developed, manufactured and approved, may not generate significant revenues.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifwe are unsuccessful in dealing with any of these risks, or if we are unable to successfully commercialize our oral insulin capsulefor some other reason, it would likely seriously harm our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wehave limited experience in conducting clinical trials.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicaltrials must meet FDA and foreign regulatory requirements. We have limited experience in designing, conducting and managing thepreclinical studies and clinical trials necessary to obtain regulatory approval for our product candidates in any country. Wehave entered into agreements with Integrium LLC to assist us in designing, conducting and managing our various clinical trialsin the United States and Europe. Any failure of Integrium LLC or any other consultant to fulfill their obligations could resultin significant additional costs as well as delays in designing, consulting and completing clinical trials on our products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourclinical trials may encounter delays, suspensions or other problems.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wemay encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend or terminateour clinical trials at any phase. These problems could include the possibility that we may not be able to conduct clinical trialsat our preferred sites, enroll a sufficient number of patients for our clinical trials at one or more sites or begin or successfullycomplete clinical trials in a timely fashion, if at all. Furthermore, we, the FDA or foreign regulatory agencies may suspend clinicaltrials at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risksor if we or they find deficiencies in the clinical trial process or conduct of the investigation. If clinical trials of any ofthe product candidates fail, we will not be able to market the product candidate which is the subject of the failed clinical trials.The FDA and foreign regulatory agencies could also require additional clinical trials, which would result in increased costs andsignificant development delays. Our failure to adequately demonstrate the safety and effectiveness of a pharmaceutical productcandidate under development could delay or prevent regulatory approval of the product candidate and could have a material adverseeffect on our business, prospects, financial condition and results of operations. Finally, the COVID-19 pandemic has impactedclinical trials broadly. We may experience delays in site initiation and patient enrollment, failures to comply with study protocols,delays in the manufacture of our product candidates for clinical testing and other difficulties in starting or competing our clinicaltrials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Clinicaltrials of our products conducted by third parties may encounter delays, suspensions or other problems and are outside of our control.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thirdparties who conduct clinical trials of our products may encounter problems that may cause delays, suspensions or other problemsat any phase. These problems could include the possibility that they may not be able to conduct clinical trials at their preferredsites, enroll a sufficient number of patients for their clinical trials at one or more sites or begin or successfully completeclinical trials in a timely fashion, if at all. In addition, these third parties are not controlled by us and may conduct thesetrials in a manner in which we disagree or which may prove to be unsuccessful. Furthermore, domestic or foreign regulatory agenciesmay suspend clinical trials at any time if they believe the subjects participating in the trials are being exposed to unacceptablehealth risks or if they find deficiencies in the clinical trial process or conduct of the investigation. If such clinical trialsconducted by third parties fail, it could have a material adverse effect on our business, prospects, financial condition and resultsof operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 18; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wecan provide no assurance that our products will obtain regulatory approval or that the results of clinical studies will be favorable.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thetesting, marketing and manufacturing of any of our products will require the approval of the FDA or regulatory agencies of othercountries. We have completed certain non-FDA clinical trials and pre-clinical trials for our products. In addition, we have completeda Phase IIb clinical trial in patients with type 2 diabetes under an IND with the FDA and we have completed Phase IIa clinicaltrials of ORMD-0801 in patients with type 1 diabetes under an IND with the FDA. However, success in pre-clinical testing and earlyclinical trials does not ensure that later clinical trials will be successful. Even within a clinical trial there might be discrepanciesfrom statistically significant data, as occurred at two of the sites in the initial cohort of our Phase IIb trial, which we excludedwhile we investigate such discrepancies. For example, a number of companies in the pharmaceutical industry have suffered significantsetbacks in advanced clinical trials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wecannot predict with any certainty the amount of time necessary to obtain regulatory approvals, including from the FDA or otherforeign regulatory authorities, and whether any such approvals will ultimately be granted. In any event, review and approval bythe regulatory bodies is anticipated to take a number of years. Preclinical and clinical trials may reveal that one or more ofour products are ineffective or unsafe, in which event further development of such products could be seriously delayed or terminated.Moreover, obtaining approval for certain products may require the testing on human subjects of substances whose effects on humansare not fully understood or documented. Delays in obtaining necessary regulatory approvals of any proposed product and failureto receive such approvals would have an adverse effect on the product’s potential commercial success and on our business,prospects, financial condition and results of operations. In addition, it is possible that a product may be found to be ineffectiveor unsafe due to conditions or facts which arise after development has been completed and regulatory approvals have been obtained.In this event we may be required to withdraw such product from the market. See “Item 1. Business—Description of Business—GovernmentRegulation.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare dependent upon third party suppliers of our raw materials.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare dependent on outside vendors for our entire supply of the oral insulin and GLP-1 capsules and do not currently have any long-termagreements in place for the supply of oral insulin or GLP-1 capsules. While we believe that there are numerous sources of supplyavailable, if the third party suppliers were to cease production, including as a result of the COVID-19 pandemic, or otherwisefail to supply us with quality raw materials in sufficient quantities on a timely basis and we were unable to contract on acceptableterms for these services with alternative suppliers, our ability to produce our products and to conduct testing and clinical trialswould be materially adversely affected.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourfuture revenues from HTIT are dependent upon third party suppliers and Chinese regulatory approvals.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourfuture revenues from HTIT are dependent upon the achievement of certain milestones and conditions, and the success of HTIT toimplement our technology and to manufacture the oral insulin capsule. Our future revenues from HTIT are also dependent upon theability of third parties to scale-up one of our oral capsule ingredients and to scale-up the manufacturing process of our capsules.Our future revenues from royalties from HTIT are further dependent upon the granting of regulatory approvals in the Territory.Accordingly, if any of the foregoing does not occur, we may not be successful in receiving future revenues from HTIT and may notsucceed with our business plans in China.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         If we do not resolve our dispute withHTIT favorably, we may need to reverse deferred revenue of up to $2 million and may not receive an additional $4 million in royalties.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On August 21, 2020,we received a letter from HTIT, disputing certain pending payment obligations of HTIT under the TLA. We estimate this obligationto be between $2 million and $6 million. While we wholly dispute said claims and have been engaged in discussions and exchangeswith HTIT in an attempt to clarify and resolve disagreements between the parties regarding milestone payments and work plan implementation,we may be subsequently required to repay to HTIT up to $2 million, which has been received and has been included in our deferredrevenue in each of the consolidated balance sheets fiscal years ended August 31, 2020 and 2019. In addition, we may not receivean additional $4 million in Royalties if HTIT is entitled to the full disputed amount of $6 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare highly dependent upon our ability to enter into agreements with collaborative partners to develop, commercialize and marketour products.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our long-term strategy is to ultimately seek a strategic commercialpartner, or partners, such as large pharmaceutical companies, with extensive experience in the development, commercialization,and marketing of insulin applications and/or other orally digestible drugs. Although phase III clinical trials for our oral insulincandidate, ORMD-0801 will start without a partner, if we engage such a partner, we anticipate such partner or partners would beresponsible for, or substantially support, late stage clinical trials, and sales and marketing of our oral insulin capsule andother products. Such planned strategic partnership, or partnerships, may provide a marketing and sales infrastructure for our productsas well as financial and operational support for global clinical trials, post marketing studies, label expansions and other regulatoryrequirements concerning future clinical development in the United States and elsewhere. While our strategy is to partner with anappropriate party for our expected phase III clinical trials, no assurance can be given that any third party would be interestedin partnering with us. We currently lack the resources to manufacture any of our product candidates on a large scale and we haveno sales, marketing or distribution capabilities. In the event we are not able to enter into a collaborative agreement with a partner,or partners, on commercially reasonable terms, or at all, we may be unable to commercialize our products, which would have a materialadverse effect upon our business, prospects, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 19; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Thebiotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition.We may be unable to compete with more substantial enterprises.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thebiotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition.As a result, our products could become obsolete before we recoup any portion of our related research and development and commercializationexpenses. These industries are highly competitive, and this competition comes both from biotechnology firms and from major pharmaceuticaland chemical companies. Many of these companies have substantially greater financial, marketing and human resources than we do(including, in some cases, substantially greater experience in clinical testing, manufacturing and marketing of pharmaceuticalproducts). We also experience competition in the development of our products from universities and other research institutionsand compete with others in acquiring technology from such universities and institutions. In addition, certain of our productsmay be subject to competition from products developed using other technologies. See “Item 1. Business—Descriptionof Business—Competition.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wehave limited senior management resources and may be required to obtain more resources to manage our growth.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weexpect the expansion of our business to place a significant strain on our limited managerial, operational and financial resources.We will be required to expand our operational and financial systems significantly and to expand, train and manage our work forcein order to manage the expansion of our operations. Our failure to fully integrate our new employees into our operations couldhave a material adverse effect on our business, prospects, financial condition and results of operations. Our ability to attractand retain highly skilled personnel is critical to our operations and expansion. We face competition for these types of personnelfrom other technology companies and more established organizations, many of which have significantly larger operations and greaterfinancial, technical, human and other resources than we have. We may not be successful in attracting and retaining qualified personnelon a timely basis, on competitive terms or at all. If we are not successful in attracting and retaining these personnel, our business,prospects, financial condition and results of operations will be materially adversely affected. See “Item 7. Management’sDiscussion and Analysis of Financial Condition and Results of Operations,” “Item 1. Business—Description ofBusiness—Strategy” and “—Employees.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Wedepend upon our senior management and skilled personnel and their loss or unavailability could put us at a competitive disadvantage.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wecurrently depend upon the efforts and abilities of our senior executives, as well as the services of several key consultants andother key personnel, including Dr. Miriam Kidron, our Chief Scientific Officer. The loss or unavailability of the services ofany of these individuals for any significant period of time could have a material adverse effect on our business, prospects, financialcondition and results of operations. We do not maintain “key man” life insurance policies for any of our senior executives.In addition, recruiting and retaining qualified scientific personnel to perform future research and development work will be criticalto our success. There is currently a shortage of employees with expertise in developing, manufacturing and commercialization ofproducts and related clinical and regulatory affairs, and this shortage is likely to continue. Competition for skilled personnelis intense and turnover rates are high. Our ability to attract and retain qualified personnel may be limited. Our inability toattract and retain qualified skilled personnel would have a material adverse effect on our business, prospects, financial conditionand results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 20; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Healthcarepolicy changes, including pending legislation recently adopted and further proposals still pending to reform the U.S. healthcaresystem, may harm our future business.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Healthcarecosts have risen significantly over the past decade. There have been and continue to be proposals by legislators, regulators andthird-party payors to keep these costs down. Certain proposals, if passed, would impose limitations on the prices we will be ableto charge for the products that we are developing, or the amounts of reimbursement available for these products from governmentalagencies or third-party payors. These limitations could in turn reduce the amount of revenues that we will be able to generatein the future from sales of our products and licenses of our technology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         In2010, the federal government enacted healthcare reform legislation that has significantly impacted the pharmaceutical industry.In addition to requiring most individuals to have health insurance and establishing new regulations on health plans, this legislationrequires discounts under the Medicare drug benefit program and increased rebates on drugs covered by Medicaid. In addition, thelegislation imposes an annual fee, which has increased annually, on sales by branded pharmaceutical manufacturers. There can beno assurance that our business will not be materially adversely affected by these increased rebates, fees and other provisions.In addition, these and other initiatives in the United States may continue the pressure on drug pricing, especially under theMedicare and Medicaid programs, and may also increase regulatory burdens and operating costs. The announcement or adoption ofany such initiative could have an adverse effect on potential revenues from any product that we may successfully develop. An expansionin government’s role in the U.S. healthcare industry may lower the future revenues for the products we are developing andadversely affect our future business, possibly materially.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InSeptember 2017, members of the U.S. Congress introduced legislation with the announced intention to repeal and replace major provisionsof the Patient Protection and Affordable Care Act, or the ACA. In addition to those efforts, on October 12, 2017, President Trumpsigned an executive order that modified certain aspects of the ACA. Various litigation to invalidate parts of the ACA are pendingin court and, despite an upcoming change in presidential administration, attempts to repeal or to repeal and replace the ACA maycontinue. In addition, various other healthcare reform proposals have also emerged at the federal and state level. We cannot predictwhat healthcare initiatives, if any, will be implemented at the federal or state level, or the effect any future legislation orregulation will have on us.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare exposed to fluctuations in currency exchange rates.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Aconsiderable amount of our expenses are generated in dollars or in dollar-linked currencies, but a significant portion of ourexpenses such as some clinical studies and payroll costs are generated in other currencies such as NIS and Euro. Most of the time,our non-dollar assets are not totally offset by non-dollar liabilities. Due to the foregoing and to the fact that our financialresults are measured in dollars, our results could be adversely affected as a result of a strengthening or weakening of the dollarcompared to these other currencies. During the fiscal years ended August 31, 2016, 2017, 2019 and 2020, the dollar depreciatedin relation to the NIS, which raised the dollar cost of our Israeli based operations and adversely affected our financial results,while during the fiscal years ended August 31, 2015 and 2018 the dollar increased in relation to the NIS, which reduced the dollarcost of our Israeli based operations costs. In addition, our results could also be adversely affected if we are unable to guardagainst currency fluctuations in the future. Although we may in the future decide to undertake foreign exchange hedging transactionsto cover a portion of our foreign currency exchange exposure, we currently do not hedge our exposure to foreign currency exchangerisks. These transactions, however, may not adequately protect us from future currency fluctuations and, even if they do protectus, may involve operational or financing costs we would not otherwise incur.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          TheCOVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may materially and adversely affect ourbusiness and operations.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15pt 0pt 0; text-align: justify; text-indent: 0.5in">        The recentoutbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread globally, including to the United States,Israel and other European countries where we expected to initiate clinical trials. On March 11, 2020, the World Health Organizationdeclared the outbreak a pandemic. While COVID-19 is still spreading and the final implications of the pandemic are difficult toestimate at this stage, it is clear that it has affected the lives of a large portion of the global population. At this time, thepandemic has caused states of emergency to be declared in various countries, travel restrictions imposed globally, quarantinesestablished in certain jurisdictions and various institutions and companies being closed. On March 10, 2020, the Government ofIsrael announced that effective March 12, 2020 foreign travelers arriving from any country will be required to remain in home quarantineuntil 14 days have passed since the date of entry into Israel, and effective March 18, 2020, non-Israeli residents or citizens,except for non-nationals whose lives are based in Israel, are not allowed to enter Israel. In addition, the Ministry of Healthin the State of Israel issued guidelines on March 11, 2020, which were most recently updated in October 2020, recommending peopleavoid gatherings in one space and providing that no gathering of more than 10 people should be held under any circumstances.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15pt 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15pt 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 21; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15pt 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Employers(including us) are also required to prepare and increase as much as possible the capacity and arrangement for employees to workremotely. In addition, on March 11, 2020, the President of the United States issued a proclamation to restrict travel to the UnitedStates from foreign nationals who have recently been in certain European and Latin America countries. Although to date these restrictionshave not impacted our operations other than the delay of one of our trials, the effect on our business, from the spread of COVID-19and the actions implemented by the governments of the State of Israel, the United States and elsewhere across the globe, may worsenover time.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thespread of COVID-19 may also result in the inability of our suppliers to deliver supplies to us on a timely basis. In addition,health professionals may reduce staffing and reduce or postpone meetings with clients in response to the spread of an infectiousdisease. Though we have not yet experienced such events, if they would occur, they could result in a period of business disruption,and in reduced operations, any of which could materially affect our business, financial condition and results of operations. Although,as of the date of this Annual Report on Form 10-K, we do not expect any material impact on our long-term activity, the extentto which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted,including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat itsimpact, among others. We are actively monitoring the pandemic and we are taking any necessary measures to respond to the situationin cooperation with the various stakeholders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theoutbreak of COVID-19 may materially and adversely affect our clinical trial operations and our financial results.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theoutbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the UnitedStates, Israel and several European countries where we expected to initiate clinical trials. The extent to which COVID-19 mayimpact our clinical trial operations will depend on future developments, which are highly uncertain and cannot be predicted withconfidence, such as the duration of the outbreak, the severity of COVID-19, or the effectiveness of actions to contain and treatfor COVID-19. The continued spread of COVID-19 globally could adversely impact our clinical trial operations in the United States,Israel and in Europe, including our ability to recruit and retain patients and principal investigators and site staff who, ashealthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography or due to government orinstitutional quarantines or stay-at-home measures.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Moreover,COVID-19 may also affect employees of third-party contract research organizations located in affected geographies that we relyupon to carry out such enrollments and trials. Any negative impact COVID-19 has to patient enrollment or treatment could causecostly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and tocommercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          RisksRelated to our Common Stock         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Futuresales of our common stock by our existing stockholders could adversely affect our stock price.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The market price of ourcommon stock could decline as a result of sales of a large number of shares of our common stock in the market, or the perceptionthat these sales could occur. These sales also might make it more difficult for us to sell equity securities in the future ata time and at a price that we deem appropriate. As of November 24, 2020, we had outstanding 23,675,530 shares of common stock,a large majority of which are freely tradable. Giving effect to the exercise in full of all of our outstanding warrants, optionsand restricted stock units, or RSUs, including those currently unexercisable or unvested, we would have outstanding 28,948,286shares of common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 22; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourissuance of warrants, options and RSUs to investors, employees and consultants may have a negative effect on the trading pricesof our common stock as well as a dilutive effect.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have issued and maycontinue to issue warrants, options, RSUs and convertible notes at, above or below the current market price. As of November 24,2020, we had outstanding warrants and options exercisable for 3,407,819 shares of common stock at a weighted average exercise priceof $6.97. We also had outstanding RSUs exercisable for 164,636 shares of common stock at a total exercise price of $900. In additionto the dilutive effect of a large number of shares of common stock and a low exercise price for the warrants and options, thereis a potential that a large number of underlying shares of common stock may be sold in the open market at any given time, whichcould place downward pressure on the trading of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Becausewe will not pay cash dividends in the foreseeable future, investors may have to sell shares of our common stock in order to realizetheir investment.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave not paid any cash dividends on our common stock and do not intend to pay cash dividends in the foreseeable future. We intendto retain future earnings, if any, for reinvestment in the development and expansion of our business. Any credit agreements whichwe may enter into with institutional lenders or otherwise may restrict our ability to pay dividends. Whether we pay cash dividendsin the future will be at the discretion of our Board and will be dependent upon our financial condition, results of operations,capital requirements and any other factors that our Board decides is relevant.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Becausecertain of our stockholders control a significant number of shares of our common stock, they may have effective control over actionsrequiring stockholder approval.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof November 24, 2020, our directors, executive officers and principal affiliated stockholders beneficially own approximately 16.7%of our outstanding shares of common stock, excluding shares issuable upon the exercise of options, warrants and RSUs. As a result,these stockholders, should they act together, may have the ability to control the outcome of matters submitted to our stockholdersfor approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets.In addition, these stockholders, should they act together, may have the ability to control our management and affairs. Accordingly,this concentration of ownership might harm the market price of our common stock by:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Delaying,                                         deferring or preventing a change in corporate control,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Impeding                                         a merger, consolidation, takeover or other business combination involving us, or           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Discouraging                                         a potential acquirer from making a tender offer or otherwise attempting to obtain control                                         of us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          RisksRelated to Conducting Business in Israel         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Weare affected by the political, economic and military risks of having operations in Israel.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave operations in the State of Israel, and we are directly affected by political, economic and security conditions in that country.Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arabneighbors and a state of hostility, varying in degree and intensity, has led to security and economic problems for Israel. Inaddition, acts of terrorism, armed conflicts or political instability in the region could negatively affect local business conditionsand harm our results of operations. We cannot predict the effect on the region of any diplomatic initiatives or political developmentsinvolving Israel or the Palestinians or other countries and territories in the Middle East. Recent political events, includingpolitical uprisings, social unrest and regime change, in various countries in the Middle East and North Africa have weakened thestability of those countries and territories, which could result in extremists coming to power. In addition, Iran has threatenedto attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence amongextremist groups in the region, such as Hamas in Gaza and Hezbollah in Lebanon. This situation has escalated in the past and maypotentially escalate in the future to violent events which may affect Israel and us. Our business, prospects, financial conditionand results of operations could be materially adversely affected if major hostilities involving Israel should occur or if tradebetween Israel and its current trading partners is interrupted or curtailed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 23; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Alladult male permanent residents of Israel, unless exempt, may be required to perform military reserve duty annually. Additionally,all such residents are subject to being called to active duty at any time under emergency circumstances. Some of our officers,directors and employees currently are or in the future may be obligated to perform annual military reserve duty. We can provideno assurance that such requirements will not have a material adverse effect on our business, prospects, financial condition andresults of operations in the future, particularly if emergency circumstances occur.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Becausewe received grants from the Israel Innovation Authority of the Israeli Ministry of Economy &amp; Industry we are subject to ongoingrestrictions.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wereceived royalty-bearing grants from the Israel Innovation Authority of the Israeli Ministry of Economy &amp; Industry, or IIA,for research and development programs that meet specified criteria. We did not recognize any grants in fiscals 2020, 2019 and2018. We do not expect to receive further grants from the IIA in the future. The terms of the IIA grants limit our ability totransfer know-how developed under an approved research and development program outside of Israel, regardless of whether the royaltieswere fully paid.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Itmay be difficult to enforce a U.S. judgment against us or our officers and directors and to assert U.S. securities laws claimsin Israel.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Almostall of our directors and officers are nationals and/or residents of countries other than the United States. As a result, serviceof process upon us, our Israeli subsidiary and our directors and officers, may be difficult to obtain within the United States.Furthermore, because the majority of our assets and investments, and most of our directors and officers are located outside theUnited States, it may be difficult for investors to enforce within the United States any judgments obtained against us or anysuch officers or directors. Additionally, it may be difficult to assert U.S. securities law claims in original actions institutedin Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the mostappropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determinethat Israeli law and not U.S. law is applicable to such claim. If U.S. law is found to be applicable, the content of applicableU.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also begoverned by Israeli law.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Subjectto specified time limitations and legal procedures, under the rules of private international law currently prevailing in Israel,Israeli courts may enforce a U.S. judgment in a civil matter, including a judgment based upon the civil liability provisions ofthe U.S. securities laws, as well as a monetary or compensatory judgment in a non-civil matter, provided that the following keyconditions are met:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            subject                                         to limited exceptions, the judgment is final and non-appealable;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the                                         judgment was given by a court competent under the laws of the state in which the court                                         is located and is otherwise enforceable in such state;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the                                         judgment was rendered by a court competent under the rules of private international law                                         applicable in Israel;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the                                         laws of the state in which the judgment was given provides for the enforcement of judgments                                         of Israeli courts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            adequate                                         service of process has been effected and the defendant has had a reasonable opportunity                                         to present its arguments and evidence;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the                                         judgment and its enforcement are not contrary to the law, public policy, security or                                         sovereignty of the State of Israel;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the                                         judgment was not obtained by fraud and does not conflict with any other valid judgment                                         in the same matter between the same parties; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an                                         action between the same parties in the same matter was not pending in any Israeli court                                         at the time the lawsuit was instituted in the U.S. court.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifany of these conditions are not met, Israeli courts will likely not enforce the applicable U.S. judgment.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 24; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          GeneralRisk Factors         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Changesto tax laws could have a negative effect on us or our stockholders.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Atany time, the U.S. federal or state income tax laws, or the administrative interpretations of those laws, may be amended. Federaland state tax laws are constantly under review by persons involved in the legislative process, the U.S. Internal Revenue Service,the U.S. Department of the Treasury and state taxing authorities. Changes to the tax laws, regulations and administrative interpretations,which may have retroactive application, could adversely affect us.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Taxreform legislation in December 2017 made substantial changes to the Internal Revenue Code of 1986, as amended, or the Code, particularlyas it relates to the taxation of both corporate income and international income. Among those changes are a significant permanentreduction in the generally applicable corporate income tax rate and the modification of tax policies, credits and deductions forbusinesses and individuals. This legislation also imposes additional limitations on the deduction of net operating losses, whichcould negatively impact our ability to utilize our net operating losses to offset our taxable income in future taxable years.The effect of these and other changes made in this legislation is still uncertain in many respects, both in terms of their directeffect on the taxation of an investment in our securities and their indirect effect on the value of assets owned by us. Furthermore,many of the provisions of the new law will require additional guidance in order to assess their effect. It is also possible thatthere will be technical corrections or other legislation proposed with respect to the tax reform legislation, the effect of whichcannot be predicted and may be adverse to us or our stockholders. Further, a new presidential administration in 2021 may resultin additional amendments to the Code or reversal of 2017 changes. Our stockholders are encouraged to consult with their tax advisorsabout the potential effects that changes in law may have on them and their ownership of our securities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Asthe market price of our common stock may fluctuate significantly, this may make it difficult for you to sell your shares of commonstock when you want or at prices you find attractive.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theprice of our common stock is currently listed on Nasdaq and on the Tel Aviv Stock Exchange and constantly changes. In recent years,the stock market in general has experienced extreme price and volume fluctuations. We expect that the market price of our commonstock will continue to fluctuate. These fluctuations may result from a variety of factors, many of which are beyond our control.These factors include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Clinical                                         trial results and the timing of the release of such results,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The                                         amount of cash resources and our ability to obtain additional funding,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Announcements                                         of research activities, business developments, technological innovations or new products                                         by us or our competitors,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Entering                                         into or terminating strategic relationships,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Changes                                         in government regulation,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The                                         impact of the recent outbreak of COVID-19 on our business or on the economy generally,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Departure                                         of key personnel,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Disputes                                         concerning patents or proprietary rights,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Changes                                         in expense level,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future                                         sales of our equity or equity-related securities,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Public                                         concern regarding the safety, efficacy or other aspects of the products or methodologies                                         being developed,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Activities                                         of various interest groups or organizations,           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Media                                         coverage, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Statusof the investment markets.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 25; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Futuresales of common stock or the issuance of securities senior to our common stock or convertible into, or exchangeable or exercisablefor, our common stock could materially adversely affect the trading price of our common stock, and our ability to raise fundsin new equity offerings.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Futuresales of substantial amounts of our common stock or other equity-related securities in the public market or privately, or theperception that such sales could occur, could adversely affect prevailing trading prices of our common stock and could impairour ability to raise capital through future offerings of equity or other equity-related securities. We anticipate that we willneed to raise capital through offerings of equity and equity related securities. We can make no prediction as to the effect, ifany, that future sales of shares of our common stock or equity-related securities, or the availability of shares of common stockfor future sale, will have on the trading price of our common stock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourstockholders may experience significant dilution as a result of any additional financing using our equity securities.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Tothe extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Ourmanagement will have significant flexibility in using the net proceeds of any offering of securities.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weintend generally to use the net proceeds from any offerings of our securities for expenses related to our clinical trials, researchand product development activities, and for general corporate purposes, including general working capital purposes. Our managementwill have significant flexibility in applying the net proceeds of any such offering. The actual amounts and timing of expenditureswill vary significantly depending on a number of factors, including the amount of cash used in our operations and our researchand development efforts. Management’s failure to use these funds effectively would have an adverse effect on the value ofour common stock and could make it more difficult and costly to raise funds in the future.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Delawarelaw could discourage a change in control, or an acquisition of us by a third party, even if the acquisition would be favorableto you, and thereby adversely affect existing stockholders.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheDelaware General Corporation Law contains provisions that may have the effect of making more difficult or delaying attempts byothers to obtain control of our Company, even when these attempts may be in the best interests of stockholders. Delaware law imposesconditions on certain business combination transactions with “interested stockholders.” These provisions and othersthat could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in our control or management,including transactions in which stockholders might otherwise receive a premium for their shares of common stock over then currentmarket prices. These provisions may also limit the ability of stockholders to approve transactions that they may deem to be intheir best interests.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_004">          </a>          ITEM1B. UNRESOLVED STAFF COMMENTS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Notapplicable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_005">          </a>          ITEM2. PROPERTIES.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that our existing facilities are suitable and adequate to meet our current business requirements. In the event that weshould require additional or alternative facilities, we believe that such facilities can be obtained on short notice at competitiverates.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_006">          </a>          ITEM3. LEGAL PROCEEDINGS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Fromtime to time we may become subject to litigation incidental to our business. We are not currently a party to any material legalproceedings.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_007">          </a>          ITEM4. MINE SAFETY DISCLOSURES.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Notapplicable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 26; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-align: center; margin-top: 0; margin-bottom: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-align: center; margin-top: 0; margin-bottom: 0">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <a name="a_008">          </a>          PARTII         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_009">          </a>          ITEM5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          MarketPrice for our Common Stock         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourcommon stock is traded on Nasdaq and on the Tel Aviv Stock Exchange, in each case under the symbol “ORMP.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Holders         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof November 24, 2020, there were 23,675,530 shares of our common stock issued and outstanding held of record by approximately36 registered stockholders. We believe that a significant number of stockholders hold their shares of our common stock in brokerageaccounts and registered in the name of stock depositories and are therefore not included in the number of stockholders of record.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          UnregisteredSales of Equity Securities and Use of Proceeds         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Nounregistered sales of equity securities were made during the three months ended August 31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_010">          </a>          ITEM6. SELECTED FINANCIAL DATA.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theselected data presented below under the captions Statements of Comprehensive Loss and Balance Sheet for, and as of the end of,each of the fiscal years in the five-year period ended August 31, 2020, are derived from, and should be read in conjunction with,our audited consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theselected information contained in this table should also be read in conjunction with “Management’s Discussion andAnalysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes theretoincluded elsewhere in this Annual Report on Form 10-K. The selected consolidated statements of comprehensive loss data for fiscals2020 and 2019 and the selected consolidated balance sheet data as of August 31, 2020 and 2019, are derived from the audited consolidatedfinancial statements included elsewhere in this Annual Report. The statement of operations data for the years ended August 31,2018, 2017 and 2016 and the balance sheet data as of August 31, 2018, 2017 and 2016 are derived from financial statements notincluded in this Annual Report. The historical results presented below are not necessarily indicative of future results.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             For    the year ended             <br/>             August 31,            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019*           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2017           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2016           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="18" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (in    thousands except share and per share data)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Statements    of Comprehensive Loss:            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Revenues           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,710           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,703           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,449           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,456           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            641           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cost    of revenues (income)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            90           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (86           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            187           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            490           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Research    and development expenses           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,235           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,522           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,979           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,281           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,709           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            General    and administrative expenses           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,232           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,722           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,083           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,759           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,452           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial    income           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            690           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,061           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            903           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            792           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            474           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Financial    expenses           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            444           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            485           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            103           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            93           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss    before taxes on income           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,511           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14,055           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12,727           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,080           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,629           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Taxes    on income           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            300           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            400           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,335           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net    loss for the year           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,511           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14,355           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12,727           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,480           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,964           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss    per common share – basic and diluted           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.56           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.82           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.86           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.79           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.87           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted    average common shares outstanding           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,532,347           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17,454,489           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14,882,356           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,309,372           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12,624,           </font>           <font style="font-family: Times New Roman, Times, Serif">            356           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 27; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             As    of             <br/>             August 31,            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019*           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2017           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2016           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="18" style="text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            (in thousands of dollars           </font>           )          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Balance Sheet Data:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash, cash    equivalents, short-term deposits, restricted cash and marketable securities           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            39,900           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32,282           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            30,463           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,138           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31,032           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other current assets           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            611           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,042           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            574           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            159           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            198           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long-term deposits    and other assets           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,575           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            16,262           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,070           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long-term marketable    securities           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,928           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,295           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,785           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,151           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            530           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total assets           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            44,633           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            34,663           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47,397           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            38,712           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            42,830           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Current liabilities           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,536           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,308           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,553           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,165           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,621           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long-term liabilities           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,218           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,962           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,732           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14,309           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,019           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stockholders’    equity           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32,879           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            19,393           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31,112           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            19,238           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            26,190           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Asdiscussed in Note 1(k) to our audited consolidated financial statements included in this Annual Report on Form 10-K, the Companychanged the manner in which it accounts for revenues from contracts with customers during fiscal 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_011">          </a>          ITEM7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing discussion and analysis of our financial condition and results of operations should be read in conjunction with theconsolidated financial statements and the related notes included elsewhere herein and in our consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inaddition to our consolidated financial statements, the following discussion contains forward-looking statements that reflect ourplans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements.Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Reporton Form 10-K, particularly in “Cautionary Statement Regarding Forward-Looking Statements” and “Item 1A. RiskFactors.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Overviewof Operations         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, includingan orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestiblecapsules or pills for delivery of other polypeptides. An overview of our current clinical studies can be found in “Item1. Business - Research and Development.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Resultsof Operations         </b>        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Criticalaccounting policies          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Oursignificant accounting policies are more fully described in the notes to our accompanying consolidated financial statements. Webelieve that the accounting policies below are critical for one to fully understand and evaluate our financial condition and resultsof operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thediscussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,which we prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of our consolidatedfinancial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilitiesand the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reportedrevenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments. We base ourestimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the resultsof which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparentfrom other sources. Actual results may differ from these estimates under different assumptions or conditions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 28; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Valuationof options and warrants          </i>         </b>         : We grant options to purchase shares of our common stock to employees and consultants and haveand may in the future issue warrants in connection with some of our financings and to certain other consultants.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weaccount for share-based payments to employees, directors and consultants in accordance with the guidance that requires awardsclassified as equity awards to be accounted for using the grant-date fair value method. The fair value of share-based paymenttransactions is based on the Black Scholes option-pricing model or Monte Carlo model when appropriate and is recognized as anexpense over the vesting period.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weelected to recognize compensation cost for awards to employees, directors and consultants that have a graded vesting scheduleusing the accelerated method based on the multiple-option award approach.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Revenuerecognition          </i>         </b>         : Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks andrewards for the products are transferred to the customer and collection is reasonably assured.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         UnderAccounting Standards Codification, or ASC, 605 (which was the authoritative revenue recognition guidance applied for all periodsprior to September 1, 2018) given our continuing involvement through the expected product submission in June 2023, amounts receivedrelating to the License Agreement were recognized over the period from which we were entitled to the respective payment, and theexpected product submission date using a time-based model approach over the periods that the fees were earned.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         However,under ASC 606, we are required to recognize the total transaction price (which includes consideration related to milestones oncethe criteria for recognition have been satisfied) using the input method over the period the performance obligation is fulfilled.Accordingly, once the consideration associated with a milestone is included in the transaction price, incremental revenue is recognizedimmediately based on the period of time that has elapsed towards complete satisfaction of the performance obligation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Sincethe customer benefits from the services as the entity performs, revenue is recognized over time through the expected product submissiondate in June 2023, using the input method. The Company used the input method to measure the process for the purpose of recognizingrevenue, which approximates the straight line attribution. The Company used significant judgment when it determined the productsubmission date.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         UnderASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingentupon the occurrence of future events, are a form of variable consideration. When assessing the portion, if any, of such milestones-relatedconsideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone andexcludes the consideration related to milestones of which the occurrence is not considered the most likely outcome.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompany then evaluates if any of the variable consideration determined in the first step is constrained by including in the transactionprice variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenuerecognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Companyused significant judgment when it determined the first step of variable consideration.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 29; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Comparisonof Fiscal 2020 to Fiscal 2019          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table summarizes certain statements of operations data for us for the twelve month periods ended August 31, 2020 and2019:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <p style="margin-top: 0; margin-bottom: 0">            Year ended           </p>           <p style="margin-top: 0; margin-bottom: 0">            August 31,           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">           Operating Data:          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            (dollar amounts in thousands)           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%">           Revenues          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,710          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,703          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">           Cost of revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           90          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Research and development expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10,235          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,522          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           General and administrative expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,232          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,722          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Financial income, net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           246          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           576          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Loss before taxes on income          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11,511          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,055          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Taxes on income          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           300          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Net loss for the year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           11,511          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           14,355          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Loss per common share – basic and diluted          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           0.56          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           0.82          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           Weighted average common shares outstanding          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           20,532,347          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           17,454,489          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Revenues          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Revenuesconsist of proceeds related to the License Agreement that are recognized over the period from which the Company is entitled tothe respective payments and through June 2023.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Revenuesfor fiscal 2020 totaled $2,710,000, consistent with $2,703,000 for fiscal 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Costof revenues          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Costof revenues consists of royalties related to the License Agreement that will be paid over the term of the License Agreement inaccordance with revenue recognition accounting and the Law for the Encouragement of Industrial Research, Development and TechnologicalInnovation, 1984, as amended, including any regulations or tracks promulgated thereunder, or the R&amp;D Law.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Costof revenues for fiscal 2020 decreased to no expense compared to expense of $90,000 for fiscal 2019. The decrease is attributableto a milestone payment which was received during fiscal 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Researchand development expenses          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Researchand development expenses include costs directly attributable to the conduct of research and development programs, including thecost of salaries, employee benefits, costs of materials, supplies, the cost of services provided by outside contractors, includingservices related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research andpreclinical development. All costs associated with research and development are expensed as incurred.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicaltrial costs are a significant component of research and development expenses and include costs associated with third-party contractors.We outsource a substantial portion of our clinical trial activities, utilizing external entities such as CROs, independent clinicalinvestigators and other third-party service providers to assist us with the execution of our clinical studies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicalactivities which relate principally to clinical sites and other administrative functions to manage our clinical trials are performedprimarily by CROs. CROs typically perform most of the start-up activities for our trials, including document preparation, siteidentification, screening and preparation, pre-study visits, training and program management.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 30; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Clinicaltrial and pre-clinical trial expenses include regulatory and scientific consultants’ compensation and fees, research expenses,purchase of materials, cost of manufacturing of the oral insulin and exenatide capsules, payments for patient recruitment andtreatment, as well as salaries and related expenses of research and development staff.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         FromAugust 2009 to March 2014, Oramed Ltd. was awarded five government grants amounting to a total net amount of NIS 8 million (approximately$2,194,000) from the IIA. We used the funds to support further research and development and clinical studies of our oral insulincapsule and oral GLP-1 analog during the period from February 2009 to December 2014. The five grants are subject to repaymentaccording to the terms determined by the IIA and applicable law. See “—Government grants” below.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        Research and developmentexpenses for fiscal 2020 decreased by 24% to $10,235,000 from $13,522,000 for fiscal 2019. The decrease is mainly attributed toexpenses related to our Phase IIb three-month dose-ranging clinical trial which was terminated during fiscal 2020 and is partiallyoffset by an increase in regulatory expenses and an increase in raw material expenses related to our phase III trial. During fiscal2020, stock-based compensation costs totaled $458,000, as compared to $218,000 during fiscal 2019. The increase is mainly attributableto new grants in fiscal 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Governmentgrants          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheGovernment of Israel encourages research and development projects through the IIA, pursuant to the R&amp;D Law. Under the R&amp;DLaw, a research and development plan that meets specified criteria is generally eligible for a grant of up to 50% of certain approvedresearch and development expenditures. Each plan must be approved by the IIA.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Infiscals 2020 and 2019, we did not recognize any research and development grants. As of August 31, 2020, our liability to pay royaltiesto the IIA was $317,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Underthe terms of the grants we received from the IIA, we are obligated to pay royalties of 3% on all revenues derived from the saleof the products developed pursuant to the funded plans, including revenues from licensed ancillary services. Royalties are generallypayable up to a maximum amount equaling 100% of the grants received (dollar linked) with the addition of interest at an annualrate based on the LIBOR rate.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheR&amp;D Law generally requires that a product developed under a program be manufactured in Israel. However, when applying fora grant, the applicant may declare that part of the manufacturing will be performed outside of Israel or by non-Israeli residentsand if the IIA is convinced that performing some of the manufacturing abroad is essential for the execution of the program, itmay still approve the grant. This declaration will be a significant factor in the determination of the IIA as to whether to approvea program and the amount and other terms of the benefits to be granted. If a company wants to increase the volume of manufacturingoutside of Israel after the grant has been approved, it may transfer up to 10% of the company’s approved Israeli manufacturingvolume, measured on an aggregate basis, outside of Israel after first notifying the IIA thereof (provided that the IIA does notobject to such transfer within 30 days). In addition, upon the approval of the IIA, a portion greater than 10% of the manufacturingvolume may be performed outside of Israel. In any case of transfer of manufacturing out of Israel, the grant recipient is requiredto pay royalties at an increased rate, which may be substantial, and the aggregate repayment amount is increased up to 120%, 150%or 300% of the grant, depending on the portion of the total manufacturing volume that is performed outside of Israel. The approvalwe received from the IIA for the License Agreement was subject to payment of increased royalties and an increased ceiling, allin accordance with the provisions of the R&amp;D Law. The R&amp;D Law further permits the IIA, among other things, to approvethe transfer of manufacturing rights outside of Israel in exchange for the import of different manufacturing into Israel as asubstitute, in lieu of the increased royalties.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheR&amp;D Law also provides that know-how developed under an approved research and development program may not be transferred orlicensed to third parties in Israel without the approval of the research committee. Such approval is not required for the saleor export of any products resulting from such research or development. The R&amp;D Law further provides that the know-how developedunder an approved research and development program may not be transferred or licensed to any third parties outside Israel absentIIA approval which may be granted in certain circumstances as follows: (a) the grant recipient pays to the IIA a portion of thesale or license price paid in consideration for the purchase or license of such IIA-funded know-how or the price paid in considerationfor the sale of the grant recipient itself, as the case may be, in accordance with certain formulas included in the R&amp;D Law;(b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; or (c) such transfer ofIIA-funded know-how is made in the context of IIA approved research and development cooperation projects or consortia.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 31; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheR&amp;D Law imposes reporting requirements with respect to certain changes in the ownership of a grant recipient. The R&amp;DLaw requires the grant recipient to notify the IIA of any change in control of the recipient or a change in the holdings of themeans of control of the recipient that results in a non-Israeli entity becoming an interested party in the recipient, and requiresthe new non-Israeli interested party to undertake to the IIA to comply with the R&amp;D Law. In addition, the rules of the IIAmay require the provision of additional information or representations in respect of certain such events. For this purpose, “control”is defined as the ability to direct the activities of a company other than any ability arising solely from serving as an officeror director of the company. A person is presumed to have control if such person holds 50% or more of the means of control of acompany. “Means of control” refers to voting rights or the right to appoint directors or the chief executive officer.An “interested party” of a company includes a holder of 5% or more of its outstanding share capital or voting rights,its chief executive officer and directors, someone who has the right to appoint its chief executive officer or at least one director,and a company with respect to which any of the foregoing interested parties holds 25% or more of the outstanding share capitalor voting rights or has the right to appoint 25% or more of the directors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Failureto meet the R&amp;D Law’s requirements may subject us to mandatory repayment of grants received by us (together with interestand penalties), as well as expose us to criminal proceedings. In addition, the Israeli government may from time to time auditsales of products which it claims incorporate technology funded through IIA programs which may lead to additional royalties beingpayable on additional products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Generaland administrative expenses          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Generaland administrative expenses include the salaries and related expenses of our management, consulting costs, legal and professionalfees, travel expenses, business development costs, insurance expenses and other general costs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        General and administrativeexpenses increased by 14% from $3,722,000 for fiscal 2019 to $4,232,000 for fiscal 2020. The increase in costs incurred relatedto general and administrative activities during fiscal 2020, is primarily attributable to an increase in costs related to the directorsand officers insurance policy and an increase in legal expenses and increase in stock-based compensation costs and is partiallyoffset by a decrease in travel expenses and a decrease in costs related to patents. During fiscal 2020, as part of our generaland administrative expenses, we incurred expenses of $714,000 related to stock-based compensation costs, as compared to an expenseof $591,000 during fiscal 2019. The increase is mainly attributable to new grants during fiscal 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Financialincome, net          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Netfinancial income, was $246,000 for fiscal 2020 as compared to net financial income of $576,000 for fiscal 2019. The decrease ismainly attributable to a decrease in the fair market value of some investments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Taxeson income          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Notaxes on income were recognized for fiscal 2020 as compared to $300,000 for fiscal 2019. The decrease is due to withholding taxesin connection with the receipt of a milestone payment pursuant to the License Agreement during 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Fiscal2019 compared with Fiscal 2018         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Fora discussion of fiscal 2019 compared with fiscal 2018, see Management’s Discussion and Analysis of Financial Condition andResults of Operations included in our Annual Report on Form 10-K for the fiscal year ended August 31, 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Liquidityand Capital Resources         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Fromour inception through August 31, 2020, we have incurred losses in an aggregate amount of $92,614,000. During that period we havefinanced our operations through several private placements of our common stock, as well as public offerings of our common stock,raising a total of $101,509,000, net of transaction costs. During that period we also received cash consideration of $5,892,000from the exercise of warrants and options. We will seek to obtain additional financing through similar sources in the future asneeded. As of August 31, 2020, we had $19,296,000 of available cash, $11,060,000 of short term deposits and $13,472,000 of marketablesecurities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 32; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Managementcontinues to evaluate various financing alternatives for funding future research and development activities and general and administrativeexpenses through fundraising in the public or private equity markets. Although there is no assurance that we will be successfulwith those initiatives, management believes that it will be able to secure the necessary financing as a result of future thirdparty investments. Based on our current cash resources and commitments, we believe we will be able to maintain our current planneddevelopment activities and the corresponding level of expenditures for at least the next 12 months.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof August 31, 2020, our total current assets were $40,511,000 and our total current liabilities were $4,536,000. On August 31,2020, we had a working capital surplus of $35,975,000 and an accumulated loss of $92,614,000. As of August 31, 2019, our totalcurrent assets were $33,324,000 and our total current liabilities were $5,308,000. On August 31, 2019, we had a working capitalsurplus of $28,016,000 and an accumulated loss of $81,103,000. The increase in working capital surplus from August 31, 2019 toAugust 31, 2020 was primarily due to an increase in cash and cash equivalents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringfiscal 2020, cash and cash equivalents increased to $19,296,000 from $3,329,000 as of August 31, 2019, which is due to the reasonsdescribed below.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Operatingactivities used cash of $12,440,000 in fiscal 2020 compared to $12,940,000 used in fiscal 2019. Cash used in operating activitiesin fiscal 2020 and 2019 primarily consisted of net loss resulting from research and development and general and administrativeexpenses and changes in stock based compensation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Investingactivities provided cash of $4,626,000 in fiscal 2020, as compared to $11,259,000 used in fiscal 2019. Cash provided in investingactivities in fiscal 2020 consisted primarily of the proceeds from short term deposits and redemption of held to maturity securities,partially offset by the acquisition of short and long terms marketable securities, while cash used in investing activities infiscal 2019 consisted primarily of the proceeds from short term deposits, partially offset by the acquisition of short and longterm marketable securities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Financingactivities provided cash of $23,786,000 in fiscal 2020, as compared to no financing activities in fiscal 2019. Cash provided byfinancing activities during fiscal 2020 consisted of proceeds from our issuance of common stock and warrants and proceeds fromexercise of warrants and options. Our primary financing activities in fiscal 2020 were as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During                                         fiscal 2020, no warrants were exercised and 12,253 options were exercised for cash and                                         resulted in the issuance of 12,253 shares of common stock. The cash consideration received                                         for the exercise of options was $12,253. During fiscal 2019, no warrants or options were                                         exercised.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In                                         September and November 2019 and February and May 2020, we issued a total of 10,000 shares                                         of our common stock, valued approximately $38,000, in the aggregate, to certain service                                         providers as remuneration for services rendered.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         September 5, 2019, we entered into an Equity Distribution Agreement, or the Sales Agreement,                                         pursuant to which we may, from time to time and at our option, issue and sell shares                                         of our common stock having an aggregate offering price of up to $15,000,000 through a                                         sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant                                         to our effective shelf registration statement on Form S-3 including a prospectus and                                         prospectus supplement, each dated February 10, 2020 (which superseded a prior registration                                         statement, prospectus and prospectus supplement that related to shares sold under the                                         Sales Agreement). We will pay the sales agent a cash commission of 3.0% of the gross                                         proceeds of the sale of any shares sold through the sales agent under the Sales Agreement.                                         As of August 31, 2020, 839,537 shares were issued under the Sales Agreement for aggregate                                         net proceeds of $3,879,000.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         February 27, 2020, we entered into an underwriting agreement with National Securities                                         Corporation, or the Underwriter, in connection with a public offering, or the Offering                                         of 5,250,000 shares of our common stock, at an offering price of $4.00 per share. We                                         also granted the Underwriter a 45-day option to purchase from us up to an additional                                         787,500 shares of common stock at the public offering price, or the Over-Allotment Option.                                         In connection with the Offering, we also agreed to issue to the Underwriter, or its designees,                                         warrants, or the Underwriter’s Warrants, to purchase up to an aggregate of 7% of                                         the shares of common stock sold in the Offering (including any additional shares sold                                         during the 45-day option period), at an exercise price of $4.80 per share. The Underwriter’s                                         Warrants issued in the Offering will be exercisable at any time and from time to time,                                         in whole or in part, commencing six months from issuance for a period of three years                                         from the date of issuance. The closing of the sale of the Offering occurred on March                                         2, 2020. On April 9, 2020, we issued 180,561 shares of our common stock and 12,640 Underwriter’s                                         Warrants pursuant to a partial exercise by the Underwriter of the Over-Allotment Option,                                         or the Partial Over-Allotment Option Exercise. The net proceeds to us from the Offering,                                         including from the Partial Over-Allotment Option Exercise, after deducting the underwriting                                         discount and our Offering expenses were $19,894,000.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 33; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ContractualObligations         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table summarizes our significant contractual obligations and commercial commitments at August 31, 2020, and the effectssuch obligations are expected to have on our liquidity and cash flows in future periods (in thousands):        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">           Contractual Obligations          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Less than           <br/>           1 year          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           1-3 years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           3-5 years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Over           <br/>           5 years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">           Clinical research study obligations          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           4,801          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,967          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           1,834          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Operating lease obligations          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           698          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           147          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           292          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           259          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Royalty payment obligations          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           289          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           81          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           208          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Accrued severance pay, net          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           18          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           18          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           5,806          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           3,195          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           2,334          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           259          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           18          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Off-BalanceSheet Arrangements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof August 31, 2020, we had no off balance sheet arrangements that have had or that we expect would be reasonably likely to havea future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,liquidity, capital expenditures or capital resources.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          PlannedExpenditures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weinvest heavily in research and development, and we expect that in the upcoming years our research and development expenses, net,will continue to be our major operating expense.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_012">          </a>          ITEM7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weare exposed to a variety of risks, including changes in interest rates, foreign currency exchange rates, changes in the valueof our marketable securities and inflation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asof August 31, 2020, we had $19.3 million in cash and cash equivalents, $11 million in short term bank deposits and $13.5 millionin marketable securities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weaim to preserve our financial assets, maintain adequate liquidity and maximize return while minimizing exposure to market risks.Such policy further provides that we should hold most of our current assets in bank deposits. As of today, the currency of ourfinancial assets is mainly in U.S. dollars.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Marketablesecurities         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weown 1,701,357         <sup>          1         </sup>         common shares of D.N.A,117,000 ordinary shares of Entera and other tradable mutual funds which arepresented in our financial statements as marketable securities. Marketable securities are presented at fair value and their realizationis subject to certain limitations if sold through the market, and we are therefore exposed to market risk. There is no assurancethat at the time of sale of the marketable securities the price per share will be the same or higher, nor that we will be ableto sell all of the securities at once given the volume of securities we hold. Entera shares are traded on Nasdaq in U.S. dollars,while D.N.A shares are traded on the Tel Aviv Stock Exchange and the D.N.A shares’ price is denominated in NIS. We are alsoexposed to changes in the market price of the Entera and D.N.A shares, as well as to exchange rates fluctuations in the NIS currencycompared to the U.S. dollar with respect to the D.N.A shares.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             1            </sup>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            OnNovember 10, 2019, D.N.A announced a reverse split so that every 6 common shares will become 1 common share. Consequently, our10,208,144 shares become 1,701,357 shares.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 34; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          InterestRate Risk         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weinvest a major portion of our cash surplus in bank deposits in banks in Israel. Since the bank deposits typically carry fixedinterest rates, financial income over the holding period is not sensitive to changes in interest rates, but only the fair valueof these instruments. However, our interest gains from future deposits may decline in the future as a result of changes in thefinancial markets. In any event, given the historic low levels of the interest rate, we estimate that a further decline in theinterest rate we are receiving will not result in a material adverse effect to our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          ForeignCurrency Exchange Risk and Inflation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asignificant portion of our expenditures, including salaries, clinical research expenses, consultants’ fees and office expensesrelate to our operations in Israel. The cost of those Israeli operations, as expressed in U.S. dollars, is influenced by the extentto which any increase in the rate of inflation in Israel is not offset (or is offset on a lagging basis) by a devaluation of theNIS in relation to the U.S. dollar. If the U.S. dollar declines in value in relation to the NIS, it will become more expensivefor us to fund our operations in Israel. In addition, as of August 31, 2020, we own net balances in NIS of approximately $160,000.Assuming a 10% appreciation of the NIS against the U.S. dollar, we would experience exchange rate gain of approximately $18,000,while assuming a 10% devaluation of the NIS against the U.S. dollar, we would experience an exchange rate loss of approximately$15,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theexchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year Ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2018          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%">           Average rate for period          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3.490          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3.623          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3.544          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">           Rate at period-end          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.326          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.535          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.604          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wedo not use any currency hedging transactions of options or forwards to decrease the risk of financial exposure from fluctuationsin the exchange rate of the U.S. dollar against the NIS.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_013">          </a>          ITEM8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         SeeItem 15 of this Annual Report on Form 10-K.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_014">          </a>          ITEM9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         None.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_015">          </a>          ITEM9A. CONTROLS AND PROCEDURES.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          DisclosureControls and Procedures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourmanagement, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controlsand procedures as of August 31, 2020. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concludedthat our disclosure controls and procedures are effective.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 35; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Management’sAnnual Report on Internal Control over Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourmanagement, under the supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishingand maintaining adequate internal control over our financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgatedunder the Exchange Act. The Company’s internal control over financial reporting is defined as a process designed to providereasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with GAAP. Internal control over financial reporting includes policies and procedures that:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            pertain                                         to the maintenance of records that in reasonable detail accurately and fairly reflect                                         our transactions and asset dispositions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provide                                         reasonable assurance that transactions are recorded as necessary to permit the preparation                                         of our financial statements in accordance with GAAP, and that our receipts and expenditures                                         are being made only in accordance with authorizations of our management and directors;                                         and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provide                                         reasonable assurance regarding the prevention or timely detection of unauthorized acquisition,                                         use or disposition of assets that could have a material effect on our financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Underthe supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,we evaluated the effectiveness of our internal control over financial reporting as of August 31, 2020 based on the current frameworkfor Internal Control-Integrated Framework (2013) set forth by The Committee of Sponsoring Organizations of the Treadway Commission.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Basedon this evaluation, our management concluded that the Company’s internal control over financial reporting was effectiveas of August 31, 2020 at a reasonable assurance level.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Changesin Internal Control over Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Therewere no changes in our internal control over financial reporting that occurred during the quarter ended August 31, 2020 that havematerially affected, or are reasonable likely to materially affect, our internal control over financial reporting.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_016">          </a>          ITEM9B. OTHER INFORMATION.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Notapplicable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 36; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_017">          </a>          PARTIII         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_018">          </a>          ITEM10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Setforth below is certain information with respect to the individuals who are our directors and executive officers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; width: 15%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; width: 74%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Position            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nadav Kidron           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            46           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President, Chief Executive Officer and Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Miriam Kidron           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            80           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Scientific Officer and Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Avraham Gabay           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            35           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer, Treasurer and Secretary           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Joshua Hexter           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Operating &amp; Business Officer           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Aviad Friedman           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            49           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Arie Mayer           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            64           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Kevin Rakin           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            60           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman, Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Leonard Sank           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gao Xiaoming           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>          <td>          </td>          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Dr.Miriam Kidron is Mr. Nadav Kidron’s mother. There are no other directors or officers of the Company who are related by bloodor marriage.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 37; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          BusinessExperience         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing is a brief account of the education and business experience during at least the past five years of each director andour executive officers who are not also directors, indicating the principal occupation during that period, and the name and principalbusiness of the organization in which such occupation and employment were carried out.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Nadav Kidron          </i>         </b>         was appointed         <b>          <i>           President, Chief Executive Officer          </i>         </b>         and a         <b>          <i>           director          </i>         </b>         in March 2006.He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd.In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003,he was a legal intern at Wine, Mishaiker &amp; Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an InternationalMBA from Bar Ilan University, Israel, and is a member of the Israel Bar Association.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Mr. Kidron’s qualifications to serve on our Board include his familiarity with the Company as its founder,his experience in capital markets, as well as his knowledge and familiarity with corporate management.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Miriam Kidron          </i>         </b>         was appointed         <b>          <i>           Chief Scientific Officer          </i>         </b>         and a         <b>          <i>           director          </i>         </b>         in March 2006. Dr. Kidronis a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in theDiabetes Unit at Hadassah University Hospital in Jerusalem, Israel. During 2003 and 2004, Dr. Kidron served as a consultant toEmisphere Technologies Inc., a company that specializes in developing broad-based proprietary drug delivery platforms. Dr. Kidronwas formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American,European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Dr. Kidron’s qualifications to serve on our Board include her expertise in the Company’s technology,as it is based on her research, as well as her experience and relevant education in the fields of pharmacology and diabetes.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Avraham Gabay          </i>         </b>         was appointed         <b>          <i>           Chief Financial Officer, Treasurer and Secretary          </i>         </b>         effective June 2019. Priorto his appointment, from 2015 until 2019, Mr. Gabay served as a corporate controller at Orcam Technologies Ltd., a company whichdevelops, manufactures and sells a wearable assistive technology device for people who are blind, visually impaired or have readingor other disabilities. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certifiedpublic accounting firm. From 2013 until 2014, Mr. Gabay worked in the tax department of the law firm, Gornitzky &amp; Co. Mr.Gabay holds a bachelor’s degree in law and accounting from Tel-Aviv University and is a certified public accountant in Israeland a member of the Israeli Bar Association.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Joshua Hexter          </i>         </b>         was appointed         <b>          <i>           Chief Operating &amp; Business Officer          </i>         </b>         , effective September 2019. Prior to hisappointment, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, commercial stagemedical device company focused on the development and sale of non-invasive neuromodulation products. From 2013 to 2018, Mr. Hexterserved as Chief Operating Officer and VP Business Development of the Company and from 2007 to 2013, Mr. Hexter was a Directoror Executive Director of BioLineRx Ltd. (Nasdaq/TASE: BLRX), a biopharmaceutical development company dedicated to identifying,in-licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was a memberof the board of directors and Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market-driven biosensors.Mr. Hexter holds a bachelor’s degree from the University of Wisconsin and a master’s degree in management from BostonUniversity.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 38; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Aviad Friedman          </i>         </b>         became a         <b>          <i>           director          </i>         </b>         in August 2016. Mr. Friedman is an international businessman. Since 2007,he has been Chief Executive Officer of Most Properties 1998 Ltd. Mr. Friedman was the first Director General of Israel’sMinistry of Diaspora Affairs and served as personal advisor to Prime Minister Ariel Sharon from 2001 to 2005. Mr. Friedman servedas Chief Operating Officer of one of Israel’s premier newspapers, Ma’ariv from 2003 to 2007, and has more than 18years of experience serving on boards of public and private companies including Maayan Ventures, Capital Point, Rosetta GreenLtd. and Aerodrome Groupe Ltd. Mr. Friedman additionally served as an investor and consultant at Rhythmia Medical Inc. from 2007,and was actively involved in the sale of the company to Boston Scientific in 2012. Mr. Friedman holds a bachelor’s degreeand master’s degree with honors in Public Administration from Bar-Ilan University.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Mr. Friedman’s qualifications to serve on our Board include his experience in serving as a director of publicand private companies as well as his knowledge and familiarity with corporate finance.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Dr.Arie Mayer          </i>         </b>         became a         <b>          <i>           director          </i>         </b>         in December 2019. Dr. Mayer is currently the Managing Director and Chairmanof the Board of Merck Life Science Israel (formerly Sigma-Aldrich Israel Ltd.) and has held that position since January 2010.Dr. Mayer has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developingthe Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree inchemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Dr. Mayer’s qualifications to serve on our Board include his experience as an executive in the biotechnologyindustry, as well as his experience and relevant education in the fields of chemistry and biochemistry.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Kevin Rakin          </i>         </b>         became a         <b>          <i>           director          </i>         </b>         in August 2016 and Chairman of the Board in July 2017. Mr. Rakin is a co-founderand partner at HighCape Partners, a growth equity life sciences fund where he has served since 2013. From June 2011 to November2012, Mr. Rakin was the President of Regenerative Medicine at Shire plc, or Shire, a leading specialty biopharmaceutical company.Prior to joining Shire, Mr. Rakin served as the Chairman and Chief Executive Officer of Advanced BioHealing, Inc. from 2007 untilits acquisition by Shire for $750 million in June 2011. Mr. Rakin currently serves on the boards of Nyxoah SA, HighCape CapitalAcquisition Corp., Aziyo Biologics, Inc. and on the boards of number of private companies. Mr. Rakin holds an MBA from ColumbiaUniversity and received his graduate and undergraduate degrees in Commerce from the University of Cape Town, South Africa.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Mr. Rakin’s qualifications to serve on our Board include his extensive experience as an executive in the biotechnologyindustry, as well as his service in positions in various companies as a chief executive officer, chief financial officer and presidentand his involvement in public and private financings and mergers and acquisitions in the biotechnology industry.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Leonard Sank          </i>         </b>         became a         <b>          <i>           director          </i>         </b>         in October 2007. Mr. Sank is a South African entrepreneur and businessman,whose interests lie in entrepreneurial endeavors and initiatives, with over 20 years’ experience of playing significantleadership roles in developing businesses. For the past nineteen years, Mr. Sank has served on the boards of a few national businessesand local non-profit charity organizations in Cape Town and South Africa, where he resides.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Mr. Sank’s qualifications to serve on our Board include his years of experience in development stage businesses,as well as his experience serving as a director of many entities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Mr.Gao Xiaoming          </i>         </b>         became a         <b>          <i>           director          </i>         </b>         in July 2019. Mr. Gao has more than 25 years’ experience in the bio-pharmaceuticalfield. Mr. Gao has experience in the registration, license-in, sales and promotion of pharmaceuticals and was involved in theintroduction of Novo Nordisk (Denmark)’s insulin into China. Mr. Gao is proficient in the insulin industry. From 2005 to2009, Mr. Gao led a team for the registration of imported Insulin-SciLin in China and obtained an Imported Drug License. Since2007, Mr. Gao founded Hefei Tianmai Biotechnology Development Co., Ltd. and HTIT, which are committed to the research, developmentand commercialization of high-tech bio-pharmaceutical products. Mr. Gao is the Chairman and chief executive officer of HTIT.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that Mr. Gao’s qualifications to serve on our Board include his years of experience in the bio-pharmaceutical industryas well as his experience and familiarity with the Eastern market.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 39; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Boardof Directors         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thereare no agreements with respect to the election of directors. Each director is elected for a period of one year at our annual meetingof stockholders and serves until the next such meeting and until his or her successor is duly elected or until his or her earlierresignation or removal. The Board may also appoint additional directors. A director so chosen or appointed will hold office untilthe next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlierresignation or removal. The Board has determined that Aviad Friedman, Arie Mayer, Kevin Rakin, Leonard Sank and Gao Xiaoming areindependent as defined under the rules promulgated by the Nasdaq. Mr. Gao is the chief executive officer of HTIT, a stockholderholding more than 5% of our common stock and was initially appointed to serve on our Board pursuant to the terms of the securitiespurchase agreement with HTIT dated November 30, 2015, but does not otherwise have any relationship with us. The Board consideredthis relationship and determined that they would not interfere with Mr. Gao’s exercise of independent judgment in carryingout the responsibilities of a director.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave determined that each of the directors is qualified to serve as a director of the Company based on a review of the experience,qualifications, attributes and skills of each director. In reaching this determination, we have considered a variety of criteria,including, among other things: character and integrity; ability to review critically, evaluate, question and discuss informationprovided, to exercise effective business judgment and to interact effectively with the other directors; and willingness and abilityto commit the time necessary to perform the duties of a director.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          BoardMeeting Attendance         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringfiscal 2020, our Board held 7 meetings and took actions by written consent on 8 occasions. Board members are encouraged to attendour annual meetings of stockholders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Allof our directors, except Mr. Gao Xiaoming, attended at least 75% of the aggregate number of meetings of the Board and the committeesthat were held during the period such director served on the Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Committees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          AuditCommittee and Audit Committee Financial Expert         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Themembers of our Audit Committee are Aviad Friedman, Arie Mayer and Kevin Rakin. Our Board has determined that Aviad Friedman isan “audit committee financial expert” as set forth in Item 407(d)(5) of Regulation S-K and that all members of theAudit Committee are “independent” as defined by the rules of the SEC and the Nasdaq rules and regulations. The AuditCommittee operates under a written charter that is posted on the “Investors” section of our website, www.oramed.com.The primary responsibilities of our Audit Committee include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Overseeing                                         the accounting and financial reporting processes of the Company and the audits of the                                         financial statements of the Company;           </font>          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Appointing,compensating and retaining our registered independent public accounting firm;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Overseeingthe work performed by any outside accounting firm;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Assisting                                         the Board in fulfilling its responsibilities by reviewing: (i) the financial reports                                         provided by us to the SEC, our stockholders or to the general public and (ii) our internal                                         financial and accounting controls; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Recommending,                                         establishing and monitoring procedures designed to improve the quality and reliability                                         of the disclosure of our financial condition and results of operations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          CompensationCommittee         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Themembers of our Compensation Committee are Aviad Friedman, Kevin Rakin and Leonard Sank. The Board has determined that all of themembers of the Compensation Committee are “independent” as defined by the rules of the SEC and Nasdaq rules and regulations.The Compensation Committee operates under a written charter that is posted on the “Investors” section of our website,www.oramed.com. The primary responsibilities of our Compensation Committee include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 40; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Reviewing,                                         negotiating and approving, or recommending for approval by our Board the salaries and                                         incentive compensation of our executive officers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Administering                                         our equity based plans and making recommendations to our Board with respect to our incentive-compensation                                         plans and equity-based plans; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Making                                         recommendations to our Board with respect to director compensation.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          NominatingCommittee         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Themembers of our Nominating Committee are Aviad Friedman and Leonard Sank. The Board has determined that all of the members of theNominating Committee are “independent” as defined by the rules of the SEC and Nasdaq rules and regulations. The NominatingCommittee operates under a written charter that is posted on the “Investors” section of our website, www.oramed.com.The primary responsibilities of our Nominating Committee include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Overseeing                                         the composition and size of the Board, developing qualification criteria for Board members                                         and actively seeking, interviewing and screening individuals qualified to become Board                                         members for recommendation to the Board;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Recommending                                         the composition of the Board for each annual meeting of stockholders; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.5in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Reviewing                                         periodically with the Chairman of the Board and the Chief Executive Officer the succession                                         plans relating to positions held by directors, and making recommendations to the Board                                         with respect to the selection and development of individuals to occupy those positions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          DelinquentSection 16(a) Reports         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Basedsolely upon a review of Forms 3, 4 and 5, and amendments thereto, furnished to us during fiscal 2020, we believe that during fiscal2020, our executive officers, directors and all persons who own more than ten percent of a registered class of our equity securitiescomplied with all Section 16(a) filing requirements, except: (a) Aviad Friedman, one of our directors, failed to timely file aForm 4 reporting his January 8, 2020 acquisition of options to purchase 20,000 shares of our common stock. Mr. Friedman fileda Form 4 reporting this transaction on January 14, 2020, (b) Gao Xiaoming, one of our directors, failed to timely file a Form4 reporting his January 8, 2020 acquisition of options to purchase 20,000 shares of our common stock. Mr. Gao filed a Form 4 reportingthis transaction on January 14, 2020, (c) Miriam Kidron, our Chief Scientific Officer and one of our directors, failed to timelyfile a Form 4 reporting her January 8, 2020 acquisition of options to purchase 100,000 shares of our common stock. Ms. Kidronfiled a Form 4 reporting this transaction on January 14, 2020, (d) Nadav Kidron, our President, Chief Executive Officer and oneof our directors, failed to timely file a Form 4 reporting his January 8, 2020 acquisition of options to purchase 190,000 sharesof our common stock. Mr. Kidron filed a Form 4 reporting this transaction on January 14, 2020, (d) Arie Mayer, one of our directors,failed to timely file a Form 4 reporting his January 8, 2020 acquisition of options to purchase 20,000 shares of our common stock.Mr. Mayer filed a Form 4 reporting this transaction on January 14, 2020, (e) Kevin Rakin, one of our directors, failed to timelyfile a Form 4 reporting his January 8, 2020 acquisition of options to purchase 20,000 shares of our common stock. Mr. Rakin fileda Form 4 reporting this transaction on January 14, 2020, and (f) Leonard Sank, one of our directors, failed to timely file a Form4 reporting his January 8, 2020 acquisition of options to purchase 20,000 shares of our common stock. Mr. Sank filed a Form 4reporting this transaction on January 14, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Codeof Ethics         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave adopted a Code of Ethics and Business Conduct for our senior officers, directors and employees. A copy of the Code of Ethicsand Business Conduct is located at our website at www.oramed.com. We intend to satisfy the disclosure requirement regarding anyamendment to, or a waiver from, a provision of the Code of Ethics that applies to our Chief Executive Officer, or CEO, Chief FinancialOfficer or controller, or persons performing similar functions and that relates to the Code of Ethics by posting such informationon our website, www.oramed.com.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 41; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_019">          </a>          ITEM11. EXECUTIVE COMPENSATION.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          CompensationDiscussion and Analysis         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thissection explains the policies and decisions that shape our executive compensation program, including its specific objectives andelements, as it relates to our “named executive officers,” or NEOs. Our NEOs for fiscal 2020 are those four individualslisted in the “Summary Compensation Table” below. The Compensation Committee believes that our executive compensationis appropriately designed to incentivize our named executive officers to work for our long-term prosperity, is reasonable in comparisonwith the levels of compensation provided by comparable companies and reflects a reasonable cost. We believe our named executiveofficers are critical to the achievement of our corporate goals, through which we can drive stockholder value.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompensation Committee of our Board is comprised solely of independent directors as defined by Nasdaq and non-employee directorsas defined by Rule 16b-3 under the Exchange Act. The Compensation Committee has the authority and responsibility to review andapprove the compensation of our CEO and other executive officers. Other information concerning the structure, roles and responsibilitiesof our Compensation Committee is set forth in “Board Meetings and Committees—Compensation Committee” section.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourexecutive compensation program and our NEOs’ compensation packages are designed around the following objectives:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            attract, hire, and retain    talented and experienced executives;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             motivate,reward and retain executives whose knowledge, skills and performance are critical to our success;            </font>           </p>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ensure fairness among the executive management    team via recognizing the contributions of each executive to our success;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            focus executive behavior    on achievement of our corporate objectives and strategy; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            align the interests of management    and stockholders by providing management with longer-term incentives through equity ownership.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompensation Committee reviews the allocation of compensation components regularly to ensure alignment with strategic and operatinggoals, competitive market practices and legislative changes. The Compensation Committee does not apply a specific formula to determinethe allocation between cash and non-cash forms of compensation. Certain compensation components, such as base salaries, benefitsand perquisites, are intended primarily to attract, hire, and retain well-qualified executives. Other compensation elements, suchas long-term incentive opportunities, are designed to motivate and reward performance. Long-term incentives are intended to rewardNEOs for our long-term performance and executing our business strategy, and to strongly align NEOs’ interests with thoseof stockholders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Withrespect to equity compensation, the Compensation Committee makes awards to executives under our 2019 Stock Incentive Plan, asamended and restated, or the 2019 Plan. Executive compensation is paid or granted based on such matters as the Compensation Committeedeems appropriate, including our financial and operating performance and the alignment of the interests of the executive officersand our stockholders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 42; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Elementsof Compensation          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourexecutive officer compensation program is comprised of: (i) base salary or monthly compensation; (ii) discretionary bonus; (iii)long-term equity incentive compensation in the form of stock option grants; and (iv) benefits and perquisites.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inestablishing overall executive compensation levels and making specific compensation decisions for our NEOs in fiscal 2020, theCompensation Committee considered a number of criteria, including the executive’s position, scope of responsibilities, priorbase salary and annual incentive awards and expected contribution.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Generally,our Compensation Committee reviews and, as appropriate, approves compensation arrangements for the NEOs from time to time butnot less than once each year. The Compensation Committee also takes into consideration the CEO’s recommendations for executivecompensation of the other NEOs. The CEO generally presents these recommendations at the time of our Compensation Committee’sreview of executive compensation arrangements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          BaseSalary         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompensation Committee performs a review of base salaries and monthly compensation for our NEOs from time to time as appropriate.In determining salaries, the Compensation Committee members also take into consideration the scope of the NEOs’ responsibilitiesand independent third-party market data, such as compensation surveys to industry, individual experience and performance and contributionto our clinical, regulatory, commercial and operational performance. None of the factors above has a dominant weight in determiningthe compensation of our named executive officers, and our Compensation Committee considers the factors as a whole when consideringsuch compensation. In addition, our Compensation Committee uses comparative data regarding compensation paid by peer companiesin order to obtain a general understanding of current trends in compensation practices and ranges of amounts being awarded byother public companies, and not as part of an analysis or a formula.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that a competitive base salary and monthly compensation is a necessary element of any compensation program that is designedto attract and retain talented and experienced executives. We also believe that attractive base salaries can motivate and rewardexecutives for their overall performance. Base salary and monthly compensation are established in part based on the individualexperience, skills and expected contributions to our performance, as well as such executive’s performance during the prioryear. Generally, we believe that executives’ base salaries should be targeted near the median of the range of salaries forexecutives in similar positions with similar responsibilities, experience and performance at comparable companies. Compensationadjustments are made occasionally based on changes in an executive’s level of responsibility, company progress or on changedlocal and specific executive employment market conditions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Infiscal 2020, our Compensation Committee increased the base salaries of two of our NEOs by 10% and 15% as it deemed this to bea reasonable rate based on, among other factors, such NEO’s increased responsibilities and time passed since the last salaryincrease.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          PerformanceBased Bonus         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OurNEOs are eligible to receive discretionary annual bonuses based upon performance. The amount of annual bonus to our NEOs is basedon various factors, including, among others, the achievement of scientific and business goals and our financial and operationalperformance. The Compensation Committee takes into account the overall performance of the individuals, as well as the overallperformance of the Company over the period being reviewed and the recommendation of management. For any given year, the compensationobjectives vary, but relate generally to strategic factors such as developments in our clinical path, the execution of a licenseagreement for the commercialization of product candidates, the establishment of key strategic collaborations, the build-up ofour pipeline and financial factors such as capital raising. Bonuses are awarded generally based on corporate performance, withadjustments made within a range for individual performance, at the discretion of the Compensation Committee. The CompensationCommittee determines, on a discretionary basis, the size of the entire bonus pool and the amount of the actual award to each NEO.The overall payment is also based on historic compensation of the NEOs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 43; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Webelieve that annual bonuses payable based on the achievement of short-term corporate goals incentivize our NEOs to create stockholdervalue and attain short-term performance objectives.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Long-TermEquity Incentive Compensation         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Long-termincentive compensation allows the NEOs to share in any appreciation in the value of our common stock. The Compensation Committeebelieves that stock participation aligns executive officers’ interests with those of our stockholders. Equity incentiveawards are generally made at the commencement of employment and following a significant change in job responsibilities, or tomeet other special retention or performance objectives. The amounts of the awards are designed to reward past performance andcreate incentives to meet long-term objectives. Awards are made at a level expected to be competitive within the biotechnologyindustry, as well as with Israeli-based companies. Awards are made on a discretionary basis and not pursuant to specific criteriaset out in advance. In determining the amount of each grant, the Compensation Committee also takes into account the number ofshares held by the executive prior to the grant. The vesting schedule for NEOs generally provides for annual installments fornew grants, though the Compensation Committee also utilizes quarterly vesting from time to time, as well as performance-basedvesting. The Compensation Committee believes that time-based vesting encourages recipients to build stockholder value over a longperiod of time and that performance-based vesting encourages recipients to achieve goals that benefit the Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Benefitsand Perquisites         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Generally,benefits available to NEOs are available to all employees on similar terms and include welfare benefits, paid time-off, life anddisability insurance and other customary or mandatory social benefits in Israel. We provide our NEOs with a phone and a companycar, which are customary benefits in Israel to managers and officers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wedo not believe that the benefits and perquisites described above deviate materially from the customary practice for compensationof executive officers by other companies similar in size and stage of development in Israel. These benefits represent a relativelysmall portion of the executive officers’ total compensation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        The Company pays forcertain direct costs, related taxes and expenses incurred in connection with the relocation of our CEO to United States. Duringfiscal 2020, such relocation expenses totaled approximately $515,693, and included mainly payments intended to reflect the differencein the cost of living between Israel and the United States, relocation expenses, accommodation allowances, education allowances,health insurance and related taxes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Say-on-PayVote         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.2pt 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourstockholders approved, on an advisory basis, our executive compensation program at our annual meeting of stockholders held onAugust 3, 2020. We did not seek or receive any specific feedback from our stockholders concerning our executive compensation programduring the past fiscal year. The Compensation Committee did not specifically rely on the results of the prior vote in making anycompensation-related decisions during fiscal 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.2pt 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          REPORTOF THE COMPENSATION COMMITTEE         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.55in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheCompensation Committee has reviewed and discussed the foregoing Compensation Discussion and Analysis required by Item 402(b) ofRegulation S-K with our management and, based on such review and discussions, the Compensation Committee recommended to our Boardthat the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K and in our proxy statement relatingto our next annual meeting of stockholders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="width: 60%">          </td>          <td style="width: 40%">           <font style="font: 10pt Times New Roman, Times, Serif">            CompensationCommittee Members:           </font>          </td>         </tr>         <tr>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td>          </td>          <td>           <font style="font: 10pt Times New Roman, Times, Serif">            AviadFriedman           </font>          </td>         </tr>         <tr>          <td>          </td>          <td>           <font style="font: 10pt Times New Roman, Times, Serif">            KevinRakin           </font>          </td>         </tr>         <tr>          <td>          </td>          <td>           <font style="font: 10pt Times New Roman, Times, Serif">            LeonardSank           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 44; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          SUMMARYCOMPENSATION TABLE         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table sets forth the compensation earned by our NEOs for fiscals 2020, 2019 and 2018.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">           Name and Principal Position          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year           <br/>           (1)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Salary           <br/>           ($)           <br/>           (2)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Bonus           <br/>           ($)           <br/>           (2)(3)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             OptionAwards            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             ($)            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             (4)(5)            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           All Other           <br/>           Compensation           <br/>           ($)           <br/>           (2)(6)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 30%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Nadav Kidron          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: center">           2020          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           439,076          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           220,582          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           569,062          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            539,131           </p>          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            1,767,851           </p>          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           President and CEO and director           <sup>            (7)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2019          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           419,460          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           224,975          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           398,910          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           507,750          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,551,095          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2018          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           436,310          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           148,795          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           522,569          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           442,326          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,550,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Miriam Kidron          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2020          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           305,840          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           70,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           299,506          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,354          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           688,700          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Chief Scientific Officer and director           <sup>            (8)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2019          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           267,386          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           123,149          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           211,128          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,503          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           616,166          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2018          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           273,595          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           46,614          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           253,204          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,643          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           587,056          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Avraham Gabay          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2020          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           130,554          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15,591          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,912          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           191,418          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Chief Financial Officer           <sup>            (9)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2019          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           32,122          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           73,928          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,441          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           115,491          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Joshua Hexter          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2020          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           190,801          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12,169          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           351,128          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54,735          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            608,833           </p>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Chief Operating &amp; Business Officer(10)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2019          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           52,848          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,022          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           61,870          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           2018          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           161,002          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            26,895           </p>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           269,196          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           50,505          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           507,598          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The                                         information is provided for each fiscal year, which begins on September 1 and ends on                                         August 31.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts                                         paid for Salary, Bonus and All Other Compensation were originally denominated in NIS                                         and were translated into U.S. Dollars at the then current exchange rate for each payment.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Bonuses                                         were granted at the discretion of the Compensation Committee.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The                                         amounts reflect the grant date fair value, as calculated pursuant to FASB ASC Topic 718,                                         of these option awards. The assumptions used to determine the fair value of the option                                         awards are set forth in Note 8 to our audited consolidated financial statements included                                         in this Annual Report on Form 10-K. Our NEOs will not realize the value of these awards                                         in cash unless and until these awards are exercised and the underlying shares subsequently                                         sold.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amounts                                         exclude the fair market value of the options that were re-granted on September 11, 2020,                                         as it was offset by the negative amount created by the cancelled options (that is, it                                         was accounted for as a modification under FASB ASC Topic 718, and no incremental compensation                                         expense was recorded). For more information about the regrant see Note 7(a) to our audited                                         consolidated financial statements included in this Annual Report on Form 10-K. For more                                         information about the regrant fair market value see “Grants of Plan-Based Awards”                                         below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            See                                         “All Other Compensation Table” below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr.                                         Kidron receives certain compensation from Oramed Ltd. through KNRY, Ltd., an Israeli                                         entity owned by Dr. Miriam Kidron, or KNRY. See “—Employment and Consulting                                         Agreements” below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dr.                                         Kidron receives compensation from Oramed Ltd. through KNRY. See “—Employment                                         and Consulting Agreements” below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.5in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr.Gabay was appointed as Chief Financial Officer, effective June 1, 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr.                                         Hexter was appointed Chief Operating &amp; Business Officer, effective September 19,                                         2019. From 2013 to 2018, Mr. Hexter served as Chief Operating Officer and VP Business                                         Development of the Company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 45; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          AllOther Compensation Table         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The“All Other Compensation” amounts set forth in the Summary Compensation Table above consist of the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">           Name          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Automobile-           <br/>           Related Expenses           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Manager’s           <br/>           Insurance*           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Education           <br/>           Fund*           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Relocation Expenses**           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; text-align: left">           Nadav Kidron          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: center">           2020          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           23,438          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           --          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           --          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            515,693           </p>          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            539,131           </p>          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           21,090          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           486,660          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           507,750          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2018          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12,596          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           429,730          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           442,326          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Miriam Kidron          </td>          <td>          </td>          <td style="text-align: center">           2020          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,354          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,354          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,503          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,503          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2018          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,643          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,643          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Avraham Gabay          </td>          <td>          </td>          <td style="text-align: center">           2020          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           16,625          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           18,606          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,681          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           44,912          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,808          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,405          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,228          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,441          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Joshua Hexter          </td>          <td>          </td>          <td style="text-align: center">           2020          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,685          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           26,820          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,230          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54,735          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,409          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,985          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,628          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            --           </p>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,022          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: center">           2018          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,909          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24,623          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11,973          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           50,505          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Manager’s                                         insurance and education funds are customary benefits provided to employees based in Israel.                                         Manager’s insurance is a combination of severance savings (in accordance with Israeli                                         law), defined contribution tax-qualified pension savings and disability insurance premiums.                                         An education fund is a savings fund of pre-tax contributions to be used after a specified                                         period of time for educational or other permitted purposes.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Relocation                                         expenses represents additional compensation for the period during which Mr. Kidron was                                         in the United States. These expenses mainly include relocation expenses, supplemental                                         living expenses, accommodation allowances, education allowances, health insurance and                                         related costs.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Employmentand Consulting Agreements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnJuly 1, 2008, Oramed Ltd. entered into a consulting agreement with KNRY, whereby Mr. Nadav Kidron, through KNRY, provides servicesas President and Chief Executive Officer of both the Company and Oramed Ltd., or the Nadav Kidron Consulting Agreement. Additionally,on July 1, 2008, Oramed Ltd. entered into a consulting agreement with KNRY whereby Dr. Miriam Kidron, through KNRY, provides servicesas Chief Scientific Officer of both the Company and Oramed Ltd., or the Miriam Kidron Consulting Agreement. We refer to the MiriamKidron Consulting Agreement and Nadav Kidron Consulting Agreement collectively as the Consulting Agreements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheConsulting Agreements are both terminable by either party upon 140 days prior written notice. The Consulting Agreements, as amended,provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreementsand that Nadav Kidron receives a monthly consulting fee of NIS 127,570 and Miriam Kidron receives a monthly consulting fee ofNIS 92,522. Pursuant to the Consulting Agreements, KNRY, Nadav Kidron and Miriam Kidron each agree that during the term of theConsulting Agreements and for a 12-month period thereafter, none of them will compete with Oramed Ltd. nor solicit employees ofOramed Ltd.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 46; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         We,through Oramed Ltd., have entered into an employment agreement with Avraham Gabay as of May 16, 2019, pursuant to which Mr. Gabaywas appointed as Chief Financial Officer, Treasurer and Secretary of the Company and Oramed Ltd., effective June 1, 2019. In accordancewith the employment agreement, as amended, Mr. Gabay’s current gross monthly salary is NIS 38,500. In addition, Mr. Gabayis provided with a cellular phone and a company car pursuant to the terms of his agreement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         We,through Oramed Ltd., have entered into an employment agreement with Joshua Hexter as of August 5, 2019, pursuant to which Mr.Hexter was appointed as Chief Operating &amp; Business Officer of the Company and Oramed Ltd., effective September 19, 2019. Inaccordance with the employment agreement, as amended, Mr. Hexter’s current gross monthly salary is NIS 56,000. In addition,Mr. Hexter is provided with a cellular phone and a company car pursuant to the terms of his agreement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave entered into indemnification agreements with our directors and officers pursuant to which we agreed to indemnify each directorand officer for any liability he or she may incur by reason of the fact that he or she serves as our director or officer, to themaximum extent permitted by law.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          PotentialPayments upon Termination or Change-in-Control         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave no plans or arrangements in respect of remuneration received or that may be received by our named executive officers to compensatesuch officers in the event of termination of employment (as a result of resignation, retirement, change-in- control) or a changeof responsibilities following a change-in-control.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Pension,Retirement or Similar Benefit Plans         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave no arrangements or plans under which we provide pension, retirement or similar benefits for directors or executive officers.Our directors and executive officers may receive stock options, RSUs or restricted shares at the discretion of our CompensationCommittee in the future.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 47; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          GRANTSOF PLAN-BASED AWARDS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table shows grants of plan-based equity awards made to our NEOs during fiscal 2020:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Name          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Grant Date          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Options Awards:              <br/>              Number of              <br/>              Securities              <br/>              Underlying              <br/>              Options             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              (#)             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Grant Date              <br/>              Fair Value of              <br/>              Stock Awards             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              ($)             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Avraham    Gabay            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 11%; text-align: center">           9/11/2019          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           33,146          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           61,893          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Joshua    Hexter            <sup>             (2)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           9/11/2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           224,123          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Joshua    Hexter            <sup>             (3)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           9/11/2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           127,005          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Miriam    Kidron            <sup>             (4)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           9/11/2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           104,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           211,128          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nadav    Kidron            <sup>             (5)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           9/11/2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           196,500          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           398,910          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Miriam    Kidron            <sup>             (6)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           1/8/2020          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           299,506          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nadav    Kidron            <sup>             (7)            </sup>           </font>          </td>          <td style="text-align: left">          </td>          <td style="text-align: center">           1/8/2020          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           190,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           569,062          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were canceled    and re-granted under our 2019 Plan, in the same amounts and under the same terms as the original grants. These options were    originally granted on June 17, 2019. 5,396 vested on December 31, 2019, and the balance vests in 3 equal installments of 9,250    on each of December 31, 2020, December 31, 2021 and December 31, 2022.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were granted under our 2019 Plan    and vest in 16 equal installments of 6,250 on the first day of each three months period beginning November 1, 2019. 25,000    of the options vested as of August 31, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were granted under the 2019 Plan    and vest upon achievement of certain performance conditions, such as consummating licensing agreements and entering into R&amp;D    collaboration agreements.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were canceled and re-granted under    the 2019 Plan in the same amounts and under the same terms as the original grants. These options were originally granted on    February 26, 2019. 26,000 vested on December 31, 2019, and the balance vests in 3 equal installments of 26,000 on each of    December 31, 2020, December 31, 2021 and December 31, 2022.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were canceled and re-granted under    the 2019 Plan in the same amounts and under the same terms as the original grants. These options were originally granted on    February 26, 2019. 49,125 vested on December 31, 2019, and the balance vests in 3 equal installments of 49,125 on each of    December 31, 2020, December 31, 2021 and December 31, 2022.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were granted under our 2019 Plan    and vest in 4 equal installments of 25,000 on each of December 31, 2020, December 31, 2021, December 31, 2022 and December    31, 2023.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These options were granted under our 2019 Plan    and vest in 4 equal installments of 47,500 on each of December 31, 2020, December 31, 2021, December 31, 2022 and December    31, 2023.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 48; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          OUTSTANDINGEQUITY AWARDS AT FISCAL YEAR-END         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table sets forth information concerning stock options and stock awards held by the NEOs as of August 31, 2020.        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td colspan="10" style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr>          <td colspan="2" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="8" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option    Awards            </b>           </font>          </td>          <td style="vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="3" style="vertical-align: top; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock    Awards            </b>           </font>          </td>          <td>          </td>         </tr>         <tr>          <td style="text-align: left; vertical-align: bottom; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="text-align: center; vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number    of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options (#)             <br/>             Exercisable            </b>           </font>          </td>          <td style="text-align: center; vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number    of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options (#)             <br/>             Unexercisable            </b>           </font>          </td>          <td style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Exercise             <br/>             Price             <br/>             ($)            </b>           </font>          </td>          <td style="text-align: center; vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Expiration             <br/>             Date            </b>           </font>          </td>          <td style="text-align: center; vertical-align: bottom; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Numberof              <br/>              shares that              <br/>              have not              <br/>              vested              <br/>              (#)             </b>            </font>           </p>          </td>          <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Market              <br/>              value of              <br/>              shares that              <br/>              have not              <br/>              vested              <br/>              ($)             </b>            </font>           </p>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; width: 28%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nadav    Kidron           </font>          </td>          <td style="vertical-align: bottom; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom; width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; width: 3%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; width: 9%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            72,000           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.08           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/8/22           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47,134           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12.45           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/9/24           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            49,000           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (3)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7.77           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/30/27           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48,500           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (4)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48,500           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (4)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8.14           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/31/28           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (7)(8)            </sup>           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            49,125           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (10)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            147,375           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (10)(13)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.16           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2/26/29           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            190,000           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (15)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.80           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/8/30           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Miriam Kidron           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            72,000           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.08           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/8/22           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47,134           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12.45           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/9/24           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            69,999           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (5)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7.77           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/30/27           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23,500           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (6)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23,500           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (6)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8.14           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/31/28           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (9)            </sup>           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            26,000           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (11)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            78,000           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (11)(13)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.16           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2/26/29           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            100,000           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (16)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.80           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/8/30           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Avraham Gabay           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,396           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (12)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            27,750           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (12)(13)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.55           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/17/29           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Joshua Hexter           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            25,000           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (14)            </sup>           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            175,000           </font>          </td>          <td style="white-space: nowrap; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (14)            </sup>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.69           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/11/29           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         August 8, 2012, 72,000 options were granted to each of Nadav Kidron and Miriam Kidron                                         under the Second Amended and Restated 2008 Stock Incentive Plan, or the 2008 Plan, at                                         an exercise price of $4.08 per share; 21,000 of such options vested immediately on the                                         date of grant and the remainder vested in seventeen equal monthly installments, commencing                                         on August 31, 2012. The options have an expiration date of August 8, 2022.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         April 9, 2014, 47,134 options were granted to each of Nadav Kidron and Miriam Kidron                                         under the 2008 Plan at an exercise price of $12.45 per share; 15,710 of such options                                         vested on April 30, 2014 and the remainder vested in eight equal monthly installments,                                         commencing on May 31, 2014. The options have an expiration date of April 9, 2024.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         June 30, 2017, 147,000 options were granted to Nadav Kidron under the 2008 Plan at an                                         exercise price of $7.77 per share; 49,000 of such options vested on December 31, 2017                                         and the remainder vest in two equal installments of 49,000 on each of December 31, 2018                                         and December 31, 2019, subject to the Company share price reaching the target of $9.50                                         and $12.50 per share, respectively. The options expire on June 30, 2027. As of August                                         31, 2020, 98,000 options were forfeited.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 49; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         January 31, 2018, 97,000 options were granted to Nadav Kidron under the 2008 Plan at                                         an exercise price of $8.14 per share; 48,500 of such options vested on each of January                                         1, 2019 and January 1, 2020 and the reminder vest in two equal installments of 24,250                                         on each of January 1, 2021 and January 1, 2022. The options expire on January 31, 2028.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         June 30, 2017, 69,999 options were granted to Miriam Kidron under the 2008 Plan at an                                         exercise price of $7.77 per share; Such options vested in 3 equal installments of 23,333                                         on each of December 31, 2017, December 31, 2018 and December 31, 2019. The options have                                         an expiration date of June 30, 2027.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         January 31, 2018, 47,000 options were granted to Miriam Kidron under the 2008 Plan at                                         an exercise price of $8.14 per share; 23,500 of such options vested in 2 equal installments                                         of 11,750 on each of January 1, 2019 and January 1, 2020 and the reminder shall vest                                         in 2 equal installments of 11,750 on each of January 1, 2021 and January 1, 2022. The                                         options expire on January 31, 2028.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         November 13, 2014, 9,788 RSUs, representing a right to receive shares of the Company’s                                         common stock, were granted to Nadav Kidron. The RSUs vested in two equal installments,                                         each of 4,894 shares, on November 30 and December 31, 2014. The shares of common stock                                         underlying the RSUs will be issued upon request of the grantee.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         February 23, 2015, 79,848 RSUs, representing a right to receive shares of the Company’s                                         common stock, were granted to Nadav Kidron. The RSUs vested in 23 installments consisting                                         of one installment of 6,654 shares on February 28, 2015 and 22 equal monthly installments                                         of 3,327 shares each, commencing March 31, 2015. The shares of common stock underlying                                         the RSUs will be issued upon request of the grantee.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         June 30, 2017, 75,000 RSUs, representing a right to receive shares of the Company’s                                         common stock, were granted to Miriam Kidron. The RSUs vested immediately, have an exercise                                         price of $0.012 per share of common stock and expire on June 30, 2027.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         February 26, 2019, 196,500 options were granted to Nadav Kidron under the 2008 Plan at                                         an exercise price of $3.16 per share; 49,125 of such option vested on December 31, 2019                                         and the reminder shall vest in three equal installments of 49,125 on each of December                                         31, 2020, December 31, 2021 and December 31, 2022. The options expire on February 26,                                         2029. For additional information please see note 13 below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (11)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         February 26, 2019, 104,000 options were granted to Miriam Kidron under the 2008 Plan                                         at an exercise price of $3.16 per share; 26,000 of such option vested on December 31,                                         2019 and the reminder shall vest in three equal installments of 26,000 on each of December                                         31, 2020, December 31, 2021 and December 31, 2022. The options expire on February 26,                                         2029. For additional information please see note 13 below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (12)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         June 17, 2019, 33,146 options were granted to Avraham Gabay under the 2008 Plan at an                                         exercise price of $3.55 per share; 5,396 of the options vested on December 31, 2019 and                                         the remining options shall vest in 3 equal installments of 9,250 on each of December                                         31, 2020, December 31, 2021 and December 31, 2022. The options expire on June 17, 2029.                                         For additional information please see note 13 below.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         September 11, 2019, the options in this table were canceled and re-granted under the                                         2019 Plan in the same amounts and under the same terms as the original grants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (14)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         September 11, 2019, 200,000 options were granted to Joshua Hexter under the 2019 Plan                                         at an exercise price of $3.69 per share; 100,000 of such options shall vest in 16 equal                                         installments of 6,250 on the first day of every three month period beginning November                                         1, 2019 and the remaining 100,000 shall vest upon achievement of certain performance                                         conditions, such as consummating licensing agreements and entering into R&amp;D collaboration                                         agreements. The options expire on November 9, 2029.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (15)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         January 8, 2020, 190,000 options were granted to Nadav Kidron under the 2019 Plan at                                         an exercise price of $4.80 per share. Such options will vest in 4 equal installments                                         of 47,500 on each of December 31, 2020, December 31, 2021, December 31, 2022 and December                                         31, 2023. The options expire on January 8, 2030.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0; text-align: justify">          </td>          <td style="width: 0.5in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (16)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On                                         January 8, 2020, 100,000 options were granted to Miriam Kidron under the 2019 Plan at                                         an exercise price of $4.80 per share. Such options will vest in 4 equal installments                                         of 25,000 on each of December 31, 2020, December 31, 2021, December 31, 2022 and December                                         31, 2023. The options expire on January 8, 2030.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          CompensationCommittee Interlocks and Insider Participation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringfiscal 2020, Mr. Aviad Friedman, Mr. Kevin Rakin and Mr. Leonard Sank served as the members of our Compensation Committee. Noneof the members of our Compensation Committee is, or has been, an officer or employee of ours.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringthe last year, none of our NEOs served as: (1) a member of the compensation committee (or other committee of the Board performingequivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whoseexecutive officers served on the compensation committee; (2) a director of another entity, one of whose executive officers servedon the compensation committee; or (3) a member of the compensation committee (or other committee of the board of directors performingequivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whoseexecutive officers served as a director on our Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 50; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          DIRECTORCOMPENSATION         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table provides information regarding compensation earned by, awarded or paid to each person for serving as a directorwho is not an executive officer during fiscal 2020:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">           Name of Director          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Fees           <br/>           Earned or           <br/>           Paid in           <br/>           Cash           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Stock           <br/>           Awards           <br/>           (2)    ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              Option              <br/>              Awards              <br/>              (3) ($)             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           All Other           <br/>           Compensation           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total           <br/>           ($)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nadav Kidron            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Miriam Kidron            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">           Aviad Friedman          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           20,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           55,505          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           75,505          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Arie    Mayer            <sup>             (4)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55,505          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           70,505          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           Kevin Rakin          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55,505          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           75,505          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           Leonard Sank          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55,505          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           75,505          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           Gao Xiaoming          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55,505          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           75,505          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.5in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pleaserefer to the Summary Compensation Table for executive compensation with respect to the named individual.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.5in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Asof August 31, 2020, our non-employee directors then in office held options to purchase shares of our common stock as follows:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">           Name of Director          </td>          <td style="font-weight: bold">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Aggregate Number           <br/>           of Shares           <br/>           Underlying           <br/>           Stock           <br/>           Awards          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Aviad Friedman          </td>          <td style="width: 1%">          </td>          <td style="width: 12%; text-align: right">           40,857          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Arie Mayer          </td>          <td>          </td>          <td style="text-align: right">           20,000          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Kevin Rakin          </td>          <td>          </td>          <td style="text-align: right">           92,470          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Leonard Sank          </td>          <td>          </td>          <td style="text-align: right">           69,867          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Gao Xiaoming          </td>          <td>          </td>          <td style="text-align: right">           20,000          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.5in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Theamounts reflect the grant date fair value, as calculated pursuant to FASB ASC Topic 718, of these option awards. The assumptionsused to determine the fair value of the option awards are set forth in Note 8 to our audited consolidated financial statementsincluded in this Annual Report on Form 10-K. Our directors will not realize the value of these awards in cash unless and untilthese awards are exercised and the underlying shares subsequently sold.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.5in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr.Mayer joined the Board as of December 5, 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourdirectors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with attendanceat meetings of our Board. Each independent director is entitled to receive as remuneration for his or her service as a memberof the Board a sum equal to $20,000 per annum, to be paid quarterly after the close of each quarter. Our executive officers didnot receive additional compensation for service as directors. The Board may award special remuneration to any director undertakingany special services on behalf of us other than services ordinarily required of a director.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Otherthan as described above, we have no present formal plan for compensating our directors for their service in their capacity asdirectors. Other than indicated above, no director received and/or accrued any compensation for his services as a director, includingcommittee participation and/or special assignments during fiscal 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 51; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_020">          </a>          ITEM12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          StockOption Plans         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OurBoard adopted the 2008 Plan and the 2019 Plan in order to attract and retain quality personnel.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The2008 Plan, which is no longer utilized for new grants, provided for the grant of stock options, restricted stock, RSUs, and stockappreciation rights, collectively referred to as “awards.” Under the 2008 Plan, as amended, 2,400,000 shares werereserved for the grant of awards. As of August 31, 2020, options with respect to 2,287,989 shares had been granted, of which 563,804had been forfeited, 182,227 had been exercised and 841,303 have expired. As of August 31, 2020, 525,824 RSUs had been granted,of which 164,636 have vested and the shares of common stock underlying those RSUs have been issued and 33,248 have been forfeited.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         InAugust 2019, the Company became aware of a shareholder derivative claim and putative class action alleging, among other things,that the 2008 Plan may have terminated in 2018. However, the Company disputes these claims and believes that the 2008 Plan doesnot terminate until 2026, and any suggestion to the contrary is not well-founded. For the sake of clarity and out of an abundanceof caution, the Company adopted the 2019 Plan, which was approved on August 29, 2019, at the Company’s 2019 shareholdersmeeting.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         The2019 Plan provides for the grant of stock options, restricted stock, RSUs, and stock appreciation rights, collectively referredto as “awards.” Under the 2019 Plan, 1,000,000 shares were initially reserved for the grant of awards. On June 29,2020, and August 3, 2020, respectively, our Board and stockholders approved to amend and restate the 2019 Plan, the principalchange being an increase in the number of shares of common stock available under the 2019 Plan from 1,000,000 shares to 3,000,000shares. Stock options granted under the 2019 Plan may be either incentive stock options under the provisions of Section 422 ofthe Code, or non-qualified stock options. Under the 2019 Plan, as amended, 3,000,000 shares are reserved for the grant of awards,which may be issued at the discretion of our Board from time to time. As of August 31, 2020, options with respect to 999,646 shareshave been granted, of which 20,000 have expired and none of them were exercised or forfeited. No RSUs have been granted underthe 2019 Plan. Since the Company had granted options during the time after the 2008 Plan allegedly terminated, and out of an abundanceof caution, the Company canceled these grants and re-granted certain of the options under 2019 Plan in the same amounts and underthe same terms as the original grants.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table sets forth additional information with respect to our equity compensation plans as of August 31, 2020:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in">           Plan category          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           securities to           <br/>           be issued           <br/>           upon           <br/>           exercise of           <br/>           outstanding           <br/>           options, RSUs           <br/>           and rights           <br/>           (a)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weight-           <br/>           average           <br/>           exercise           <br/>           price of           <br/>           outstanding           <br/>           options, RSUs           <br/>           and rights           <br/>           (b)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           securities           <br/>           remaining           <br/>           available for           <br/>           future           <br/>           issuance           <br/>           under equity           <br/>           compensation           <br/>           plans           <br/>           (excluding           <br/>           securities           <br/>           reflected in           <br/>           column (a))           <br/>           (c)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Equity compensation plans approved by security holders          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           1,864,664          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           4.97          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           2,000,354          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Equity compensation plans not approved by security holders          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           --          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">           Total          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,864,664          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.97          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,000,354          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          SecurityOwnership of Certain Beneficial Owners and Management         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing table sets forth certain information regarding the beneficial ownership of our common stock as of November 24, 2020by: (1) each person who is known by us to own beneficially more than 5% of our common stock; (2) each director; (3) each of ourNEOs listed above under “Summary Compensation Table”; and (4) all of our directors and current executive officersas a group. On such date, we had 23,675,530 shares of common stock outstanding.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asused in the table below and elsewhere in this form, the term “beneficial ownership” with respect to a security consistsof sole or shared voting power, including the power to vote or direct the vote, and/or sole or shared investment power, includingthe power to dispose or direct the disposition, with respect to the security through any contract, arrangement, understanding,relationship, or otherwise, including a right to acquire such power(s) during the next 60 days following November 24, 2020. Inclusionof shares in the table does not, however, constitute an admission that the named stockholder is a direct or indirect beneficialowner of those shares. Unless otherwise indicated, (1) each person or entity named in the table has sole voting power and investmentpower (or shares that power with that person’s spouse) with respect to all shares of common stock listed as owned by thatperson or entity and (2) the address of each of the individuals named below is: c/o Oramed Pharmaceuticals Inc., 1185 Avenue ofthe Americas, Third Floor, New York, NY 10036.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in">           Name and Address of Beneficial Owner          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           Shares          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Percentage           <br/>           of Shares           <br/>           Beneficially           <br/>           Owned          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">           Regals Fund LP          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           152 West 57th Street, 9th Floor          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">           New York, NY 10019          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           1,317,123          </td>          <td style="width: 1%; text-align: left">           <sup>            (1)           </sup>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           5.6          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Nadav Kidron #+          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,718,813          </td>          <td style="text-align: left">           <sup>            (2)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11.4          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Miriam Kidron #+          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           376,383          </td>          <td style="text-align: left">           <sup>            (3)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1.6          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Aviad Friedman #          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           49,714          </td>          <td style="text-align: left">           <sup>            (4)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Avraham Gabay+          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,646          </td>          <td style="text-align: left">           <sup>            (5)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Joshua Hexter+          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           101,250          </td>          <td style="text-align: left">           <sup>            (6)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Arie Mayer #          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,666          </td>          <td style="text-align: left">           <sup>            (7)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Kevin Rakin #          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           79,136          </td>          <td style="text-align: left">           <sup>            (8)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Leonard Sank #          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           628,546          </td>          <td style="text-align: left">           <sup>            (9)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2.7          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Gao Xiaoming #          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,162,033          </td>          <td style="text-align: left">           <sup>            (10)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4.9          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           All current executive officers and directors, as a group (nine persons)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,999,881          </td>          <td style="text-align: left">           <sup>            (11)           </sup>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           16.7          </td>          <td style="text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0pt">          </td>          <td style="width: 35.3pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lessthan 1%           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt">          </td>          <td style="width: 35.3pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            #           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0pt">          </td>          <td style="width: 35.3pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            +           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NEO           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt">          </td>          <td style="width: 35.3pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Regals                                         Management is the investment manager of Regals Fund LP, the owner of record of these                                         shares of common stock. David Slager is the managing member of the general partner of                                         Regals Management. All investment decisions are made by Mr. Slager, and thus the power                                         to vote or direct the votes of these shares of common stock, as well as the power to                                         dispose or direct the disposition of such shares of common stock is held by Mr. Slager                                         through Regals Management.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         386,634 shares of common stock issuable upon the exercise of outstanding stock options                                         and 89,636 shares of Common Stock underlying vested RSUs that are issuable upon request.                                         On November 30, 2015, we entered into a securities purchase agreement with HTIT pursuant                                         to which, among other things, Nadav Kidron will serve as proxy and attorney in fact of                                         HTIT, with full power of substitution, to cast on behalf of HTIT all votes that HTIT                                         is entitled to cast with respect to 1,155,367 shares of common stock, or the Purchased                                         Shares, at any and all meetings of our stockholders, to consent or dissent to any action                                         taken without a meeting and to vote all the Purchased Shares held by HTIT in any manner                                         Mr. Kidron deems appropriate except for matters related to our activities in the People’s                                         Republic of China, on which Mr. Kidron will consult with HTIT before taking any action                                         as proxy. Mr. Nadav’s beneficial ownership includes the 1,155,367 shares of common                                         stock held by HTIT, as well as 218,603 shares of common stock held by Xiaopeng Li, a                                         former director of the Company, over which he holds a similar proxy.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 53; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         301,383 shares of common stock issuable upon the exercise of outstanding stock options                                         and 75,000 shares of Common Stock underlying vested RSUs that are issuable upon request.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         27,523 shares of common stock issuable upon the exercise of outstanding stock options                                         and 12,191 shares of common stock owned by Shikma, of which Mr. Friedman is the sole                                         owner and chief executive officer. All investment decisions are made by Mr. Friedman,                                         and thus the power to vote or direct the votes of these shares of common stock, as well                                         as the power to dispose or direct the disposition of such shares of common stock is held                                         by Mr. Friedman through Shikma.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         14,646 shares of common stock issuable upon the exercise of outstanding stock options.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         31,250 shares of common stock issuable upon the exercise of outstanding stock options.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         6,666 shares of common stock issuable upon the exercise of outstanding stock options.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         79,136 shares of common stock issuable upon the exercise of outstanding stock options           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes:                                         (a) 374,999 shares of common stock held by Mr. Sank; (b) 78,125 shares of common stock                                         held by Mr. Sank’s wife; (c) 36,533 shares of common stock issuable to Mr. Sank                                         upon the exercise of outstanding stock options; and (d) 138,889 shares of common stock                                         owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims                                         beneficial ownership of the securities referenced in (b) and (d) above.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         6,666 shares of common stock issuable upon the exercise of outstanding stock options                                         and 1,155,367 shares of Common Stock held by HTIT. Mr. Gao is the chairman of HTIT.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (11)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes                                         890,467 shares of Common Stock issuable upon the exercise of options beneficially owned                                         by the referenced persons and 164,636 shares of Common Stock underlying vested RSUs that                                         are issuable upon request.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_021">          </a>          ITEM13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Duringfiscals 2020 and 2019, except for compensation arrangements described elsewhere herein, we did not participate in any transaction,and we are not currently participating in any proposed transaction, or series of transactions, in which the amount involved exceededthe lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years,and in which, to our knowledge, any of our directors, officers, five percent beneficial security holders, or any member of theimmediate family of the foregoing persons had, or will have, a direct or indirect material interest.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ourpolicy is to enter into transactions with related persons on terms that, on the whole, are no less favorable than those availablefrom unaffiliated third parties. Based on our experience in the business sectors in which we operate and the terms of our transactionswith unaffiliated third parties, we believe that all of the transactions described below met this policy standard at the timethey occurred. All related person transactions are approved by our Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         OnNovember 30, 2015, we, our Israeli subsidiary and HTIT entered into a Technology License Agreement, which was further amended,according to which we granted HTIT an exclusive commercialization license in the Territory related to our oral insulin capsule,ORMD-0801. Pursuant to this license agreement, HTIT will conduct certain pre-commercialization and regulatory activities withrespect to our subsidiary’s technology related to the ORMD-0801 capsule, and will pay certain royalties and an aggregateof approximately $37.5 million. On November 30, 2015, we also entered into a securities purchase agreement with HTIT, pursuantto which, among other things, Mr. Kidron will serve as proxy and attorney in fact of HTIT, with full power of substitution, tocast on behalf of HTIT all votes that HTIT is entitled to cast with respect to the Purchased Shares at any and all meetings ofour stockholders to consent or dissent to any action taken without a meeting and to vote all the Purchased Shares held by HTITin any manner Mr. Kidron deems appropriate except for matters related to our activities in the People’s Republic of China,on which Mr. Kidron will consult with HTIT before taking any action as proxy.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheBoard has determined that Aviad Friedman, Arie Mayer, Kevin Rakin, Leonard Sank and Gao Xiaoming are independent as defined underthe rules promulgated by Nasdaq.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 54; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_022">          </a>          ITEM14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theaggregate fees billed by Kesselman &amp; Kesselman, independent registered public accounting firm, and member firm of PricewaterhouseCoopersInternational Limited, for services rendered to us during fiscals 2020 and 2019:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Audit    Fees            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           95,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           96,000          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Audit-Related    Fees            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           101,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Tax    Fees            <sup>             (3)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           All Other Fees          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">           Total Fees          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="text-align: left; border-bottom: Black 4pt double">           $          </td>          <td style="text-align: right; border-bottom: Black 4pt double">           198,000          </td>          <td style="text-align: left; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="text-align: left; border-bottom: Black 4pt double">           $          </td>          <td style="text-align: right; border-bottom: Black 4pt double">           97,000          </td>          <td style="text-align: left; padding-bottom: 4pt">          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt">          </td>          <td style="width: 35.3pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amount                                         represents fees paid for professional services for the audit of our consolidated annual                                         financial statements, review of our interim condensed consolidated financial statements                                         included in quarterly reports and services that are normally provided by our independent                                         registered public accounting firm in connection with statutory and regulatory filings                                         or engagements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Represents                                         fees paid for services rendered in connection with our Offering.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0pt; text-align: justify">          </td>          <td style="width: 35.3pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Represents                                         fees paid for tax consulting services.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         SECrules require that before the independent registered public accounting firm are engaged by us to render any auditing or permittednon-audit related service, the engagement be: (1) pre-approved by our Audit Committee; or (2) entered into pursuant to pre-approvalpolicies and procedures established by the Audit Committee, provided the policies and procedures are detailed as to the particularservice, the Audit Committee is informed of each service, and such policies and procedures do not include delegation of the AuditCommittee’s responsibilities to management.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheAudit Committee pre-approves all services provided by our independent registered public accounting firm. All of the above servicesand fees were reviewed and approved by the Audit Committee before the services were rendered.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 55; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="a_023">          </a>          PARTIV         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          <a name="a_024">          </a>          ITEM 15.         </b>        </font>        <font style="font: 10pt Times New Roman, Times, Serif">         <b>          EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.         </b>        </font>       </p>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (a)            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Index                                         to Financial Statements            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Thefollowing consolidated financial statements are filed as part of this Annual Report on Form 10-K:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: bottom; width: 90%; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top; width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_001">             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-1           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             CONSOLIDATED    FINANCIAL STATEMENTS:            </b>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; padding-left: 0.25in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_002">             Balance sheets            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; padding-left: 0.25in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_003">             Statements of comprehensive loss            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; padding-left: 0.25in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_004">             Statements of changes in stockholders’ equity            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; padding-left: 0.25in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_005">             Statements of cash flows            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; padding-left: 0.25in; text-indent: -0.125in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#b_006">             Notes to financial statements            </a>           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6 - F-28           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0px">        ________________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0px">        _____________________________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0px">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0px">        ________________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0px">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 56; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <img alt="" src="img_002.jpg"/>       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <a name="b_001">         </a>         Reportof Independent Registered Public Accounting Firm        </font>       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Tothe Board of Directors and Stockholders of Oramed Pharmaceuticals Inc.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Opinionon the Financial Statements          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Wehave audited the accompanying consolidated balance sheets of Oramed Pharmaceuticals Inc. and its subsidiaries (the “Company”)as of August 31, 2020 and 2019, and the related consolidated statements of comprehensive loss, changes in stockholders’equity and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidatedfinancial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects,the financial position of the Company as of August 31, 2020 and 2019, and the results of their operations and its cash flows forthe years then ended in conformity with accounting principles generally accepted in the United States of America.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <i>          Changein Accounting Principle         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Asdiscussed in Note 1(k) to the audited consolidated financial statements, the Company changed the manner in which it accounts forrevenues from contracts with customers during the year ended August 31, 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Basisfor Opinion          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Theseconsolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express anopinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registeredwith the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent withrespect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securitiesand Exchange Commission and the PCAOB.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Weconducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standardsrequire that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statementsare free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged toperform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understandingof internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’sinternal control over financial reporting. Accordingly, we express no such opinion.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ouraudits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whetherdue to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating theaccounting principles used and significant estimates made by management, as well as evaluating the overall presentation of theconsolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         /s/ Kesselman &amp; Kesselman        </font>        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         Kesselman &amp; Kesselman        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         Certified Public Accountants (Isr.)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         A member firm of PricewaterhouseCoopers International Limited        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         Tel Aviv, Israel        </font>        <font style="font: 10pt Times New Roman, Times, Serif">        </font>        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         November 24, 2020        </font>        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         We have served as the Company’s auditor since 2008.        </font>        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <i>         Kesselman &amp;Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,         <br/>         P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555,Fax:+972 -3- 7954556,         <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">          www.pwc.com/il         </font>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 57; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="b_002">          </a>          ORAMEDPHARMACEUTICALS INC.          <br/>         </b>         CONSOLIDATED BALANCE SHEETS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: center; padding-left: 0.125in; text-indent: -0.125in">           ASSETS          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           CURRENT ASSETS:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Cash and cash equivalents          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           19,296          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3,329          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Short-term deposits (note 2)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11,060          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           25,252          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Marketable securities (note 3)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,544          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,701          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">           Prepaid expenses and other current assets          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           611          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,042          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total current assets          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           40,511          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           33,324          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           LONG-TERM ASSETS:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Long-term deposits and investment (note 4)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Marketable securities (note 3)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,928          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,295          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Amounts funded in respect of employee rights upon retirement          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           18          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           19          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Property and equipment, net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           99          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">           Operating lease right of use assets          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           75          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total long-term assets          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,122          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,339          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.5in; text-indent: -0.125in">           Total assets          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           44,633          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           34,663          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: center; padding-left: 0.125in; text-indent: -0.125in">           LIABILITIES AND STOCKHOLDERS’ EQUITY          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           CURRENT LIABILITIES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Accounts payable and accrued expenses (note 5)          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1,699          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2,541          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Deferred revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,703          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,703          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Payable to related parties (note 11c)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           90          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           64          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">           Operating lease liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           44          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total current liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,536          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           5,308          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           LONG-TERM LIABILITIES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Deferred revenues          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,947          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,658          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Employee rights upon retirement          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           18          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           22          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Provision for uncertain tax position (note 10f)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           11          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Operating lease liabilities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           31          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in; text-indent: -0.125in">           Other liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           211          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           271          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total long-term liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           7,218          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           9,962          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <b>            COMMITMENTS           </b>           (note 6)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           STOCKHOLDERS’ EQUITY:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">           Common stock, $ 0.012 par value (60,000,000 authorized shares as of August 31, 2020 and 30,000,000 authorized shares as of August 31, 2019; 23,675,530 and 17,383,359 shares issued and outstanding as of August 31, 2020 and 2019, respectively)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           284          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           208          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           Additional paid-in capital          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           125,209          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,288          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           Accumulated deficit          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (92,614          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (81,103          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total stockholders’ equity          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           32,879          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           19,393          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.5in; text-indent: -0.125in">           Total liabilities and stockholders’ equity          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           44,633          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           34,663          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theaccompanying notes are an integral part of the financial statements.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 58; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="b_003">          </a>          ORAMEDPHARMACEUTICALS INC.          <br/>         </b>         CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Inthousands (except share and per share data)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           REVENUES          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,710          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,703          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <b>            COST OF REVENUES (INCOME)           </b>           (note 6f)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           90          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           RESEARCH AND DEVELOPMENT EXPENSES          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10,235          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,522          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           GENERAL AND ADMINISTRATIVE EXPENSES          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,232          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,722          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           OPERATING LOSS          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,757          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14,631          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <b>            FINANCIAL INCOME           </b>           (note 9a)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           690          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,061          </td>          <td style="text-align: left">           <b>           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           <b>            FINANCIAL EXPENSES           </b>           (note 9b)          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           444          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           485          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           LOSS BEFORE TAXES ON INCOME          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,511          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14,055          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           <b>            TAXES ON INCOME           </b>           (note    10d)          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           300          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           NET LOSS FOR THE YEAR          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,511          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14,355          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           UNREALIZED INCOME ON AVAILABLE FOR SALE SECURITIES          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           TOTAL OTHER COMPREHENSIVE INCOME          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           TOTAL    COMPREHENSIVE LOSS FOR THE PERIOD          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           11,511          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           14,355          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           LOSS PER SHARE OF COMMON STOCK:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           0.56          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           0.82          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           20,532,347          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           17,454,489          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theaccompanying notes are an integral part of the financial statements.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 59; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="b_004">          </a>          ORAMEDPHARMACEUTICALS INC.          <br/>         </b>         CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         inthousands        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Common Stock          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Additional             <br/>             paid-in            </b>           </font>          </td>          <td>          </td>          <td style="font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Accumulated           <br/>           other           <br/>           comprehensive          </td>          <td style="font-weight: bold">          </td>          <td>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Accumulated            </b>           </font>          </td>          <td>          </td>          <td style="font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Total stockholders’          </td>          <td style="font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid">           <b>            $           </b>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           capital          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           income          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           deficit          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           equity          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt">          </td>          <td style="font-weight: bold; padding-bottom: 2pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; padding-bottom: 2pt">           In thousands          </td>          <td style="padding-bottom: 2pt; font-weight: bold">          </td>          <td style="padding-bottom: 2pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>          <td colspan="2" style="text-align: center; padding-bottom: 2pt">          </td>          <td style="padding-bottom: 2pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           BALANCE AS OF SEPTEMBER 1, 2018          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           17,369          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           207          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           99,426          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           702          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (69,223          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           31,112          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           INITIAL ADOPTION OF ASU 2016-01          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (702          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           702          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           INITIAL ADOPTION OF ASC 606          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,773          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,773          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           SHARES ISSUED FOR SERVICES          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           STOCK-BASED COMPENSATION          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           808          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           808          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           NET LOSS          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (14,355          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (14,355          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           BALANCE AS OF AUGUST 31, 2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           17,383          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           208          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,288          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (81,103          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           19,393          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           SHARES ISSUED FOR SERVICES          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           38          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           38          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           ISSUANCE OF COMMON STOCK, NET          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,270          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           75          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,698          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,773          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           EXERCISE OF WARRANTS AND OPTIONS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           STOCK-BASED COMPENSATION          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,173          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,173          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           NET LOSS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (11,511          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (11,511          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           BALANCE AS OF AUGUST 31, 2020          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           23,675          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           284          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           125,209          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (92,614          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           32,879          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         *Represents an amount of less than $1.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theaccompanying notes are an integral part of the financial statements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 60; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <a name="b_005">          </a>          ORAMEDPHARMACEUTICALS INC.          <br/>         </b>         CONSOLIDATED STATEMENTS OF CASH FLOWS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           CASH FLOWS FROM OPERATING ACTIVITIES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Net loss          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (11,511          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (14,355          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.375in; text-indent: -0.125in">           Depreciation          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Exchange differences and interest on deposits and held to maturity bonds          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           546          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (183          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Stock-based compensation          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,173          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           808          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Change at fair value of investments          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           465          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           437          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Shares issued for services          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           38          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           55          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.25in">           Changes in operating assets and liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Prepaid expenses and other current assets          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           431          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (468          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Accounts payable, accrued expenses and related parties          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (816          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           501          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Deferred revenue          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,710          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           297          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.375in; text-indent: -0.125in">           Liability for employee rights upon retirement          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (4          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in; text-indent: -0.125in">           Other liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (59          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (42          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total net cash used in operating activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (12,440          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (12,940          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           CASH FLOWS FROM INVESTING ACTIVITIES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Purchase of property and equipment          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (82          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (15          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Purchase of short-term deposits          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (27,204          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (24,990          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Purchase of mutual funds          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (3,750          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Purchase of long-term deposits          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (4,237          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Purchase of held to maturity securities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (8,428          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1,357          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Proceeds from sale of short-term deposits          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           40,891          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           38,611          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Proceeds from maturity of held to maturity securities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,200          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,250          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">           Funds in respect of employee rights upon retirement          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (1          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (3          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total net cash provided by (used in) investing activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,626          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,259          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           CASH FLOWS FROM FINANCING ACTIVITIES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">           Proceeds from issuance of common stock and warrants, net of issuance costs          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,773          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">           Proceeds from exercise of warrants and options          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           13          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.125in">           Total net cash provided by financing activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           23,786          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           EFFECT OF EXCHANGE RATE CHANGES ON CASH          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (5          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">           INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15,967          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1,667          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,329          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,996          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           CASH AND CASH EQUIVALENTS AT END OF PERIOD          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           19,296          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,329          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            </font>           </p>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">           SUPPLEMENTARY DISCLOSURE ON CASH FLOWS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">           Taxes paid          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           300          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">           Interest received          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,313          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           929          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          Theaccompanying notes are an integral part of the financial statements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font: 10pt Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <!-- Field: Page; Sequence: 61; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         <a name="b_006">         </a>         ORAMED PHARMACEUTICALSINC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           <b>            General           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           <b>            1)           </b>          </td>          <td style="text-align: justify">           <b>            Incorporation and operations           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        Oramed Pharmaceuticals Inc. (collectivelywith its subsidiaries, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, underthe laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged inthe acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with HadasitMedical Services and Development Ltd. to acquire the provisional patent related to orally ingestible insulin capsule to be usedfor the treatment of individuals with diabetes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        On May 14, 2007, the Company incorporateda wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        On March 11, 2011, the Company was reincorporatedfrom the State of Nevada to the State of Delaware.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        On July 30, 2019, the Company’s subsidiaryincorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited (the “Hong Kong Subsidiary”). As of August 31,2020, the Hong Kong Subsidiary has no operation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        On November 30, 2015, the Company enteredinto a Technology License Agreement (the “TLA”), with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”)and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amendedby the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, theCompany granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau andHong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”).Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activitieswith respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% onnet sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregateof $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreementswith certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that theCompany does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expirationof the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certaincircumstances, to 5%.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        The royalty payment obligation shall applyduring the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of(i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale ofthe Product in the Territory (the “Royalty Term”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        The License Agreement shall remain in effectuntil the expiration of the Royalty Term. The License Agreement contains customary termination provisions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        Among others, the Company’s involvementthrough the product submission date will include consultancy for the pre-commercialization activities in the Territory, as wellas advisory services to HTIT on an ongoing basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 62; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        As of August 31, 2020, the Company hasreceived milestone payments in an aggregate amount of $20,500 as follows: the initial payment of $3,000 was received in January2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were receivedin July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 wasreceived in January 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        On August 21, 2020, the Companyreceived a letter from HTIT, disputing certain pending payment obligations of HTIT under the TLA. The payment obligation beingdisputed is $4,000, out of which only an amount of $2,000 has been received and has been included in Deferred revenue in each ofthe consolidated balance sheets as of the fiscal years ended August 31, 2020, and 2019. In addition, the dispute includes a paymentobligation of $2,000 for certain milestones that the Company asserts it met under the TLA subsequent to the fiscal year ended August31, 2020. The Company wholly disputes the claims made by HTIT and has been engaged in discussions and exchanges with HTIT in anattempt to clarify and resolve disagreements between the parties regarding milestone payments and work plan implementation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        In addition, on November 30, 2015, theCompany entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        The License Agreement and the SPA wereconsidered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between theLicense Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock(less issuance expenses of $23), based on the quoted price of the Company’s shares on the closing date of the SPA on December28, 2015, and $38,883 was allocated to the License Agreement. Given the Company’s continuing involvement through the expectedproduct submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which theCompany is entitled to the respective payment, and the expected product submission date using a time-based model approach overthe periods that the fees are earned.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        In July 2015, according to the letter ofintent signed between the parties or their affiliates, HTIT’s affiliate paid the Subsidiary a non-refundable amount of $500as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement.        <br/>        <br/>        For the Company’s revenue recognition policy see note 1k.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 63; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           <b>            2)           </b>          </td>          <td style="text-align: justify">           <b>            Development and liquidity risks           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        The Company is engaged in research anddevelopment in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsuleto be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides,and has not generated significant revenues from its operations. Based on the Company’s current cash resources and commitments,the Company believes it will be able to maintain its current planned development activities and the corresponding level of expendituresfor at least the next 12 months, although no assurance can be given that the Company will not need additional funds prior to suchtime. If there are unexpected increases in its operating expenses, the Company may need to seek additional financing during thenext 12 months. Successful completion of the Company’s development programs and its transition to normal operations is dependentupon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within theUnited States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreementswith third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates,and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, ifat all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for eachof its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependenton the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the UnitedStates and in other countries. The Company cannot predict the outcome of these activities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        In addition to the foregoing, based onthe Company’s current assessment, the Company does not expect any material impact on its development timeline and its liquiditydue to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operation bymonitoring the spread of COVID-19 and the actions implemented by the governments to combat the virus throughout the world.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           <b>            Basis of presentation           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The consolidated financial statements havebeen prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           <b>            Use of estimates in the preparation of financialstatements           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The preparation of the consolidated financialstatements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amountsof assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reportedexpenses during the reporting periods. Actual results could differ from those estimates.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As applicable to these consolidated financialstatements, the most significant estimates and assumptions relate to stock-based compensation, expectation of milestone paymentsand to the expected product submission date for revenue recognition purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 64; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           <b>            Functional currency           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The currency of the primary economic environmentin which the operations of the Company and its Subsidiaries are conducted is the U.S. dollar (“$” or “dollar”).Therefore, the functional currency of the Company and its Subsidiaries is the dollar.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Transactions and balances originally denominatedin dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historicaland current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflectedin the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction datesor average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchangerates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            e.           </b>          </td>          <td style="text-align: justify">           <b>            Principles of consolidation           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The consolidated financial statements includethe accounts of the Company and its Subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            f.           </b>          </td>          <td style="text-align: justify">           <b>            Cash equivalents           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company considers all short-term, highlyliquid investments, which include short-term deposits with original maturities of three months or less from the date of purchasethat are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            g.           </b>          </td>          <td style="text-align: justify">           <b>            Fair value measurement:           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company measures fair value and disclosesfair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderlytransaction between market participants at the measurement date. In order to increase consistency and comparability in fair valuemeasurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measurefair value into three broad levels, which are described as follows:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1.25in">          </td>          <td style="width: 0.5in; text-align: left">           Level 1:          </td>          <td style="text-align: justify">           Quoted prices (unadjusted) in active markets thatare accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level1 inputs.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1.25in">          </td>          <td style="width: 0.5in; text-align: left">           Level 2:          </td>          <td style="text-align: justify">           Observable prices that are based on inputs other thanquoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1.25in">          </td>          <td style="width: 0.5in; text-align: left">           Level 3:          </td>          <td style="text-align: justify">           Unobservable inputs are used when little or no marketdata is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, the assets measuredat fair value are comprised of equity securities (Level 1). The fair value of held to maturity bonds as presented in note 3 wasbased on a Level 2 measurement.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, the carrying amountsof cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities ofthese instruments.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, the carrying amountsof long-term deposits approximate their fair values due to the stated interest rates which approximate market rates.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The amounts funded in respect of employeerights are stated at cash surrender value which approximates its fair value.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        There were no Level 3 items for the yearsended August 31, 2020 and 2019.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 65; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            h.           </b>          </td>          <td style="text-align: justify">           <b>            Marketable securities           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           <b>            1)           </b>          </td>          <td style="text-align: justify">           <b>            Equity securities           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        In January 2016,the Financial Accounting Standards Board (“FASB”) issued guidance which updates certain aspects of recognition, measurement,presentation and disclosure of financial assets and financial liabilities (“ASU 2016-01”). The guidance requires entitiesto recognize changes in fair value in net income rather than in accumulated other comprehensive income. The Company adopted theprovisions of this update in the first quarter of fiscal year 2019. Following the adoption, as of September 1, 2018, the Companyclassified the available for sale securities (investments in equity securities of D.N.A Biomedical Solutions Ltd. (“D.N.A”),Entera Bio Ltd. (“Entera”) and other mutual funds) to financial assets measured at fair value through profit or loss.The Company adopted the standard using the modified retrospective method and, accordingly, reclassified the cumulative unrealizedgain from accumulated other comprehensive income to a reduction of its accumulated deficit in an amount of $702.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           <b>            2)           </b>          </td>          <td style="text-align: justify">           <b>            Held to maturity securities           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        All debt securities are classified as held-to-maturitybecause the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are statedat amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, managementassesses whether there are any indicators that the value of the Company’s marketable securities may be impaired, which includesreviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and durationof the decline. In the Company’s evaluation, the Company considers its ability and intent to hold these investments for areasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair valueof the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To theextent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimatedfair value of the security.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            i.           </b>          </td>          <td style="text-align: justify">           <b>            Concentration of credit risks           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Financial instruments that subject theCompany to credit risk consist primarily of cash and cash equivalents, short and long-term deposits and marketable securities whichare deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balancesis remote.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of the date ofissuing these financial statements, all amounts due from HTIT with regard to the License Agreement have been received, as describedin note 1 above. However, the balance of prepaid expenses and other current assets composed of $290 was due as an expenses reimbursementfrom HTIT.        <br/>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 66; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            j.           </b>          </td>          <td style="text-align: justify">           <b>            Income taxes           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           1.          </td>          <td style="text-align: justify">           Deferred taxes          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        Deferred taxes are determined utilizingthe asset and liability method based on the estimated future tax effects of differences between the financial accounting and taxbases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expectedto be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based uponthe weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 10.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        Regarding the Subsidiary, the recognitionis prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax basesof assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that resultfrom changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected inthe computation of deferred tax assets and liabilities.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        Taxes that would apply in the event ofdisposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company’sintention to hold this investment, not to realize it.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           2.          </td>          <td style="text-align: justify">           Uncertainty in income tax          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify">        The Company follows a two-step approachto recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determiningif the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. Thesecond step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balancesheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within incometax expenses.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            k.           </b>          </td>          <td style="text-align: justify">           <b>            Revenue recognition           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The License Agreement and the SPA wereconsidered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between theLicense Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock(less issuance expenses of $23), based on the quoted price of the Company’s shares on the closing date of the SPA on December28, 2015, and $38,883 was allocated to the License Agreement.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Under Accounting Standards Codification(“ASC”) 605 (which was the authoritative revenue recognition guidance applied for all periods prior to September 1,2018) given the Company’s continuing involvement through the expected product submission in June 2023, amounts received relatingto the License Agreement were recognized over the period from which the Company was entitled to the respective payment, and theexpected product submission date using a time-based model approach over the periods that the fees were earned.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 67; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        On September 1, 2018, the Company adoptedAccounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“ASC606”), using the modified retrospective method of adoption. Under this method, the Company applied ASC 606 to the LicenseAgreement at the adoption date and was required to make an adjustment to the September 1, 2018 opening accumulated deficit balance.All prior periods continue to be presented under ASC 605. The most significant impact from adopting ASC 606 was the impact of thetiming of recognition of revenue associated with the milestone payment. Under ASC 605, which was the authoritative revenue recognitionguidance applied for all periods prior to September 1, 2018, given the Company’s continuing involvement through the expectedproduct submission in June 2023, amounts received relating to the License Agreement were recognized over the period from whichthe Company was entitled to the respective payment and the expected product submission date using a time-based model approach overthe periods that the fees were earned. However, under ASC 606, the Company is required to recognize the total transaction price(which includes consideration related to milestones once the criteria for recognition have been satisfied) using the input methodover the period the performance obligation is fulfilled. Accordingly, once the consideration associated with a milestone is includedin the transaction price, incremental revenue is recognized immediately based on the period of time that has elapsed towards completesatisfaction of the performance obligation. This method results in the recognition of revenue earlier than under ASC 605, and theresulting impact was recorded as a reduction of the opening balance of accumulated deficit at September 1, 2018, as further describedbelow.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Under ASC 606, the Company identified asingle performance obligation in the agreement and determined that the license and services are not distinct as the license andservices are highly dependent on each other. In other words, HTIT cannot benefit from the license without the related services,and vice versa.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Since the customer benefits from the servicesas the entity performs, revenue is recognized over time through the expected product submission date in June 2023, using the inputmethod. The Company used the input method to measure the process for the purpose of recognizing revenue, which approximates thestraight-line attribution. The Company used significant judgment when it determined the product submission date.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Under ASC 606, the consideration that theCompany would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of futureevents, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to beincluded in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the considerationrelated to milestones of which the occurrence is not considered the most likely outcome.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 68; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company then evaluates if any of thevariable consideration determined in the first step is constrained by including in the transaction price variable considerationto the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur whenthe uncertainty associated with the variable consideration is subsequently resolved. The Company used significant judgmentwhen it determined the first step of variable consideration.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The potential future royalty considerationis also considered a form of variable consideration under ASC 606 as it is based on a percentage of potential future sales of theCompany’s products. However, the Company applies the sales-based royalty exception and accordingly will recognize the sales-basedroyalty amounts at the earlier of the time (a) when the related sale has occurred and (b) the Company has fulfilled the relatedperformance obligation. To date, the Company has not recognized any royalty-related revenue.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of the adoption date, the Company adjustedits accumulated deficit by $1,773 against contract liabilities due to the effect of variable consideration.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Amounts that were allocated to the LicenseAgreement as of August 31, 2020 aggregated $22,383, all of which was received through the balance sheet date. Through August 31,2020, the Company recognized revenue associated with this agreement in the aggregate amount of $12,732 (of which $2,710 was recognizedin the twelve-months period ended August 31, 2020), and deferred the remaining amount of $9,650, which is presented as a contractliability on the condensed consolidated balance sheet.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            l.           </b>          </td>          <td style="text-align: justify">           <b>            Cost of revenues           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Cost of revenues consists of royaltiesto the IIA related to the License Agreement with HTIT. The royalties are recognized when proceeds related to the License Agreementare received.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            m.           </b>          </td>          <td style="text-align: justify">           <b>            Research and development           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Research and development expenses includecosts directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits,the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinicaltrials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costsassociated with research and development are expensed as incurred.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Clinical trial costs are a significantcomponent of research and development expenses and include costs associated with third-party contractors. The Company outsourcesa substantial portion of its clinical trial activities, utilizing external entities such as Clinical Research Organizations (“CROs”),independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinicalstudies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 69; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            n.           </b>          </td>          <td style="text-align: justify">           <b>            Stock-based compensation           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Equity awards granted to employees areaccounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options andrestricted stock units (“RSUs”) with an exercise price using the Black Scholes pricing model, for stock options withmarket conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fairvalue of share based payment awards is recognized as an expense over the requisite service period. The expected term is the lengthof time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specifichistorical information of employees’ exercise behavior, unless the award includes a market condition, in which case the contractualterm is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods.The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using theaccelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense isnot reversed if the market conditions are not satisfied.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        When stock options are granted as considerationfor services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the considerationreceived or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options grantedto consultants and other non-employees is measured on a final basis at the end of the related service period using the Black Scholespricing model and is recognized over the related service period using the straight-line method.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company elects to account for forfeituresas they occur.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        <font style="background-color: white">         OnSeptember 1, 2019 the Company adopted the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) Improvementsto Nonemployee Share-based Payments. This ASU was issued to simplify the accounting for share-based transactions by expanding thescope of Topic 718 from only being applicable to share-based payments to employees to also include share-based payment transactionsfor acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions are being measured by estimatingthe fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performanceconditions.        </font>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            o.           </b>          </td>          <td style="text-align: justify">           <b>            Loss per common share           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Basic and diluted net loss per common shareare computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for eachperiod. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share becauseall such securities are anti-dilutive for all periods presented. The weighted average number of stock options, warrants and RSUsexcluded from the calculation of diluted net loss was 5,025,723 and 4,423,325 for the years ended August 31, 2020 and 2019, respectively.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">       </p>       <!-- Field: Page; Sequence: 70; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            p.           </b>          </td>          <td style="text-align: justify">           <b>            Newly issued and recently adopted Accounting Pronouncements           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           1.          </td>          <td style="text-align: justify">           In February 2016, the FASB issued ASU No. 2016-02,“Leases (Topic 842)”, which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standardrequires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leaseswill be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee’sincome statement. The Company adopted this standard as of September 1, 2019 on a modified retrospective basis and will notrestate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance withinthe new standard which, among other things, allows the Company to carryforward the historical lease classification. The Companymade an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Companyrecognized those lease payments in its statements of operations on a straight-line basis over the lease period. As of the adoptiondate, the Company recognized an operating lease asset and liability of $168 and $168, respectively, as of September 1, 2019 onits balance sheet.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 1in">          </td>          <td style="width: 0.25in; text-align: left">           2.          </td>          <td style="text-align: justify">           <font style="background-color: white">            On September 1,2019 the Company adopted the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718) Improvements to NonemployeeShare-based Payments. This ASU was issued to simplify the accounting for share-based transactions by expanding the scope of Topic718 from only being applicable to share-based payments to employees to also include share-based payment transactions for acquiringgoods and services from nonemployees. As a result, nonemployee share-based transactions are being measured by estimating the fairvalue of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions.The adoption of this slandered had no material impact on the Company’s consolidated financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            q.           </b>          </td>          <td style="text-align: justify">           <b>            Recently issued Accounting Pronouncements, notyet adopted           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        <font style="background-color: white">         InJune 2016, the FASB issued ASU        </font>        2016-13        <font style="background-color: white">         “Financial Instruments—CreditLosses—Measurement of Credit Losses on Financial Instruments.” This guidance replaces the current incurred loss impairmentmethodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonableand supportable information to inform credit loss estimates. The guidance will be effective for the fiscal year beginning afterDecember 15, 2022, including interim periods within that year. The adoption of this guidance will not have a significant impacton the Company’s consolidated financial statements.        </font>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 71; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 2 - SHORT-TERM DEPOSITS:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>         Composition        </b>        :       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Annual interest rate          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Annual           <br/>           interest rate          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Amount          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: justify; padding-bottom: 4pt">           Dollar deposits          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right">            0.85-1.60           </p>          </td>          <td style="width: 1%; padding-bottom: 2pt; text-align: left">           %          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           11,060          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right">            1.80-3.44           </p>          </td>          <td style="width: 1%; padding-bottom: 2pt; text-align: left">           %          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           25,252          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 3 - MARKETABLE SECURITIES:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           <b>            Composition:           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company’s marketable securitiesinclude investments in equity securities of D.N.A, Entera, mutual funds and in held to maturity bonds.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        <b>         Composition        </b>        :       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify">           Short-term:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           D.N.A (see b below)          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           246          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           557          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Entera (see c below)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           150          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           304          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Held to maturity bonds (see d below)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,369          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,840          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Preferred equity          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           481          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Mutual funds*          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,298          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9,544          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,701          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           Long-term:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Held to maturity bonds (see d below)          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,928          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,295          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           13,472          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           4,996          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 3pt; width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           *          </td>          <td style="text-align: justify">           Mutual funds include equity funds only          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           <b>            D.N.A           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        <b>         <br/>        </b>        The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at thequoted prices of the securities on the measurement date.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        During the years ended August 31, 2020and 2019, the Company did not sell any of the D.N.A ordinary shares. As of August 31, 2020, the Company owns approximately 5.6%of D.N.A’s outstanding ordinary shares.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The cost of the securities as of August31, 2020 and 2019 is $595.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           <b>            Entera           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Entera ordinary shares have been tradedon The Nasdaq Capital Market since June 28, 2018. The Company measures the investment at fair value from such date, since it hasa readily determinable fair value (prior to such date the investment was accounted for as a cost method investment (amounting to$1)).       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 72; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 3 - MARKETABLE SECURITIES        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           <b>            Held to maturity bonds           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The amortized cost and estimated fair valueof held-to-maturity securities at August 31, 2020, are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31, 2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Amortized cost          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Gross unrealized gains (losses)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">            <b>             Estimated fair value            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">            <b>             Averageyield to maturity rate            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           Short-term:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: justify">           Commercial bonds          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           5,295          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (29          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           5,266          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           2.26          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Accrued interest          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           74          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           74          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Long-term          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,928          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           56          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,984          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           2.20          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9,297          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           27          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9,324          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        The amortized cost and estimated fair valueof held-to-maturity securities at August 31, 2019, are as follows:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31, 2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Amortized cost          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Gross unrealized gains (losses)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">            <b>             Estimated fair value            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center">            <b>             Averageyield to maturity rate            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           Short-term:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: justify">           Commercial bonds          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,808          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           6          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,814          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           2.90          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Accrued interest          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           32          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           32          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Long-term          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,295          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,299          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           2.47          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           4,135          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           10          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           4,145          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Held to maturity securities which willmature during the 12 months from the balance sheet date are included in short-term marketable securities. Held to maturity securitieswith maturity dates of more than one year are considered long-term marketable securities.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 73; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 4 - LONG-TERM DEPOSITS AND INVESTMENT:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify; padding-left: 0.5in">           Composition:          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">           Lease car deposits          </td>          <td style="width: 1%; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">           2          </td>          <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          </td>          <td style="width: 1%; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">           1          </td>          <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify; padding-left: 0.5in">           Composition:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Accounts payable          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           594          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           1,337          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Payroll and related accruals          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           25          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Institutions          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           19          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           33          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Accrued liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,032          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,146          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,699          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,541          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 6 - COMMITMENTS:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           In March 2011, the Subsidiary sold shares of its investeecompany, Entera, to D.N.A, retaining 117,000 ordinary shares (after giving effect to a stock split by Entera in July 2018). Inconsideration for the shares sold to D.N.A, the Company received, among other payments, ordinary shares of D.N.A (see also note3).          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As part of this agreement, the Subsidiaryentered into a patent transfer agreement (the “Patent Transfer Agreement”) according to which the Subsidiary assignedto Entera all of its right, title and interest in and to a certain patent application related to the oral administration of proteinsthat it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royaltiesof 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respectof diabetes and influenza. As of August 31, 2020, Entera had not yet realized any revenues and had not paid any royalties to theSubsidiary. On December 11, 2018, Entera announced that it had entered into a research collaboration and license agreement (the“Amgen License”) with Amgen related to research of inflammatory disease and other serious illnesses. As reported byEntera, under the terms of the Amgen License, Entera will receive a modest initial technology access fee from Amgen and will beresponsible for preclinical development at Amgen’s expense. Entera will be eligible to receive up to $270,000 in aggregatepayments, as well as tiered royalties up to mid-single digits, upon achievement of various clinical and commercial milestones ifAmgen decides to move all of these programs forward. Amgen is responsible for clinical development, manufacturing and commercializationof any of the resulting programs. To the extent the Amgen License results in net revenues as defined in the Patent Transfer Agreement,the Subsidiary will be entitled to the aforementioned royalties.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        In addition, as part of a consulting agreementwith a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royaltiesreceived in respect of the patent that was sold to Entera in March 2011.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 74; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 6 - COMMITMENTS        </b>        (continued)        <b>         :        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           On January 3, 2017, the Subsidiary entered into alease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The annual lease payment was New IsraeliShekel (“NIS”) 119,000 ($35) from October 2016 through September 2018 and NIS 132,000 ($39) from October 2018 throughSeptember 2021, and is linked to the increase in the Israeli consumer price index (“CPI”).       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        On August 2, 2020, the Subsidiary enteredinto a new lease agreement for its facilities in Israel. The new lease agreement is for a period of 60 months commencing September1, 2020. The Company has the option to extend the period in another 60 months. The annual lease payment, including management fees,is NIS 435,000 ($130). The Company intends to terminate its current lease agreement before moving to the new office.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As security for its obligation under theselease agreements, the Company provided a bank guarantee in an amount equal to three monthly lease payments.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           On December 18, 2017, the Subsidiary entered intoan agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of$2,905 that will be paid over the term of the engagement and based on the achievement of certain development milestones, of which$1,542 was recognized in research and development expenses through August 31, 2020.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           On September 2, 2020 (effective as of January 15,2020), the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary’sphase 3 clinical trial for its oral insulin. As consideration for its services, the Subsidiary will pay the CRO a total amountof $21,589 during the term of the engagement and based on achievement of certain milestones, of which $178 was recognized in researchand development expenses through August 31, 2020.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            e.           </b>          </td>          <td style="text-align: justify">           On September 16, 2020 (effective as of January 15,2020), the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary’sphase 3 clinical trial for its oral insulin. As consideration for its services, the Subsidiary will pay the CRO a total amountof $12,343 during the term of the engagement and based on achievement of certain milestones, of which $400 was recognized in researchand development expenses through August 31, 2020.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            f.           </b>          </td>          <td style="text-align: justify">           <b>            Grants from the Israel Innovation Authority (“IIA”)           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Under the terms of the Company’sfunding from the IIA, royalties of 3% are payable on sales of products developed from a project so funded, up to a maximum amountequaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        At the time the grants were received, successfuldevelopment of the related projects was not assured. The total amount that was received through August 31, 2020 was $2,207. Allgrants were received before fiscal year 2020 and recorded as a reduction of Research and development expenses at that time.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The royalty expenses which are relatedto the funded project were recognized in cost of revenues in the year ended August 31, 2020 and in prior periods.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            g.           </b>          </td>          <td style="text-align: justify">           <b>            Grants from the European Commission (“EC”)           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        During fiscal year 2020, the Company receivedan aggregate payment of €50 from the EC under The European Innovation Council Accelerator (previously known as SME Instrument)of the European Innovation Programme Horizon 2020.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As part of the grant terms, the Companyis required to use the proceeds from the grant in Europe. The Company intends on using the grant to explore the possibility ofrunning clinical trials in Europe.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 75; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 7 - STOCKHOLDERS’ EQUITY:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        The following are the significant capitalstock transactions that took place during the years ended August 31, 2020 and 2019:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           In August 2019, the Company became aware of a shareholderderivative claim and putative class action alleging, among other things, that the Second Amended and Restated 2008 Stock IncentivePlan (the “2008 Plan”) may have terminated in 2018. However, the Company disputed these claims and believes thatthe 2008 Plan does not terminate until 2026 and any suggestion to the contrary is not well-founded. For the sake of clarity andout of an abundance of caution, the Company adopted a new option plan, which was approved at its 2019 shareholder meeting. Such2019 Stock Incentive Plan, as amended and restated (the “2019 Plan”) originally allowed the Company to grant up to1,000,000 options. Since the Company had granted options during the time after the old plan allegedly terminated, and out of anabundance of caution, the Company canceled these grants and reissued the options under the new option plan in the same amountsand under the same terms as the original grants. The cancelation and grants were approved by the Company’s board on September11, 2019. Out of the available options under the 2019 Plan, the Company have been granted 563,646 to replace the options underdispute as mentioned above. The cancellation of the award accompanied by the concurrent grant of a replacement award was accountedfor as modification of the terms of the cancelled award. Since the replacement award was given under the same terms as the cancelledaward, no incremental compensation cost was recognized. On August 3, 2020, the stockholders of the Company adopted the amendedand restated 2019 Plan which increased the shares available to grant under the plan by an additional 2,000,000 to 3,000,000 options.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           On September 5, 2019, the Company entered into anEquity Distribution Agreement (the “Sales Agreement”), pursuant to which the Company may, from time to time and atthe Company’s option, issue and sell shares of Company common stock having an aggregate offering price of up to $15,000,through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effectiveshelf registration statement on Form S-3 including a prospectus and prospectus supplement, each dated February 10, 2020 (whichsuperseded a prior registration statement, prospectus and prospectus supplement that related to shares sold under the Sales Agreement).The Company will pay the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through thesales agent under the Sales Agreement. As of August 31, 2020, 839,357 shares were issued under the Sales Agreement for aggregatenet proceeds of $3,879.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           On February 27, 2020, the Company entered into anunderwriting agreement (“Agreement”) with National Securities Corporation (“Underwriter”), in connectionwith a public offering (“Offering”) of 5,250,000 shares of the Company’s common stock, at an offering priceof $4.00 per share. Under the terms of the Agreement, the Company granted the Underwriter a 45-day option to purchase from theCompany up to an additional 787,500 shares of common stock at the public offering price (“Over-Allotment Option”).In connection with the Offering, the Company also agreed to issue to the Underwriter, or its designees, warrants (“Underwriter’sWarrants”), to purchase up to an aggregate of 7% of the shares of common stock sold in the Offering (including any additionalshares sold during the 45-day option period), at an exercise price of $4.80 per share. The Underwriter’s Warrants issuedin the Offering will be exercisable at any time and from time to time, in whole or in part, commencing six months from issuancefor a period of three years from the date of issuance. The closing of the sale of the Offering occurred on March 2, 2020. On April9, 2020, the Company issued 180,561 shares of Common Stock and 12,640 Underwriter’s Warrants pursuant to a partial exerciseby the Underwriter of the Over-Allotment Option (“Partial Over-Allotment Option Exercise”). The net proceeds to theCompany from the Offering, including from the Partial Over-Allotment Option Exercise, after deducting the underwriting discountand the Company’s estimated Offering expenses were $19,894.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           As of August 31, 2020, the Company had outstandingwarrants exercisable commencing January 6, 2019 for 3,407,820 shares of common stock at exercise prices ranging from $4.80 to$7.8125 per share and expiring from January 6, 2022 to April 10, 2029.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The following table presents the warrantactivity for the years ended August 31, 2020 and 2019:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Warrants          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-           <br/>           Average Exercise Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Warrants          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-           <br/>           Average Exercise Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: justify; padding-left: 0.125in; text-indent: -0.125in">           Warrants outstanding at beginning of year          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3,007,680          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           7.27          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3,007,680          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           7.27          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">           Issued          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           400,140          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           4.77          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">           Exercised          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">           Expired          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           Warrants outstanding at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,407,820          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6.98          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,007,680          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7.27          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">           Warrants exercisable at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,407,820          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6.98          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,007,680          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7.27          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 76; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 8 - STOCK-BASED COMPENSATION:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        The Company makes awards only under the2019 Plan, under which, the Company had reserved a pool of 3,000,000 shares of the Company’s common stock which may be issuedat the discretion of the Company’s Board of Directors from time to time. Under this 2019 Plan, each option is exercisableinto one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting scheduleswhich will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        The following are the significant stockoptions transactions with employees, board members and non-employees made during the years ended August 31, 2020 and 2019:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           On February 26, 2019, the Company granted optionsto purchase an aggregate of 360,000 shares of common stock of the Company at an exercise price of $3.16 per share (equivalentto the closing price of the Company’s common stock on the date of grant) as follows: 196,500 to the CEO; 104,000 to theCSO; and 59,500 to employees of the Subsidiary. 49,125, 26,000 and 14,875 options of the CEO, CSO and the employees, respectively,were vested and the remainder will vest in three equal annual installments on each of December 31, 2020, 2021 and 2022. Theseoptions expire on February 26, 2029. The fair value of all these options on the date of grant was $731, using the Black Scholesoption-pricing model and was based on the following assumptions: stock price of $3.16; dividend yield of 0% for all years; expectedvolatility of 69.05%; risk-free interest rates of 2.54%; and expected term of 6.25 years.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             b.            </b>           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On April 10, 2019 and April 15, 2019, the Company granted options to its directors to purchase an aggregate of 30,000 shares of common stock of the Company at an exercise price of $4.17 and $4.13 per share, respectively (equivalent to the closing price of the Company’s common stock on the date of grant). 20,000 of such options vested immediately and the remaining 10,000 options vested on December 31, 2019. The fair value of all these options on the date of grant was $64, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $4.13 and $4.17, respectively; dividend yield of 0% for all years; expected volatility of 54.64% and 66.40%, respectively; risk-free interest rates of 2.37% and 2.28%, respectively; and expected term of 5 and 5.5 years, respectively.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           On June 17, 2019, the Company granted options to itschief financial officer to purchase an aggregate of 33,146 shares of common stock of the Company at an exercise price of $3.55per share (equivalent to the closing price of the Company’s common stock on the date of grant). 5,396 of such options vestedwill vest on December 31, 2019 and the remaining 27,750 will vest in 3 equal installments on each of December 31, 2020, December31, 2021 and December 31, 2022. The fair value of all these options on the date of grant was $74, using the Black Scholes option-pricingmodel and was based on the following assumptions: stock price of $3.55; dividend yield of 0% for all years; expected volatilityof 67.79%; risk-free interest rates of 2.03%; and expected term of 6.25 years.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             d.            </b>           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On September 11, 2019, the Company granted options to its chief business and operation officer to purchase an aggregate of 100,000 shares of common stock of the Company at an exercise price of $3.69 per share (equivalent to the closing price of the Company’s common stock on the date of grant). The options shall vest in 16 equal installments of 6,250 on the first day of every three months period beginning November 1, 2019. As of August 31, 2020, 25,000 of such options are vested. The options expire on September 11, 2029. The fair value of all these options on the date of grant was $224, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $3.69; dividend yield of 0% for all years; expected volatility of 65.60%; risk-free interest rates of 1.89%; and expected term of 6.14 years.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             e.            </b>           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On September 11, 2019, the Company granted options to its chief business and operation officer to purchase an aggregate of 100,000 shares of common stock of the Company at an exercise price of $3.69 per share (equivalent to the closing price of the Company’s common stock on the date of grant). The options shall vest in 4 installments upon achievement of certain performance conditions. As of August 31, 2020, no such options are vested. The options expire on September 11, 2029. The fair value of all these options on the date of grant was $127, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $3.69; dividend yield of 0% for all years; expected volatility of 67.96%; risk-free interest rates of 1.68%; expected term of 6.91 years; and the probability that such performance conditions will occur.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            f.           </b>          </td>          <td style="text-align: justify">           On January 8, 2020, the Company granted options toits directors to purchase an aggregate of 100,000 shares of common stock of the Company at an exercise price of $4.80 per share(equivalent to the closing price of the Company’s common stock on the date of grant). The options shall vest in three equalinstallments on each of December 31, 2020, December 31, 2021 and December 31, 2022. The options expire on January 8, 2030. Thefair value of all these options on the date of grant was $278, using the Black Scholes option-pricing model and was based on thefollowing assumptions: stock price of $4.80; dividend yield of 0% for all years; expected volatility of 62.55%; risk-free interestrates of 1.67%; and expected term of 5.99.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 77; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 8 - STOCK-BASED COMPENSATION        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            g.           </b>          </td>          <td style="text-align: justify">           On January 8, 2020, the Company granted options topurchase an aggregate of 290,000 shares of common stock of the Company at an exercise price of $4.80 per share (equivalent tothe closing price of the Company’s common stock on the date of grant) as follows: 190,000 to the CEO and 100,000 to theCSO. The options will vest in four equal annual installments, on each of December 31, 2020, 2021, 2022 and 2023. These optionsexpire on January 8, 2030. The fair value of all these options on the date of grant was $868, using the Black Scholes option-pricingmodel and was based on the following assumptions: stock price of $4.80; dividend yield of 0% for all years; expected volatilityof 67.87%; risk-free interest rates of 1.67%; and expected term of 6.24 years.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            h.           </b>          </td>          <td style="text-align: justify">           <b>            Options to employees, directors and non-employees           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The fair value of each option grant isestimated on the date of grant using the Black Scholes option-pricing model or Monte Carlo model with the following range of assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           For options granted           <br/>           in the year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Expected option life (years)          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            5.74-6.24           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            5-6.25           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Expected stock price volatility (%)          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            57.77-68.14           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            54.64-69.05           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Risk free interest rate (%)          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            1.67-1.89           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2.03-2.54           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 78%; text-align: justify">           Expected dividend yield (%)          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: center">           0.0          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: center">           0.0          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        A summary of the status of the stock optionsgranted to employees and directors as of August 31, 2020, and 2019, and changes during the years ended on those dates, is presentedbelow:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Year ended           <br/>           August 31,          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Number           <br/>           of           <br/>           options          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           average           <br/>           exercise           <br/>           price          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Number           <br/>           of           <br/>           options          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           average           <br/>           exercise           <br/>           price          </td>          <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center; text-indent: -0.125in">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             $            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 52%; text-align: left; text-indent: -0.125in">           Options outstanding at beginning of year          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           1,264,645          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           6.11          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           1,208,634          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           7.25          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">           Changes during the year:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Granted          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           943,646          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.98          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           423,146          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.26          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Forfeited          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (392,646          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3.79          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (136,084          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5.79          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Expired          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (206,243          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6.02          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (231,051          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7.07          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; padding-bottom: 1.5pt; text-indent: -0.125in">           Exercised          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (12,253          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1.00          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Options outstanding at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,597,149          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           5.47          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,264,645          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           6.11          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Options exercisable at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           687,024          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           709,383          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Weighted average fair value of options granted during the year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2.79          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2.06          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Expenses recognized in respect of stockoptions granted to employees and directors, for the years ended August 31, 2020 and 2019 were $1,086 and $791, respectively.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The total intrinsic value of employees’options exercised during the year ended August 31, 2020 was $27. None of the options were exercised by employees during the yearended August 31, 2019.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 78; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 8 - STOCK-BASED COMPENSATION        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The following tablepresents summary information concerning the options granted to employees and directors outstanding as of August 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Exercise           <br/>           prices          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Number           <b>            outstanding           </b>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           Average           <br/>           Remaining           <br/>           Contractual           <br/>           Life          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           average           <br/>           exercise           <br/>           price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 1%; text-align: center">          </td>          <td style="width: 23%; text-align: center">           <font style="font-size: 10pt">            1.00 to 6.00           </font>          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           1,117,980          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           8.06          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           3.98          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            6.23 to 7.88           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           225,251          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6.82          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7.73          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="padding-bottom: 1.5pt; text-align: center">           <font style="font-size: 10pt">            8.14 to 12.45           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           253,918          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           5.77          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           10.01          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; text-align: center">          </td>          <td style="padding-bottom: 4pt; text-align: center">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,597,149          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7.52          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5.47          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        687,024 of options granted to employeesand directors that were outstanding as of August 31, 2020, were also exercisable as of August 31, 2020.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, there were $1,167of unrecognized compensation costs related to non-vested options previously granted to employees and directors. The unrecognizedcompensation costs are expected to be recognized over a weighted average period of 2.1 years.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        A summary of the status of the stock optionsgranted to non-employees outstanding as of August 31, 2020 and 2019, and changes during the years ended on those dates, is presentedbelow:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number           <br/>           of           <br/>           options          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted           <br/>           average           <br/>           exercise           <br/>           price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number           <br/>           of           <br/>           options          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted           <br/>           average           <br/>           exercise           <br/>           price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: justify; text-indent: -0.125in">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 52%; text-align: left; text-indent: -0.125in">           Options outstanding at beginning of year          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           47,152          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           9.51          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           55,486          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           6.71          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">           Changes during the year:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Granted          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           56,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4.21          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Exercised          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-indent: -0.125in">           Forfeited          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; padding-bottom: 1.5pt; text-indent: -0.125in">           Expired          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (8,334          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           9.12          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Options outstanding at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           103,152          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6.64          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           47,152          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           9.51          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Options exercisable at end of year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           65,152          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5.58          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           41,992          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           6.32          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Weighted average fair value of options granted during the year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2.47          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="font-size: 0.5pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 0.5pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 0.5pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; font-size: 0.5pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="font-size: 0.5pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 0.5pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 0.5pt; text-align: right">          </td>          <td style="padding-bottom: 4pt; font-size: 0.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        The Company recorded stock-based compensationof $87 and $22 during the years ended August 31, 2020 and 2019, respectively, related to non-employees’ awards.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        None of the options were exercised by non-employeesduring the years ended August 31, 2020 and 2019.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 79; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 8 - STOCK-BASED COMPENSATION        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The following tablepresents summary information concerning the options granted to non-employees outstanding as of August 31, 2020:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Range of           <br/>           exercise           <br/>           prices          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Number           <b>            outstanding           </b>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           Average           <br/>           Remaining           <br/>           Contractual           <br/>           Life          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Weighted           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           $          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 1%; text-align: center">          </td>          <td style="width: 23%; text-align: center">           <font style="font-size: 10pt">            3.74-5.08           </font>          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           56,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           9.30          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 22%; text-align: right">           4.22          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="padding-bottom: 1.5pt; text-align: center">           <font style="font-size: 10pt">            6.00-7.36           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           47,152          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           5.21          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6.29          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; text-align: center">          </td>          <td style="padding-bottom: 4pt; text-align: center">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           103,152          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7.43          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5.16          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        65,152 options granted to non-employeesthat were outstanding as of August 31, 2020, were also exercisable as of August 31, 2019.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, there were $51 ofunrecognized compensation costs related to non-vested options previously granted to non-employees. The unrecognized compensationcosts are expected to be recognized over a weighted average period of 1.5 years.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            i.           </b>          </td>          <td style="text-align: justify">           <b>            Restricted stock units           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The following table summarizes the activitiesfor unvested RSUs granted to employees and directors for the years ended August 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify; padding-bottom: 1.5pt">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Number of RSUs          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Unvested at the beginning of period          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           164,636          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           165,796          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Vested and issued          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (290          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Forfeited          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (870          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">           Outstanding at the end of the period          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           164,636          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           164,636          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">           Vested and unissued          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           164,636          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           164,636          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company recorded compensation incomerelated to RSUs of $5 for the year ended August 31, 2019, related to RSU awards. During the year ended August 31, 2020, the Companydid not record expense or income related to RSU.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, there are no unrecognizedcompensation costs related to RSUs.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 80; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 9 - FINANCIAL INCOME AND EXPENSES        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           <b>            Financial income           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Income from interest on deposits          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           552          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           909          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Income from interest on corporate bonds          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           138          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           152          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           690          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1,061          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           <b>            Financial expenses           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Exchange rate differences          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           6          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           14          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Bank and broker commissions          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Loss (gain) from securities, net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           432          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           436          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Other          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           31          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           444          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           485          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 10 - TAXESON INCOME:        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        Taxes on income included in the consolidatedstatements of operations represent current taxes due to taxable income of the Company and its Subsidiary.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           <b>            Corporate taxation in the U.S.           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The applicable corporate tax rate for theCompany is 21% following the U.S. Tax Cuts and Jobs Act (the “TCJA”), excluding state tax and local tax. On December22, 2017, the TCJA was signed into law, which among other changes reduced the federal corporate income tax rate from 35% to 21%,effective January 1, 2018.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 1in; text-align: justify">        <font style="font-size: 10pt">         Asof August 31, 2020, the Company has an accumulated tax loss carryforward of approximately $15,880 (as of August 31, 2019, $13,013).Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January1, 2018        </font>        ,        <font style="font-size: 10pt">         have no expiration date, but they are limited to 80% of the company's taxable incomein any given tax year. carryforward tax losses originating in tax years beginning prior to January 1, 2018        </font>        ,        <font style="font-size: 10pt">         expire20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with therelevant law, the net loss carryforward will expire in the years 2027 through 2039.        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           <b>            Corporate taxation in Israel:           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Subsidiary is taxed in accordance withIsraeli tax laws. The corporate tax rates applicable to 2020 and 2019 is 23%.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        As of August 31, 2020, the Subsidiary hasan accumulated tax loss carryforward of approximately $57,900 (as of August 31, 2019, approximately $44,469). Under the Israelitax laws, carryforward tax losses have no expiration date.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 81; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 10 - TAXES ON INCOME        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           <b>            Deferred income taxes:           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           August 31,          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           In respect of:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Net operating loss carryforward          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           16,652          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           13,239          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Research and development expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,740          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,999          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Less - valuation allowance          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (19,392          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (16,238          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">           Net deferred tax assets          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        Deferred taxes are determined based ontemporary differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted taxrates and laws that will be in effect when the differences are expected to reverse.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Realization of deferred tax assets is dependentupon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected tobe available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recordeda full valuation allowance.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The reduction of the tax rate and TCJAhad no impact on the net deferred taxes of the Company.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           <b>            Loss before taxes on income and income taxes includedin the income statements of operations:           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Loss before taxes on income:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 76%; text-align: justify">           U.S.          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,868          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           2,283          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">           Outside U.S.          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8,643          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,772          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           11,511          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           14,055          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Taxes on income (tax benefit):          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: justify">           Current:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: justify">           U.S.          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">           Outside U.S.          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           300          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           300          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        Taxes on incomeof $300 in the year ended August 31, 2019 resulted from withholding tax deducted from HTIT milestones payments, which were receivedduring the year ended August 31, 2019, according to the License Agreement. As of August 31, 2020, the Company did not expect toreach taxable income in the 5 years following the balance sheet date, and therefore recognized this amount as taxes on income.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 82; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 10 - TAXES ON INCOME        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            e.           </b>          </td>          <td style="text-align: justify">           <b>            Reconciliation of the statutory tax benefit toeffective tax expense           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        Following is a reconciliation of the theoreticaltax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actualtax expense:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Loss before income taxes as reported in the consolidated statement of comprehensive loss          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">           (11,511          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">           )          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">           (14,055          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">           Statutory tax benefit          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,417          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,952          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">           Increase in income taxes resulting from:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">           Change in the balance of the valuation allowance for deferred tax          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,154          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,356          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">           Disallowable deductions          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           135          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           86          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">           Influence of different tax rate applicable to the Subsidiary and changes in tax rates from previous years          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (872          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (490          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">           Withholding tax, see note 10d above          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           300          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Uncertain tax position          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Taxes on income for the reported year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           300          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            f.           </b>          </td>          <td style="text-align: justify">           <b>            Uncertainty in Income Taxes           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        ASC Topic 740, “Income Taxes”requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of eachtax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effectivetax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related toits tax contingencies as income tax expense.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The following table summarizes the activityof the Company unrecognized tax benefits:       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Balance at Beginning of Year          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           11          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           11          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Decrease in uncertain tax positions for the current year          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">           Balance at End of Year          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           11          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           11          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0; text-align: justify">        The Company does not expect unrecognizedtax expenses to change significantly over the next 12 months.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Company is subject to U.S. Federalincome tax examinations for the tax years of 2016 through 2018.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">        The Subsidiary is subject to Israeli incometax examinations for the tax years of 2014 through 2019.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 83; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         ORAMED PHARMACEUTICALS INC.         <br/>        </b>        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        In thousands (except share and per sharedata)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE 10 - TAXES ON INCOME        </b>        (continued):       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            g.           </b>          </td>          <td style="text-align: justify">           <b>            Valuation Allowance Rollforward           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Balance at beginning of period          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Additions          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Balance at end of period          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">           Allowance in respect of carryforward tax losses:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; width: 64%; text-align: justify; text-indent: -0.125in">           Year ended August 31, 2020          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           16,238          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3,154          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           19,392          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; text-align: justify; text-indent: -0.125in">           Year ended August 31, 2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12,882          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,356          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           16,238          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>         NOTE11 - RELATED PARTIES - TRANSACTIONS:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            a.           </b>          </td>          <td style="text-align: justify">           During each of the fiscal years of 2020 and 2019,the Company paid to directors $95 and $100, respectively, as directors’ fees.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            b.           </b>          </td>          <td style="text-align: justify">           On July 1, 2008, the Subsidiary entered into two consultingagreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the CSO, whereby the CEO and the CSO, through KNRY,provide services to the Company (the “Consulting Agreements”). The Consulting Agreements are both terminable by eitherparty upon 140 days, prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonableexpenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to theCEO and the CSO is NIS 127,570 ($38) and NIS 92,522 ($28), respectively.          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">        In addition to the Consulting Agreements,based on a relocation cost analysis prepared by consulting company ORI - Organizational Resources International Ltd., the Companypays for certain direct costs, related taxes and expenses incurred in connection with the relocation of the CEO to New York. Duringfiscal 2020 and 2019 such relocation expenses totaled $516 and $486, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            c.           </b>          </td>          <td style="text-align: justify">           Balances with related parties:          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify; padding-bottom: 4pt">           Accounts payable and accrued expenses - KNRY          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">           90          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">          </td>          <td style="width: 1%; padding-bottom: 4pt">          </td>          <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">           64          </td>          <td style="width: 1%; padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            d.           </b>          </td>          <td style="text-align: justify">           Expenses to related parties:          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended           <br/>           August 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">           KNRY          </td>          <td style="width: 1%; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           766          </td>          <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          </td>          <td style="width: 1%; padding-bottom: 1.5pt">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           730          </td>          <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">           Nadav Kidron (CEO)          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           801          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           785          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 84; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-indent: 0; text-align: justify">        All other schedules for which provisionis made in the applicable accounting regulations of the SEC are not required under the related instructions, or are inapplicable,and therefore have been omitted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0in">          </td>          <td style="width: 0.5in; text-align: left">           <b>            (b)           </b>          </td>          <td style="text-align: justify">           <b>            Exhibits           </b>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            3.1*           </font>          </td>          <td style="text-align: justify; width: 91%">           <a href="f10k2020ex3-1_oramedpharma.htm">            <font style="font-size: 10pt">             Composite Copy of Certificate of Incorporation, as amended asof January 22, 2013, corrected February 8, 2013, as amended as of July 25, 2014, corrected September 5, 2017 and as furtheramended as of August 3, 2020.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           3.2*          </td>          <td style="text-align: justify">           <a href="f10k2020ex3-2_oramedpharma.htm">            Composite Copy of Certificate of Incorporation, as amended asof January 22, 2013, corrected February 8, 2013, as amended as of July 25, 2014, corrected September 5, 2017 and as furtheramended as of August 3, 2020 (marked copy).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            3.3           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891313000205/exhibit_3-2.htm">            <font style="font-size: 10pt">             Amended and Restated By-laws (incorporated by reference from our current report on Form 8-K filed February 1, 2013).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891313000211/exhibit_4-1.htm">            <font style="font-size: 10pt">             Specimen Common Stock Certificate (incorporated by reference from our registration statement on Form S-1 filed February 1, 2013).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            4.2           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390018008780/f8k0718ex4-1_oramed.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant (incorporated by reference from our current report on Form 8-K filed July 5, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           4.3          </td>          <td style="text-align: justify">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020005018/ea119125ex1-1_oramed.htm">             Form of Underwriter’s Warrant (incorporated by reference from our current report on Form 8-K filed February 28, 2020).            </a>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            4.4*           </font>          </td>          <td style="text-align: justify">           <a href="f10k2020ex4-4_oramedpharma.htm">            <font style="font-size: 10pt">             Description of Securities.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.1+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420408038259/v119063_ex10-1.htm">            <font style="font-size: 10pt">             Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron (incorporated by reference from our current report on Form 8-K filed July 2, 2008).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.2+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891314003555/exhibit_10-2.htm">            <font style="font-size: 10pt">             Amendment, dated July 13, 2013, to Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008 for the services of Nadav Kidron (incorporated by reference from our annual report on Form 10-K filed November 14, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.3+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891314003555/exhibit_10-3.htm">            <font style="font-size: 10pt">             Amendment, dated November 13, 2014, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron and Miriam Kidron (incorporated by reference from our annual report on Form 10-K filed November 14, 2014).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 85; Options: NewSection; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            10.4+           </font>          </td>          <td style="text-align: justify; width: 91%">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390015009096/f10k2015ex10iv_oramed.htm">            <font style="font-size: 10pt">             Amendment, dated July 21, 2015, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron (incorporated by reference from our annual report on Form 10-K filed November 25, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.5+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10vi_oramed.htm">            <font style="font-size: 10pt">             Amendment, dated June 27, 2016, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron (incorporated by reference from our annual report on Form 10-K filed November 25, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.6+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390017000252/f10q1116ex10i_oramed.htm">            <font style="font-size: 10pt">             Amendment,dated November 28, 2016, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008,for the services of Nadav Kidron (incorporated by reference from our quarterly report on Form 10-Q filed January 11, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.7+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420408038259/v119063_ex10-2.htm">            <font style="font-size: 10pt">             Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (incorporated by reference from our current report on Form 8-K filed July 2, 2008).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.8+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891314003555/exhibit_10-5.htm">            <font style="font-size: 10pt">             Amendment, dated July 13, 2013, to Consulting Agreement by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008 for the services of Miriam Kidron (incorporated by reference from our annual report on Form 10-K filed November 14, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.9+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390015009096/f10k2015ex10v_oramed.htm">            <font style="font-size: 10pt">             Amendment, dated July 21, 2015, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (incorporated by reference from our annual report on Form 10-K filed November 25, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.10+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10vii_oramed.htm">            <font style="font-size: 10pt">             Amendment, dated June 27, 2016, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (incorporated by reference from our annual report on Form 10-K filed November 25, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.11+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390017012754/f10k2017ex10-11_oramed.htm">            <font style="font-size: 10pt">             Amendment, dated June 30, 2017, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (incorporated by reference from our annual report on Form 10-K filed November 29, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           10.12+          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020008653/f10q0220ex10-1_oramed.htm">            Amendment, dated January 10, 2020, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (incorporated by reference from our quarterly report on Form 10-Q filed April 6, 2020).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.13+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016015551/def14a0816_oramedpharma.htm">            <font style="font-size: 10pt">             Oramed Pharmaceuticals Inc. Second Amended and Restated 2008 Stock Incentive Plan (incorporated by reference from our definitive proxy statement on Schedule 14A filed August 4, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.14+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891314003555/exhibit_10-7.htm">            <font style="font-size: 10pt">             Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement (incorporated by reference from our annual report on Form 10-K filed November 14, 2014).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 86; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            10.15+           </font>          </td>          <td style="text-align: justify; width: 91%">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390017012754/f10k2017ex10-14_oramed.htm">            <font style="font-size: 10pt">             Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement between the Company and the CSO or CEO (incorporated by reference from our annual report on Form 10-K filed November 29, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.16+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420408038259/v119063_ex10-4.htm">            <font style="font-size: 10pt">             Form of Notice of Stock Option Award and Stock Option Award Agreement (incorporated by reference from our current report on Form 8-K filed July 2, 2008).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.17+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019014679/def14a0819_oramedpharma.htm">            <font style="font-size: 10pt">             Oramed Pharmaceuticals Inc. 2019 Stock Incentive Plan (incorporated by reference from our definitive proxy statement on Schedule 14A filed August 6, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           10.18+          </td>          <td style="text-align: justify">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020016305/ea123658-def14a_oramedpharma.htm">             Oramed Pharmaceuticals Inc. Amended and Restated 2019 Stock Incentive Plan (incorporated by reference from our definitive proxy statement on Schedule 14A filed June 30, 2020).            </a>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.19+           </font>          </td>          <td style="text-align: justify">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/f10k2019ex10-17_oramed.htm">             Form of Notice of Stock Option Award and Stock Option Award Agreement (incorporated by reference from our annual report on Form 10-K filed November 27, 2019).            </a>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.20+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019009033/f8k051319_oramedpharma.htm">            Employment Agreement, dated May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (incorporated by reference from our current report on Form 8-K filed May 16, 2019).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.21+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020000631/f10q1119ex10-1_oramed.htm">            First Amendment, dated December 19, 2019, to Employment Agreement, entered into as of May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (incorporated by reference from our quarterly report on Form 10-Q filed January 9, 2020).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.22+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000117891312003490/exhibit_10-8.htm">            <font style="font-size: 10pt">             Clinical Trial Agreement, dated September 11, 2011, between Oramed Ltd., Hadasit Medical Research Services and Development Ltd., Miriam Kidron and Daniel Schurr (incorporated by reference from our annual report on Form 10-K/A filed December 21, 2012).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.23+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420409036593/v154436_ex10-1.htm">            <font style="font-size: 10pt">             Clinical Trial Agreement, dated July 8, 2009, between Oramed Ltd., Hadasit Medical Research Services and Development Ltd., Miriam Kidron and Itamar Raz (incorporated by reference from our current report on Form 8-K filed July 9, 2009).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.24           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420409000703/v136444_ex10-1.htm">            <font style="font-size: 10pt">             Agreement, dated January 7, 2009, between Oramed Pharmaceuticals Inc. and Hadasit Medical Research Services and Development Ltd. (incorporated by reference from our current report on Form 8-K filed January 7, 2009).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.25           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000114420411016974/v215899_ex10-25.htm">            <font style="font-size: 10pt">             Patent Transfer Agreement, dated February 22, 2011, between Oramed Ltd. and Entera Bio Ltd. (incorporated by reference from our registration statement on Form S-1 filed March 25, 2011).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 87; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         55         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            10.26+           </font>          </td>          <td style="text-align: justify; width: 91%">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020000631/f10q1119ex10-2_oramed.htm">            <font style="font-size: 10pt">             Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (incorporated by reference from our quarterly report on Form 10-Q filed January 9, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.27+           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/f10k2019ex10-27_oramed.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 18, 2019, between OramedLtd. and Joshua Hexter (incorporated by reference from our annual report on Form 10-K filed November 27, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.28           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390015009761/sc13d1215a3nadavex10i_oramed.htm">             Securities Purchase Agreement, dated November 30, 2015, between Oramed Pharmaceuticals, Inc. and Hefei Tianhui Incubator of Technologies Co., Ltd. (incorporated by reference from Schedule 13D/A filed by Nadav Kidron on December 29, 2015).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.29           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016010085/f10q1115ex10ii_oramedpharma.htm">             Amended and Restated Technology License Agreement, dated December 21, 2015, between Hefei Tianhui Incubator of Technologies Co., Ltd., Oramed Pharmaceuticals, Inc. and Oramed Ltd. (Confidential treatment has been granted for portions of this document. Incorporated by reference from our quarterly report on Form 10-Q filed January 13, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.30           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10xxxi_oramed.htm">             Amendment    to the Amended and Restated Technology License Agreement, dated June 3, 2016, between Hefei Tianhui Incubator of Technologies    Co., Ltd., Oramed Pharmaceuticals, Inc. and Oramed Ltd. (Confidential treatment has been requested for portions of this    document. The confidential portions will be omitted and filed separately, on a confidential basis, with the Securities and    Exchange Commission) (incorporated by reference from our annual report on Form 10-K filed November 25, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.31           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10xxxii_oramed.htm">            <font style="font-size: 10pt">             Amendment    to the Amended and Restated Technology License Agreement, dated July 24, 2016, between Hefei Tianhui Incubator of    Technologies Co., Ltd., Oramed Pharmaceuticals, Inc. and Oramed Ltd. (Confidential treatment has been requested for portions    of this document. The confidential portions  will be omitted and filed separately, on a confidential basis, with the    Securities and Exchange Commission) (incorporated by reference from our annual report on Form 10-K filed November 25,    2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.32           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10xxxiii_oramed.htm">             Service Agreement, dated as of June 3, 2016, between Oramed Ltd. and XERTECS GmbH (Confidential treatment has been granted for portions of this document. The confidential portions have been omitted and filed separately, on a confidential basis, with the Securities and Exchange Commission) (incorporated by reference from our annual report on Form 10-K filed November 25, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.33           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390016018954/f10k2016ex10xxxiv_oramed.htm">             General Technical Agreement between Oramed Ltd. and Premas Biotech Pvt. Ltd., dated July 24, 2016 (Confidential treatment has been granted for portions of this document. The confidential portions have been omitted and filed separately, on a confidential basis, with the Securities and Exchange Commission) (incorporated by reference from our annual report on Form 10-K filed November 25, 2016).            </a>           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 88; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         56         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            10.34           </font>          </td>          <td style="text-align: justify; width: 91%">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019017287/f8k082919ex1-1_oramed.htm">             Equity Distribution Agreement, dated September 5, 2019, between Oramed Pharmaceuticals Inc. and Canaccord Genuity LLC (incorporated by reference from our current report on Form 8-K filed September 5, 2019).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           10.35          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020008653/f10q0220ex10-2_oramed.htm">            Amendment to the Equity Distribution Agreement, dated February 10, 2020, by and between the Company and Canaccord Genuity LLC (incorporated by reference from our quarterly report on Form 10-Q filed April 6, 2020).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.36           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390018004196/f10q0218ex10-1_oramed.htm">             Clinical Research Organization Services Agreement, dated February 14, 2018 and effective as of November 1, 2017, between Oramed Ltd. and Integrium, LLC (Confidential treatment has been granted for portions of this document. The confidential portions have been omitted and filed separately, on a confidential basis, with the Securities and Exchange Commission.) (incorporated by reference from our quarterly report on Form 10-Q filed April 9, 2018).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.37           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019012456/f10q0519ex10-1_oramed.htm">             Amendment #1 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (incorporated by reference from our quarterly report on Form 10-Q filed July 10, 2019).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            10.38           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019012456/f10q0519ex10-2_oramed.htm">             Amendment #2 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (incorporated by reference from our quarterly report on Form 10-Q filed July 10, 2019).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           10.39          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020025857/ea126629ex10-1_oramed.htm">            Clinical Research Organization Services Agreement, dated September 2, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (incorporated by reference from our Form 8-K filed September 9, 2020).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           10.40          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390020027361/ea127043ex10-1_oramed.htm">            Clinical Research Organization Services Agreement, dated September 16, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (incorporated by reference from our Form 8-K filed September 18, 2020).           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            21.1           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/f10k2019ex21-1_oramed.htm">            <font style="font-size: 10pt">             Subsidiaries (incorporated by reference from our annual report on Form 10-K filed November 27, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            23.1*           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="f10k2020ex23-1_oramedpharma.htm" style="-sec-extract: exhibit">             Consent of Kesselman &amp; Kesselman, Independent Registered Public Accounting Firm.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            31.1*           </font>          </td>          <td style="text-align: justify">           <a href="f10k2020ex31-1_oramedpharma.htm">            <font style="font-size: 10pt">             Certification Statement of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            31.2*           </font>          </td>          <td style="text-align: justify">           <a href="f10k2020ex31-2_oramedpharma.htm">            <font style="font-size: 10pt">             Certification Statement of the Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 89; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         57         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%">           <font style="font-size: 10pt">            32.1**           </font>          </td>          <td style="text-align: justify; width: 91%">           <a href="f10k2020ex32-1_oramedpharma.htm">            <font style="font-size: 10pt">             Certification Statement of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            32.2**           </font>          </td>          <td style="text-align: justify">           <a href="f10k2020ex32-2_oramedpharma.htm">            <font style="font-size: 10pt">             Certification Statement of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-size: 10pt">            101.1*           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            The following financial statements from the Company’s annual report on Form 10-K for the year ended August 31, 2020, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Changes in Stockholders’ Equity, (iv) Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">        <b>        </b>       </p>       <!-- Field: Rule-Page -->       <div style="width: 15%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           *          </td>          <td style="text-align: left">           Filed herewith.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           **          </td>          <td style="text-align: left">           Furnished herewith.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: left">          <td style="width: 0in">          </td>          <td style="width: 0.25in; text-align: left">           +          </td>          <td style="text-align: left">           Management contract or compensation plan.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <b>         ITEM 16.        </b>        <b>         <a name="a_025">         </a>         FORM 10-K SUMMARY.        </b>       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">        None.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">       </p>       <!-- Field: Page; Sequence: 90; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         58         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        Pursuant to the requirements of Section13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by theundersigned, thereunto duly authorized.       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            <b>             ORAMED PHARMACEUTICALS INC.            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0 0 1.5pt; width: 60%; text-align: justify; text-indent: 0">          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; width: 40%; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/ NADAV KIDRON           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Nadav Kidron,           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            President and Chief Executive Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Date: November 24, 2020           </font>          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 91; Value: 53 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         59         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        Pursuant to the requirements of the Securitiesand Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacitiesand on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding: 0 0 1.5pt; text-align: justify; text-indent: 0; width: 0.5in">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0; width: 45%">           <font style="font-size: 10pt">            /s/    NADAV KIDRON           </font>          </td>          <td style="padding: 0 0 1.5pt; text-align: justify; text-indent: 0; width: 5%">          </td>          <td style="padding: 0 0 1.5pt; text-align: justify; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Nadav    Kidron,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            President    and Chief Executive Officer and Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            (principal    executive officer)           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    AVRAHAM GABAY           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Avraham    Gabay,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Chief    Financial Officer           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            (principal    financial and accounting officer)           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    AVIAD FRIEDMAN           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Aviad    Friedman,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    MIRIAM KIDRON           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Miriam    Kidron,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    ARIE MAYER           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Arie    Mayer,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    KEVIN RAKIN           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Kevin    Rakin,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    LEONARD SANK           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Leonard    Sank,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="border-bottom: Black 1.5pt solid; padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            /s/    GAO XIAOMING           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            November    24, 2020           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Gao    Xiaoming,           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">           <font style="font-size: 10pt">            Director           </font>          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>          <td style="padding-top: 0; text-align: justify; padding-right: 0; padding-left: 0; text-indent: 0">          </td>         </tr>        </tbody>       </table>       <p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        60       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 100%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>